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SUMMARY
The thesis should be read in conjunction with the addendum that follows the summary.
xxiii
Over the years it has been well documented that there is a connection between the 
immune system and the endocrine system certainly as far as vitamin D was concerned. 
The major breakthrough came when vitamin D receptors were demonstrated on various 
cells whose principal task was to mount an immune response. 1,25 Dihydroxyvitamin 
D3 (l,25(OH)2D3), the active metabolite of vitamin D, was demonstrated to inhibit cell 
proliferation and to inhibit interleukin - 2 (IL-2) activity (Tsoukas, 1984). In this thesis 
the roles of l,25(OH)2D3 and other calciotrophic hormones as immunoregulatory agents 
are addressed.
The results presented in this thesis demonstrate that the effects of l,25(OH)2D3 on the 
immune system are both genuine and unique. The other calciotrophic hormones studied 
(24,25 dihydroxyvitamin D3(24,25(OH)2D3), 25 hydroxyvitamin D3 (25(OH)D3), 
parathyroid hormone (PTH) and calcitonin (CT)) did not have a significant effect on 
either cell proliferation or IL-2 activity. Although it had been previously demonstrated 
that sex hormones (oestrogen, progesterone and dihydrotestosterone) could inhibit the 
immune response this effect was demonstrated to be different from the inhibition by 
l,25(OH)2D3 in the immune system. l,25(OH)2D3 was demonstrated to have little effect 
on the other cytokines that were prominent in the system under review. l,25(OH)2D3 
had no significant effect on either interleukin -1 (IL-1) or interleukin - 6 (IL-6).
The capacity of l,25(OH)2D3 to act as a differentiation factor has been well 
documented. It was conceivable that l,25(OH)2D3 acts as a differentiation factor in the 
immune system. The possible target would be the suppressor cells (Ts) and the 
l,25(OH)2D3 could promote the differentiation of these cells. This scenario was not 
demonstrated but the effect of l,25(OH)2D3 was shown to be mediated through the 
helper T-cells (Th).
xxiv
l,25(OH)2D3 was demonstrated to increase the concentration of the soluble interleukin 
-2 receptor (sIL-2R) at concentrations in excess of 1011 M. This increase was a 
characteristic 'all or nothing' response. It is significant that the switch from low sIL-2R 
to high sIL-2R occurs between 1011 M and 1010 M which is the physiological range of 
l,25(OH)2D3. It was also demonstrated that l,25(OH)2D3 inhibited the message for both 
interleukin - 2 (IL-2) and the interleukin - 2 receptor (IL-2R) at 1010 M but that 
inhibition of the message for both was not seen at 107 M.
Taken together the work in thesis suggests that l,25(OH)2D3 inhibits IL-2 activity 
through two distinct mechanisms. l,25(OH)2D3 acts as a 'classic steroid hormone' 
between 0 M and 1011 M in that it inhibits IL-2 and indeed IL-2R at the genomic level 
by directly inhibiting the amount of message for these proteins. Between the 
concentrations KH0 M and 107 M the l,25(OH)2D3 increases the concentration of sIL- 
2R. The increase in sIL-2R acts as an antagonist to IL-2 and effectively 'mops' up the 
IL-2 subsequently produced thereby sustaining the inhibition of the IL-2 activity.
xxv
ADDENDUM
xxvi
The thesis confirms that l,25(OH)2D3 inhibits both IL-2 activity and lymphocyte 
proliferation. However, under the conditions of the system no inhibitory effect was 
demonstrated by the other vitamin D metabolites (25(OH)D3 or 24,25(OH)2D3) or by the 
calciotrophic hormones PTH and CT. The effect of calcitonin and parathyroid hormone 
on lymphocyte proliferation has to be interpreted carefully as the system was set up to 
look for inhibition. It is important to realise that nothing can be concluded about 
possible enhancement of response. An inhibitory response was obtained by sex 
hormones in the system but this effect produced a characteristic U - shaped curve which 
was distinct from the effect observed with l,25(OH)2D3.
Throughout this thesis the measurement of IL-2 activity was carried out using the IL-2 
dependent cell line, HT-2. This cell line was derived from a single cell that has the 
characteristics of a murine helper T - cell (Watson, 1979). The HT-2 cells were 
demonstrated to be responsive to murine, rat and human IL-2 and had the advantage of 
not being responsive to the T - cell mitogens, PHA and Con A (Watson, 1979). The HT- 
2 cells were demonstrated to be dependent on IL-2, withdrawal of IL-2 resulting in cell 
death within 2 days (Doyle, 1985) and this was confirmed (data not shown). As a 
consequence of measuring cytokines in cell supernatants it is possible that other 
cytokines presently defined or as yet undefined may stimulate HT-2 cells. This was felt 
to be less likely as two other bioassays for measuring IL-2 produced similar results (see 
section 4.3.). Further confirmation could have been obtained by observing the effect of 
a neutralising antibody against IL-2 on the IL-2 containing supernatants this antibody 
should block the IL-2 response whereas antibodies against other cytokines should have 
no effect.
It was possible that the assays may have been affected by IL-2, vitamin D metabolites 
or sex hormones in the FCS. The batch of FCS was constant throughout the studies 
therefore any effect of these factors would be consistent. The concentration of FCS was 
only 2 % thereby keeping any effect to a minimum. The biological half - life of the 
vitamin D metabolites make it unlikely that they could contribute significantly to the 
results presented. It has been reported that l,25(OH)2D3 has a biological half - life of
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1.5 days (Kanis, 1977). IL-2 is normally undetectable in serum and also has a short half 
- life. The sex hormones in FCS were not expected to be high as these hormones are 
associated with maturity. The vitamin D metabolites and sex hormones present in the 
serum used in the IL-2 production experiments however, could have been removed 
altogether by charcoal stripping the serum. The range of l,25(OH)2D3 concentrations 
studied (0 to 10*7M) was shown to have no effect on the culture of the HT-2 cells, 
LBRM TG6 and B9 (data not presented).
The majority of the work was carried out on peripheral blood mononuclear cells 
(PBMCs) obtained from normal males in order to minimise variation. The only 
exception to this was the work on the sex hormones. In all the work involving sex 
hormones the population was mixed. PBMCs from both males and females were 
cultured in the presence of all three sex hormones (oestrogen, progesterone and 
dihydrotestosterone) and no difference in response with respect to sex was observed. 
The effect of sex hormones on lymphocyte proliferation was carried out on five females 
and four males whereas the effect of sex hormones on IL-2 activity was carried out on 
two females and two males.
The IL-2 activity obtained from PBMCs varied from individual to individual. 
However, this variability was not sufficiently large that it could be accounted for by 
gene duplication in certain individuals as reported for some other cytokines (e.g. TNF a, 
(Jongeneel, 1991)). IL-2 has been demonstrated to be a product of a single gene 
consisting of four exons and three introns on the long arm of chromosome 4 in humans 
(Holbrook, 1984).
The paired Wilcoxon test (Wilcoxon, 1945) was the statistical method used 
throughout the thesis because the small sample size did not allow the assumption that 
the distribution was normal. Nonparametric statistics were thus favoured. This 
statistical technique requires a minimum of seven samples (Lehmann, 1975) hence this 
was the number used. As a consequence in situations where there were less than seven 
samples in a study, statistics were considered inappropriate. All analyses were classified 
as significant when the p value was less than 0.05 as is usual statistical practice but were
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not graded below this level e.g. p < 0.001. This could have underestimated the 
significance of the results especially those showing a gradual but increasing effect as 
demonstrated by the effect of l,25(OH)2D3 on IL-2 activity (p 126). The grading of 
significance could have shown that the effect of l,25(OH)2D3 on IL-1 and IL-6 activities 
were less significant than the effect of l,25(OH)2D3 on IL-2 and hence the one point that 
did achieve significance at the level of p < 0.05 would be discredited (see p 149 and p 
161). An alternative to the Wilcoxon test would have been the analysis of variance test. 
This assesses whether the variation among groups is significantly greater phan that 
which would be expected given the variation within a group. When this analysis was 
carried out in retrospect no significant differences were obtained in the IL-1 and EL-6 
data whereas the differences remained significant in the IL-2 data.
Chapter 8 in this thesis looks at the effects of l,25(OH)2D3 on the mRNA for IL-2 and 
IL-2R. The data suggests a reduction in the mRNA for IL-2 and IL-2R after incubation 
with 10 10 M l,25(OH)2D3 at 20 hours. However, although the pattern obtained in 
figure 8.2.1. looks quite convincing there are two areas of concern which require 
reconsideration of some of the conclusions declared on pages xxv, 199 and 203. The 
amount of RNA loaded onto the gel should have been the same as was suggested by the 
concentration of the RNA calculated by nucleic acid dip sticks and by the appearance of 
the RNA on the preparatory gel, but in fact there was no adequate control. The solution 
to this problem would be to strip the blots and reprobe with an abl or p - actin probe. 
This would verify that there was an equal amount of mRNA in each lane on the gel. A 
second problem occurs when the position of the bands are considered: the size of the 
mRNA coding for the IL-2 (about 465 bases) should be considerably smaller than the 
mRNA coding for the IL-2R (about 816 bases). This size difference was not observed in 
the blots obtained. The position of the band on the gel makes it unlikely that it was the 
IL-2 probe that was responsible for this discrepancy. Rigby (Rigby, 1987) has also 
demonstrated that l,25(OH)2D3 inhibits the mRNA for IL-2 at 20 hours. This raises 
questions about the specificity of the probe for the IL-2R. The solution would be to
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obtain another probe for the IL-2R and reprobe the blot. It would also be advisable to 
include an RNA ladder to size the bands on the blot.
The postulate that a two mechanism system exists can be clarified in several ways. 
Preliminary experiments performed after the thesis was completed suggested that the 
l,25(OH)2D3 inhibition was only partially reversed by addition of IL-2. At the higher 
concentrations of l,25(OH)2D3 (10-8M and 10-7M) there is still a slight inhibition of 
lymphocyte proliferation which could possibly be accounted for by a second 
mechanism. In order to ascertain whether or not the l,25(OH)2D3 is regulating the IL-2 
gene the next stage would be to search for and possibly locate a vitamin D acceptor site. 
This work would involve searching the DNA sequence upstream from the IL-2 gene for 
the presence of a consensus sequence similar to the one known to act as an acceptor site 
for the vitamin D in other systems.
Nevertheless, the thesis clearly demonstrates that l,25(OH)2D3 inhibits both IL-2 
activity and lymphocyte proliferation and that the other calciotrophic hormones tested 
were unable to do so. The inhibition by l,25(OH)2D3 was demonstrated to be different 
from the effect documented for the sex hormones. l,25(OH)2D3 was shown to increase 
the concentration of sIL-2R present in cell supernatants thus suggesting a double 
mechanism of action of l,25(OH)2D3 on cell proliferation i.e. by reducing IL-2 
production and by increasing soluble IL-2 receptor production.
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CHAPTER 1.
GENERAL INTRODUCTION.
1
1.1 INTRODUCTION.
Vitamin D in its active form is an important regulator of extracellular calcium 
homeostasis and has therefore a fundamental role in the physiology of bone. 
Historically, this importance in mineral metabolism was highlighted by the clinical 
condition of rickets - osteomalacia where there was usually a deficiency of, or a 
resistance to the action of vitamin D. However, in more recent years it has become 
apparent that the physiological role of vitamin D may extend to promotion of cell 
differentiation and immunoregulation.
The importance of these further actions of vitamin D has led to further 
pharmacological applications. Holick's group and others have successfully used such 
active metabolites of vitamin D in the treatment of psoriasis (Smith, 1988), and these 
metabolites have also been used as an adjunct to chemotherapy in the treatment of 
lymphoma (Cunningham, 1985). The treatment of leukaemias with vitamin D 
metabolites has limitations in that the effective therapeutic concentrations are 10 to 100 
times higher than their physiological serum levels (Porteous, 1987). Gepner has also 
suggested that vitamin D may be potentially useful in the management of rheumatoid 
arthritis (RA) (Gepner, 1989).
A full appreciation of these additional roles of vitamin D and its metabolites on 
haematopoietic cell differentiation and on the immune system requires firstly an 
understanding of physiological roles of vitamin D, secondly its biochemistry and 
metabolism and thirdly an appreciation of the role of cytokines in the immune system.
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1.2 VITAMIN D PHYSIOLOGY.
1.2.1 Is vitamin D a vitamin ?
The classical definition of a vitamin was that it is a trace dietary constituent required 
to effect normal physiological function. Vitamin D, however, is really a misnomer as 
higher animals can synthesise calciferol in skin when exposed to ultraviolet light (u.v.) - 
usually in the form of sunlight. This in effect means that vitamin D is only a true 
vitamin when the animal is deprived of sunlight.
As in the case of other true vitamins, absence of vitamin D is associated with specific 
biological abnormalities. These abnormalities may affect the organism as a whole 
(retardation of growth), or particular organs (development of rickets - osteomalacia by 
the skeletal system), or particular cell types (the columnar epithelial and/or goblet cells 
of the intestinal mucosa), and ultimately be manifest at the subcellular level (alteration 
of the morphology of kidney mitochondria) (Norman, 1979).
There are several theories as to the first appearance of the vitamin D deficient state in 
man. On the basis of palaeontological evidence both Solecki (Solecki, 1971 a,b) and 
Loomis (Loomis, 1967) postulated that Neanderthal man's stooped appearance may in 
fact be due to vitamin D deficiency as opposed to a "low" evolutionary status. Kjerrulf 
(Kjerrulf, 1922) claimed that rickets could be observed in human skeletons from the 
Neolithic age (c.8000 B.C.).
Although there have been suggestions of afflictions similar to the clinical symptoms of 
rickets in the archaeological records of Egyptians (c.1500 B.C.), and in the writings of 
Soranus of Ephesius (Findlay, 1917 and Hess, 1929), the first precise written definition 
of rickets was credited to both Whistler (Whistler, 1645) and Glisson (Glisson, 1650 
a,b). After independent publication of their description of rickets it became a commonly 
recognised disease entity.
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A major breakthrough occurred between 1919 and 1921, when in a comprehensive 
series of experiments using rachitic pups fed accurately defined diets Mellanby 
demonstrated that a nutritional factor possessing antirachitic activity existed (Mellanby, 
1921). Mellanby went on to suggest that this antirachitic factor was the fat soluble 
vitamin A. Furthermore, he demonstrated that cod-liver oil was an excellent antirachitic 
agent thus confirming a piece of rural wisdom that had been around for many years. 
However, McCollum et al (McCollum, 1922) demonstrated that the essential factor was 
not vitamin A and therefore proposed that the antirachitic substance be named vitamin 
D. The critical observation that supported a distinct antirachitic factor in cod-liver oil 
was that the proposed agent could survive both aeration and heating (100 °C for 14 
hours) whereas under these conditions vitamin A was inactivated.
At this time it also became apparent that ultraviolet light had an important role to play 
in the aetiology and cure of rickets. This feature was demonstrated by Huldschinsky 
(Huldschinsky, 1919, 1919-1920), who showed that u.v. rays were effective in 
increasing the degree of calcification of the epiphysis of rachitic children. This 
observation was confirmed in an animal model.
The work of Goldblatt and Soames (Goldblatt, 1923) made a connection between a 
molecular species (in cod-liver oil) responsible for the antirachitic activity and u.v. light. 
They demonstrated that if livers were excised from rachitic rats and were subjected to 
irradiation with u.v. light, and subsequently if these irradiated livers were then fed to 
other rachitic rats, the vitamin D deficiency was corrected in these rats. Steenbock and 
Black (Steenbock, 1924) showed that irradiated food possessed antirachitic properties. 
Both groups were responsible for the conclusion that ultraviolet light played a critical 
role in producing vitamin D from a provitamin present in the skin.
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Both Hess and Weinstock (Hess, 1925 a,b,c) and Steenbock and Black (Steenbock, 
1925) confirmed that antirachitic activity could be generated by u.v. irradiation of 
various foods. They also fractionated the antirachitic factor. This factor was confined 
to the nonsaponifiable fraction and exclusively resided in the phytosterol or cholesterol 
fraction. Although both groups believed that they were studying the same factor, 
Steenbock and Black had produced vitamin D2 from the irradiation of the ergosterol and 
Hess and Weinstock had generated vitamin D3 from the irradiation of skin. Having 
made the connection between antirachitic activity, ultraviolet light and sterols - in 
particular 5,7-unsaturated sterols - it was now possible to characterise vitamin D.
1.2.2 The structure of vitamin D.
The identification of the chemical structure was the result of the simultaneous efforts 
of both Windaus et al (Windaus, 1932) and Askew et al (Askew, 1932). Vitamin D3 was 
chemically characterised in 1936 by Windaus et al (Windaus, 1936). The antirachitic 
sterol was actually a secosteroid formally known as 9(10) seco cholesta 5,7,10(19)-dien- 
3B-ol. Seco-steroids are those in which one of the rings has undergone fission by 
breakage of a carbon-carbon bond (figure 1.2.1). The seco - nature of the vitamin was 
confirmed by X-ray crystallography (Crowfoot, 1948; Crowfoot - Hodgkin, 1963). 
Vitamin D3 or cholecalciferol was the naturally occurring form of the vitamin in animals 
and was normally derived by exposure of 7 dehydrocholesterol, present in the skin, to 
sunlight. On the other hand, vitamin D2 or ergocalciferol was produced through 
ultraviolet irradiation of the sterol ergosterol found in yeasts and fungi.
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FIGURE 1.2.1.
The metabolic pathway for the production of 1,25 dihydroxyvitamin D3 from 
either the photoconversion of 7 - dehydrocholesterol or from the diet.
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In the early years of vitamin D research it became evident that there was a time lag 
between administration of vitamin D and a physiological response (Irving, 1944). This 
lag was probably as much to do with the use of crude end points as anything else. 
However, with the development of radioisotopes it became apparent that this lag was a 
genuine phenomenon. Raoul and Gounelle (Raoul, 1958) and Sallis and Holdsworth 
(Sallis, 1962) speculated that a metabolic conversion of vitamin D3 to an active form 
was necessary. Of course it could have been that the lag was due to the slow absorption 
and transportation of the vitamin or perhaps it reflected an induction process involving 
expression of genetic information.
1.2.3 Vitamin D metabolites.
During the 1960's and 70's contributions from several laboratories unravelled the 
complex metabolic pathway for the production of the biologically active form of vitamin 
D. The development of randomly labelled tritiated vitamin D2 and vitamin D3 with high 
specificity by Norman and De Luca (Norman, 1963) allowed the detection of several 
metabolites that possessed antirachitic activity. These metabolites have now been 
characterised.
The important metabolites in blood were 25-hydroxyvitamin D3 (25(OH)D3) , 24,25 
dihydroxyvitamin D3 (24,25(OH)2D3) and 1,25 dihydroxyvitamin D3 (l,25(OH)2D3). 
The human plasma concentrations of these metabolites were 25(OH)D3 (10 8 M - 10 7 M 
, 15 - 30ng/ml), 24,25(OH)2D3 (10-«> M -10*9 M, 1 - 3 ng/ml) and l,25(OH)2D3 (10-n M 
- 1010 M, 30 - 40 pg/ml). At present there are a further five daughter metabolites of 
vitamin D3, none of which have been assigned a biological function. The most potent 
metabolite with regard to biological function in both the intestine and in the bone is 1,25 
dihydroxyvitamin D3.
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Whether vitamin D3 is derived from the diet or by photochemical conversion of 7 
hydroxycholesterol, the next step is conversion to 25(OH)D3. This metabolic 
conversion takes place principally in the liver and is catalysed by 25-hydroxylase 
located in hepatic mitochondria. The enzyme is regulated by a negative feedback 
mechanism. Vitamin D-25 Hydroxylase activity was also found in other tissues such as 
intestine and kidney (Tucker, 1973).
The circulating 25(OH)D3 becomes a substrate for the renal enzymes, 25(OH)D3-l- 
hydroxylase and 25(OH)D3-24-hydroxylase. These enzymes were located in the 
mitochondrial fraction of the kidney cortex (Fraser, 1970) and each enzyme can be 
described as a classical mixed function steroid hormone hydroxylase (Ghazarian, 1973). 
The enzymes have at least three components, namely a flavoprotein (an iron - sulphur 
protein), renal ferrodoxin, and a cytochrome P450. Together these components facilitate 
the transfer of electrons from NADPH to the cytochrome P450 and ultimately the 
incorporation of molecular oxygen into a hydroxyl moiety at position 1 or 24.
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1.2.4. Regulation of l,25(OH)2D3.
It is now well established that l,25(OH)2D3 is the vitamin D metabolite that plays a 
crucial role in calcium (Fraser, 1970 and Boyle, 1972) and phosphorus homeostasis (De 
Luca, 1974). The control of production of the active metabolite, l,25(OH)2D3, is 
critical. The accepted view is that l,25(OH)2D3 is produced in accordance with strict 
physiological signals, in response to calcium and phosphorus demand. The regulation 
occurs at the l a  hydroxylation of the 25(OH)D3 i.e. the enzyme 25 hydroxyvitamin D3- 
1-hydroxylase ( la  OHase). The enzymatic activity is affected by changes in serum 
calcium (Boyle, 1971), serum phosphate (Tanaka, 1973), parathyroid hormone (PTH) 
(Garabedian, 1972), calcitonin, cyclic AMP, vitamin D metabolites, and other associated 
factors including pH, steroid hormones and bisphosphonates (Norman, 1979). The 
complex interplay of hormones and other humoral factors are shown in figure 1.2.2.. 
The primary stimuli of the renal l a  OHase were PTH, low serum calcium and low 
serum phosphate. Low serum phosphate appears to act on the kidney possibly through 
changes in the ionic environment of the kidney mitochondria and thereby promoting the 
l a  hydroxylation of 25(OH)D3. Parathyroid hormone secretion is promoted by low 
serum ionised calcium and the trophic effect of PTH on 25(OH)D3-l-hydroxylase leads 
to increased levels of l,25(OH)2D3. Having raised the levels of l,25(OH)2D3 in the 
blood, the active metabolite acts on bone and intestine to mobilise and absorb calcium 
and phosphate. The loop was closed and the original hypophosphataemic and 
hypocalcaemic provocations are corrected by this classic endocrine feedback system. 
However, the system is generally challenged by one or other of the conditions but not 
usually both together. As l,25(OH)2D3 increases the concentration of both ions, one can 
envisage a situation where there can be excess phosphate in the response to a 
hypocalcaemic challenge. During the compensation of the low serum calcium the 
excess phosphate is eliminated in the urine as a direct result of PTH inhibiting the renal 
reabsorption of phosphate. In contrast, excess calcium mobilised in response to 
hypophosphatemia is corrected by a direct inhibitory action of
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Calcium and Phosohorus homeostasis : A flow chart of Calcium and 
Phosphorus homeostasis. The chart demonstrates the interaction between the 
vitamin D endocrine system and the parathyroid hormone system. The 
feedback control mechanisms are also demonstrated.
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l,25(OH)2D3 on the parathyroid gland. In this situation, PTH is suppressed and 
therefore is not able to cause enhanced renal calcium reabsorption. The homeostasis 
system works because PTH participates in one of the loops, the calcium loop and in 
addition PTH has opposite effects on the renal handling of both calcium and phosphate 
ions.
It is possible that l,25(OH)2D3 can regulate its own biosynthesis by acting as a 
feedback regulator on either the parathyroid gland or the kidney or both (Norman, 
1980). The presence of l,25(OH)2D3 can induce the formation of the renal 24- 
hydroxylase (24(OH)ase) which uses up excess 25(OH)D3 and therefore establishes a 
negative feedback loop. Both l,25(OH)2D3 and 24,25(OH)2D3 may modulate PTH 
secretion through a short feedback loop. The consensus of opinion favours the long loop 
feedback mechanism that occurs between the product, ionised calcium in blood, and the 
parathyroid gland as the main regulator of the l a  OHase. The short loop could play an 
important role as it has been established that parathyroid chief cells possess receptors for 
l,25(OH)2D3 (both cystolic and nuclear). Infusion of both l,25(OH)2D3 and 
24,25(OH)2D3 directly into the gland results in an inhibition of PTH secretion whereas 
conversely infusion of l a  hydroxyvitamin D3 into blood does not result in PTH 
inhibition (unpublished observation S. Gallacher). This modulation of PTH by the 
l,25(OH)2D3 is reminiscent of classic steroid hormones such as glucocorticoids or 
oestrogens that feedback direcdy on to the hypothalamus and pituitary to inhibit the 
secretion of adenocorticotrophic hormone (ACTH) and follicle stimulating hormone 
(FSH). Growth hormone, prolactin, oestrogens and possibly glucocorticoids may also 
modulate l,25(OH)2D3.
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1.2.5. Steroid Hormone Mode of Action.
The mode of action of l,25(OH)2D3 on target cells is analogous to that of classical 
steroid hormones. The time scale of events is in keeping with that of accepted models. 
Administration of l,25(OH)2D3 is followed by a latent period of approximately two 
hours before a detectable physiological response was noted. This lag was sufficiently 
long to allow induction of proteins but at the same time short enough to confirm 
l,25(OH)2D3 as the mediator of the response.
In simplistic terms the two step model of action of steroid hormones is represented in 
figure 1.2.3.. l,25(OH)2D3 (S) binds to a cytoplasmic high affinity receptor (R). The 
hormone-receptor complex undergoes a conformational change. The hormone-receptor 
complex then migrates to the nucleus, where it binds to the specific acceptor site. At 
this point there was a resultant stimulation of template activity, which results in the 
production of messenger RNA (mRNA). Messenger RNA then migrates into the 
cytoplasm and is translated into new proteins which facilitate biological response.
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FIGURE 1.2.3.
The mode of action of the steroid hormone is presented in this figure. The 
steroid hormone (S) interacts with its target tissue by binding to a specific 
protein receptor localised in the cytoplasmic portion of the cell. The steroid - 
hormone complex (SR) undergoes a conformational change prior to entry into 
the nucleus. The SR complex then interacts with the DNA to initiate 
transcription to produce new mRNAs which are subsequently translated to give 
new proteins and hence a biological response.
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1.3 THE IMMUNE SYSTEM.
1.3.1. Early beginnings.
The Latin words imunitas and immunis were used to describe those that were exempt 
from service (military) to the state. From this point the words developed connotations 
with the ancient observation that people who had been smitten with certain diseases and 
subsequently recovered seldom contracted these diseases again i.e. were exempt hence 
the term immunity (Silverstein, 1989). Over the last two centuries it has been 
recognised that the immune system comprises organs, cells and molecules whose 
function was to recognise and eliminate foreign bodies. The system was orchestrated by 
a number of specialised blood cells. Recently it has become apparent that the system 
was regulated by hormones in much the same way as other systems within the body. 
These immune system hormones have been termed interleukins - a communication link 
between leukocytes.
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1.3.2. Cells of the immune system.
The cells involved in the immune system (figure 1.3.1.) can be categorised as follows ; 
Monocytes.
Monocytes are cells derived from a myeloid stem cell precursor. The cells are formed 
in the bone marrow and circulate in blood, to tissues where they mature into 
macrophages (Mcp). They function as scavengers although their prime function is 
presentation of antigen.
Lymphocytes.
There are two broad sub-types of lymphocytes and they derive their names from the 
sites where the immature cells differentiate to form mature cells. There are the T- 
lymphocytes that are thymus derived and the B-lymphocytes derived from the 'bursa 
equivalent' in man. Although B and T lymphocytes are morphologically similar they 
perform distinct functions. T-lymphocytes (T-cells) participate in cell mediated 
reactions and also help regulate antibody production by B-lymphocytes (B-cells). B- 
lymphocytes mature into plasma cells that produce antibody.
T-cells do not produce antibody but they do express specific antigen receptors that 
resemble antibody. These receptors bind antigen presented by macrophages in the 
context of major histocompatability complex molecules. The binding of antigen results 
in a series of reactions culminating in the secretion of molecules that mediate their 
immune function. On the basis of the molecules secreted and the expression of surface 
receptors T-cells can be further divided into helper/inducer T-cells (Th, CD4+ve) and 
cytotoxic/suppressor T-cells (Ts, CD8+ve). Th perform their function by secreting 
interleukins whereas Ts make direct contact with infected cells, secrete toxic molecules, 
kill the cells and the microbes therein.
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FIGURE 1.3.1
The haemopoietic system : Cells involved in immunity. The diagram 
represents the cells involved in immunity and their development to 
immunocompetent cells at both the blood level and at the level of tissues. The 
differentiation pathway of the various mature cells are presented. All the cells 
are derived from a common stem cell.
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Granulocytes.
There are three subtypes of granulocytes; neutrophils, eosinophils and basophils. 
These cells are also produced in the bone marrow. Neutrophils perform phagocytosis of 
microorganisms. Eosinophils are also capable of phagocytosis possibly of larger 
organisms. Basophils are like mast cells in that they contain powerful chemicals such as 
histamine and they may be involved in the allergic response.
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1.3.3. Properties of the immune system.
The immune system has evolved the ability to sense and respond to foreign molecules. 
Foreign molecules can take the form of microorganisms such as viruses, bacteria, fungi 
and parasites whose recognition as foreign molecules is mediated by T and B 
lymphocytes. The immune system possesses three novel characteristics. Firstly, 
reaction to a foreign molecule (antigen) is both highly specific and at the same time 
diverse. This is achieved by having unique lymphocytes that can respond to unique 
antigens and is explained by the clonal selection theory (Burnet, 1958). Basically this 
infers that for every possible antigen there is a specific lymphocyte that can recognise 
this antigen. Exposure to an antigen leads to clonal expansion of a specific lymphocyte 
and hence an immune response. A second characteristic, requires that the immune 
system has the ability to distinguish between self and nonself and this ensures that the 
body does not turn on itself. This attribute is achieved by the major histocompatability 
complex located on chromosome six. In a small section of chromosome 6 there are four 
gene loci (D,B,C,A) on each strand of the chromosome, and these eight genes (four loci 
on each chromosome strand) code for the protein that make up the self antigen. These 
self antigens are expressed on every cell that make up the genetic individual known as 
self. Finally, once the system is exposed to a particular antigen, the response time and 
the force with which it responds to subsequent exposure is heightened. This final 
feature implies that the immune system has a memory. Again this can be related to 
clonal selection in that the T-cells activated in the initial exposure are still viable and are 
actively involved in surveillance hence there are more T-cells with a specific antigen 
binding protein available to meet the challenge.
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1.3.4. Interleukins - The hormones of the immune system.
Within the past ten years, it has become apparent that the immune response is 
controlled by a group of proteins that have been termed interleukins. Having defined 
interleukins it is perhaps advantageous to define the other terms commonly used in this 
research field. Lymphokines are defined as soluble mediators produced by lymphocytes 
whereas cytokines are mediators produced by cells. At present there are ten recognised 
interleukins (table 1.3.1.) but this list is likely to expand. Each interleukin is unique 
although it is possible that some of their activities may overlap. Characterisation of the 
interleukins has enabled immunologists to confirm that these proteins act on the immune 
system in much the same way as the classical hormones and their receptors act on the 
endocrine system.
Interleukin-2 (IL-2) was the first hormone of the immune system to be discovered and 
characterised (Gillis, 1978) and has a crucial role to play in the generation of an 
effective immune response. If peripheral blood mononuclear cells were challenged with 
a mitogen (phytohemagglutinin (PHA)) then a supernatant was obtained that can support 
the continual growth of T-cells (Morgan, 1976). This supernatant contains T-cell 
growth Factor (TCGF) which is now known as IL-2. In the context of an immune 
response, IL-2 mediates the clonal expansion of antigen activated T-cells.
Interleukin-1 (IL-1) is produced by many cell types including fibroblasts, endothelial 
cells, keratinocytes and smooth muscle. However by far the most important source of 
IL-1 is the monocyte/macrophage (Mizel, 1989). IL-1 has a broad range of functions to 
perform in the immune response. These include regulation of various aspects of T and 
B lymphocyte development and function, induction of interleukins and interleukin 
receptor synthesis and expression, and lymphocyte proliferation(Mizel, 1988; Dinarello, 
1984; Shirakawa, 1986). Clearly IL-1 has an important role to play in the immune 
system, but, it is also involved in bone remodelling.
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The Interleukin Family
Interleukin Previous Names
IL-1 Endogenous Pyrogen (EP)
Lymphocyte Activating Factor (LAF) 
Leukocyte Endogenous Mediator (LEM) 
Catabofin
Mononuclear Cell Factor (MCF)
IL-2 T-Cell Growth Factor (TCGF)
T-Cell Maturation/Stimulating Factor (TMF/TSF) 
Killer Helper Factor (KHF)
T-Cell Replacing Factor (TRF)
IL-3 Multiple Colony Stimulating Factor (Multi - CSF)
IL-4 B-Cell Factor I (BCGFI)
IL-5 B-Cell Factor II (BCGFII)
Eosinophil Differentiation Factor (EDF)
IL-6 Hybridoma Growth Factor (HGF)
Interferon 02 (TFN02)
B-Cell Stimulatory Growth Factor (BSF-2)
26 kDa protein
Hybridoma/Plasma-cytoma Growth Factor (H/PGF) 
B-Cell Differentiation Factor (BCDF)
B-Cell Stimulatory Factor p2 (BSFp2)
IL-7 B-Cell Growth Factor (BCGF)
IL-8 Neutrophil-Activating Peptide-1 (NAP1)
IL-9 Mast Cell Growth Factor P40
IL-10 ThI Cytokine Synthesis Inhibitor
TABLE 1.3.1.
The Interleukin Family : The table presents the defined interleukins and their previous 
names giving a strong indication as to their function. The previous name refers to how
i
! these factors have been described in the scientific literature.
2 0
Interleukin-6 (IL-6) is an immune hormone that has a broad range of cell targets. Like 
IL-1, IL-6 is produced by many cell types including fibroblasts, monocyte/macrophages, 
endothelial cells, T and B cells, mesangial cells, keratinocytes and a number of tumour 
types (Mizel, 1989). IL-6 production is stimulated by IL-1, tumour necrosis factor a  
(TNF a), platelet derived growth factor (PDGF), virus infection, double stranded RNA 
and cyclic AMP. In the immune response IL-6 influences the growth and differentiation 
of T and B lymphocytes. IL-6 is involved in the conversion of T-cells into an IL-2 
responsive state. IL-1 and IL-6 can be seen to be strongly synergistic in the induction of 
T-cell proliferation.
Although IL-1, IL-2 and IL-6 have been described above it is equally important to 
realise that the other interleukins also have important roles to play in an immune 
response.
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1.4. VITAMIN D AND THE IMMUNE SYSTEM.
1.4.1 Vitamin D - Not just a calcium homoeostatic steroid hormone.
The role of vitamin D on calcium homeostasis is well documented. The active form of 
the steroid hormone, l,25(OH)2D3, acts on the target tissues, intestine, bone and kidney, 
to mobilise calcium. As expected these so called target tissues were found to be rich in 
vitamin D receptors (VDR). However, as techniques for measuring VDR's improved it 
became apparent that many other cell types expressed these receptors. This led to an 
appreciation of the universal scope of 'the vitamin D endocrine system1.
It has long been suspected that there was a link between the vitamin D endocrine 
system and immune responses. Urist and McLean (Urist, 1956) observed that in rats on 
a low calcium / vitamin D diet there was a several hundredfold increase in their mast 
cells within the bone marrow. This was clearly evidence for involvement of vitamin D 
in some aspects of haematopoiesis. Clinical observations in rickets supported this 
theory. The rachitic patient exhibits anaemia, myelofibrosis and extramedullary 
haematopoieisis, and these are corrected by vitamin D therapy (Yetgin, 1982). Also of 
note was the observation that children with rickets were more susceptible to infections 
(Stroder, 1975). Investigation of these children revealed that they exhibit sub normal 
phagocytosis and reduced neutrophil motility (Yetgin, 1982).
1.4.2. Vitamin D receptor distribution - Universal ?
A detailed search for vitamin D receptors (VDR's) in various tissues revealed 
widespread distribution. Nearly every vertebrate cell type possessed these high affinity 
VDR's. Of particular interest was the discovery of VDR's in the cells of the immune 
system. The demonstration that monocytes and activated, but not resting, lymphocytes 
possess VDR's led to the hypothesis that l,25(OH)2D3 may play a role in 
immunoregulation (Provvedini, 1983; Bhalla, 1983). VDR's were not restricted to
mature cells and are found for example to be present in mitotically active thymoblasts 
(Ravid, 1984).
1.4.3. Vitamin D - A differentiation factor.
The widespread distribution of VDR's and in particular their presence on some tumour 
cells suggested a role for vitamin D in cell differentiation. In 1981, it was reported that 
l,25(OH)2D3 induced the differentiation of both a murine (Abe, 1981) and a human 
myeloid leukemic cell line (Miyaura, 1981), and that this occurred within the normal 
physiological range for this metabolite. The two cell lines involved were the mouse 
myeloid leukaemia cell line (Ml) and the human promyelocytic leukaemia cell line 
(HL60). Interestingly the differentiated product was different in each case : Ml were 
differentiated down to macrophages whereas HL60 were differentiated to granulocytes. 
Further evidence for a role in myeloid differentiation comes from work on a human 
monocytic cell line, U937. This cell line was also induced to differentiate by 
l,25(OH)2D3 to macrophages (Amento, 1984). Although it was clear that l,25(OH)2D3 
had anti-tumour activity in vitro it was not until 1983 that an anti-tumour effect was 
demonstrated in vivo. Work carried out on nude mice, by a group in Japan, revealed that 
the survival time of mice inoculated with Ml cells was prolonged by administration of 
either l,25(OH)2D3 or its synthetic analogue, l a  hydroxyvitamin D3 ( la  OH D3) 
(Honma, 1983).
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1.4.4. Extra-renal synthesis of l,25(OH)2D3.
It was now well established that the principle site for the synthesis of l,25(OH)2D3 
was the kidney (Fraser, 1970). Until recently, the only other source of l a  hydroxylase 
activity was in the placenta (Gray, 1979). However, it is now apparent that more 
widespread extra-renal synthesis exists and may be an important factor in the context of 
the local environment A major new insight was provided in 1981 with a case report 
describing an anephric individual with hypercalcemia and elevated l,25(OH)2D3 who 
was diagnosed to have sarcoidosis (Barbour, 1981). This disorder is granulomatous in 
nature and of unknown etiology. Following this observation it was found that sarcoid 
lymph node homogenates and alveolar macrophages possessed l a  hydroxylase activity, 
and that this may account for the raised l,25(OH)2D3 and consequently the 
hypercalcemia (Adams, 1983; Mason, 1984). The substrate specificity and enzyme 
affinity for 25(OH)D3 of this l a  hydroxylase was indistinguishable from those reported 
for the renal enzyme (Adams, 1985). Significantly, in patients with sarcoidosis, the 
degree of hypercalcemia correlates with the Vmax of alveolar macrophage l a  
hydroxylase activity measured in vitro (Adams, 1985). As a consequence monocytes 
and macrophages from normal individuals were studied to see if they possessed l a  
OHase activity. Both l a  OHase and 24 hydroxylase activity could be demonstrated in 
monocytes/macrophages cultured in the presence of either lipopolysaccharide (LPS) or 
interferon-y (IFN-y) (Koeffler, 1985; Reichel, 1987). Clinical data suggests that l a  
OHase can be induced by various other stimuli such as infection and foreign body 
reactions (Kozeny, 1984; Felsenfeld, 1986).
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1.4.5. l,25(OH)2D3 - A novel immunoregulatory hormone.
As a consequence of the distribution of vitamin D receptors and the extra-renal 
synthesis of l,25(OH)2D3 it became obvious that l,25(OH)2D3 must have a wider 
biological role than was first envisaged. In 1984, Tsoukas et al presented data that 
demonstrated l,25(OH)2D3 at picomolar concentrations inhibited cell proliferation and 
interleukin-2 activity (Tsoukas, 1984). They discussed the potential mechanism by 
which l,25(OH)2D3 mediates this effect. Several possibilities were discussed;
(1) l,25(OH)2D3 may act directly on the synthesis of IL-2 or on the secretion of IL-2
or both.
(2) l,25(OH)2D3 may increase consumption of IL-2 by increasing production of the
receptor for IL-2 either through transcription or post translational mechanisms.
(3) l,25(OH)2D3 may inhibit IL-2 by acting on the differentiation pathway of
suppressor lymphocytes.
It is these possibilities that are addressed in this thesis. Evidence from Lemire et al 
suggested that l,25(OH)2D3 inhibited both IgG and IgM production. They also 
confirmed the effect on cell proliferation (Lemire, 1984). Taken together these findings 
provide a strong case for a role for l,25(OH)2D3 in the regulation of the immune 
response.
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The precise nature of this role of l,25(OH)2D3 in the immune system remains to be 
clarified. It appears that l,25(OH)2D3 inhibits RNA synthesis between early and late G1 
in the cell cycle (Manolagas, 1986). It also transpires that l,25(OH)2D3 appears to 
mediate its antiproliferative effect through both IL-2 dependent and IL-2 independent 
mechanisms (Rigby, 1985). Furthermore, it has been suggested that l,25(OH)2D3 may 
inhibit the mRNA for IL-2 but have little effect on IL-2 receptor (IL-2R) (Rigby, 1988). 
l,25(OH)2D3 appears indirectly to regulate B-cell growth and differentiation through its 
effects on T-cells (Lemire, 1985), but effects on B-cells have to be further characterised.
The influence of l,25(OH)2D3 on the immune system is not restricted to cells of 
lymphoid origin. As discussed previously monocyte/macrophage possess vitamin D 
receptors and are capable of producing l,25(OH)2D3. l,25(OH)2D3 appears to promote 
the fusion of macrophages and augment Fc receptor expression and cytotoxic function 
(Abe, 1984). The production of l,25(OH)2D3 by monocytes may be of importance in 
the local environment, where it can induce heat shock proteins thereby protecting 
monocytes in the situation of thermal stress brought on by tissue inflammation (Polla, 
1986). It has also been reported that l,25(OH)2D3 increased IL-1, PGE2 and TNF 
production by monocytes.
1.4.6. l,25(OH)2D3: The future.
l,25(OH)2D3 may play a unique role functioning as both an endocrine and a paracrine 
hormone, in distinct biological systems. These roles may both be mediated via 
1,25(OH)2D3's immunomodulatory activity. In the context of mineral metabolism, 
l,25(OH)2D3 treated monocytes produce increased amounts of IL-1, TNF and PGE2 all 
of which can induce bone resorption. Also l,25(OH)2D3 can block IFN-y which has the 
effect of mobilizing calcium from bone (Rigby, 1988). Taken together the overall effect 
of l,25(OH)2D3 in the immune system on bone skeleton is bone resorption and increased 
calcium mobilisation.
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l,25(OH)2D3 and in particular its synthetic analogue l a  OH D3 have emerged as 
possible therapeutic agents in immunoregulatory disorders. However, treatment of 
myeloproliferative disorders with l,25(OH)2D3 has been far from convincing (Koeffler, 
1985). On the positive side, some low grade lymphomas responded to treatment 
(Cunningham, 1985). The most convincing benefits have been seen in the treatment of 
psoriasis with l,25(OH)2D3, a skin disease characterised by disturbed epidermal cell 
proliferation and altered cell mediated immune responses (Morimoto, 1986). The next 
step forward would be the development of l,25(OH)2D3 analogs without the problems 
associated with hypercalcemia. These analogs if available would be important 
immunosuppressors that do not have the toxicity of present regimes such as 
glucocorticoids and cyclosporin A therapy.
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CHAPTER 2.
MATERIALS AND METHODS.
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2.1 NORMAL VOLUNTEERS.
Peripheral blood mononuclear cells (PBMC) were obtained from a pool of normal 
healthy volunteers. This pool included staff from the laboratory, wards and clinics. In 
general wherever possible the work was carried out on males.
Blood was obtained by venepuncture and collected into a universal containing 300
i.units of preservative-free heparin (final concentration in blood; 20 i.units/ml, Leo 
Laboratories).
2.2 CELL SEPARATION.
2.2.1. Peripheral Blood Mononuclear Cells (PBMC).
PBMC's were separated by density gradient centrifugation using a modification of the 
method originally described by Boyum (Boyum, 1964, 1968) (see figure 2.2.1). 
Heparinised blood was diluted 1:1 with Eagles minimum essential medium (MEM) and 
layered on to an equal volume of lymphoprep ™ (Nyegaard and Co., Oslo, Norway) in 15 
mis. plastic conical tubes (diameter 12mm., Starstedt). Following centrifugation at 500 
x g for 30 minutes at room temperature, the mononuclear cell bands at the lymphoprep / 
plasma interface were removed using a Pasteur pipette (see figure 2.2.2). The band from 
two tubes were pooled and washed three times in MEM by centrifugation at 400 x g for 
10 minutes at 4 °C, and the cell pellet resuspended in 1 ml cell culture medium. The cell 
number was assessed in 10 |il aliquot of cells stained with 90 fil of white cell staining 
fluid (2% glacial acetic acid, a few grains of crystal violet in phosphate buffered saline 
(PBS)) and counted in a standard haemocytometer (Improved Neubauer). The cell 
suspension was stored on ice until required.
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Peripheral Blood Mononuclear Cell Separation
HEPARINISED
BLOOD
Media(MEM)
mix 1:1 and layer 
onto LYMPHOPREP
T
centrifuge;500 x g 
30 minutes at room temperature
pipette off LYMPHOCYTES 
\
wash three times in RPM11640 
(400 x g, 4 oC, 10mins)
Count cells 
\
resuspend cells in 
Complete media at 
required cell density
'  r
ASSAY 
FIGURE 2.2.1
The protocol for separating PBMC's by density gradient centrifugation over 
Lymphoprep™ as outlined by Boyum.
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Peripheral Blood Mononuclear Cells Separation - 
layered on Lymphoprep
BLOOD
(heparinised)
LYMPHOCYTES
(PBMCs)
centrifugation
Lymphoprep
RED CELLS
FIGURE 2.2.2.
Diagrammatic representation of the procedure for separating PBMCs over 
lymphoprep ™. The situation before centrifugation is represented on the left 
hand side and the end result of centrifugation is represented on the right hand 
side.
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2.2.2 Lymphocyte sorting - CD4+ve and CD8+ve.
The technique employed to separate out the required subsets from a mixed population 
of PBMCs was a commercially available immunomagnetic separation system (IMS). 
This system was preferred to the alternative panning technique which was initially used. 
The panning technique involved absorbing monoclonal antibodies against the 
appropriate antigenic subset onto polystyrene plates. The required population could be 
attained by either a positive or a negative selection procedure. Although the subsets 
could be pulled out using this method the yield was not satisfactory and consequently 
the commercial IMS was employed. The principles of the IMS were quite 
straightforward ; one has a uniform sized particle that has a magnetised core and is 
coated with a specific monoclonal antibody. These particles are incubated with a cell 
population, the coating antibody recognises a specific cell surface antigen and binds to 
the cell. A magnetic field is applied and the cells that have particles attached to them 
are attracted to the magnet, thereby separating this cell population from the rest.
The products Dynabeads ® M450 CD4, T heiper/inducer and Dynabeads ® M450 CD8, T 
cytotoxic/suppressor were obtained from Dynal (U.K.) Ltd., 24 - 26 Grove street, New Ferry, 
Wirral L62 5 AZ. Each particle is coated with a mouse monoclonal that recognises 
either a single chain 55 - 65 kd cell membrane glycoprotein in the case of CD4 or a 
double chain 32 - 43 kd cell membrane glycoprotein for CD8. Both the CD4 and the 
CD8 antigens were designated such at the First International Workshop and Conference 
on Human Leukocyte differentiation antigens.
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PBMCs were separated out as previously described in section 2.2.1.. After the final 
wash the PBMCs were resuspended in PBS + 1% FCS at a cell density of 3 x 106 
cells/ml. In order to have approximately the same number of target cells for the 
Dynabeads ® M450 CD4 and the Dynabeads ® M450 CD8, the cell suspension was split 
in a ratio of 1:2 and added to 15mls. polypropylene tubes (Bibby, U.K.). The 
Dynabeads ® were washed three times in PBS + 1% FCS, the particles retained by the 
Dynal ® Magnetic Particle Concentrator (MPC), the magnetic field was applied for two 
minutes and the wash fluid was pipetted off. Having been washed the magnetic beads 
were resuspended in their original volume of PBS + 1% FCS. Manufacturers 
recommendations for gradient cells were that there should be a ratio of 3:1 (beads:cells). 
One the basis of this the beads were added to the appropriate tubes and incubated at 4 °C 
for 10 - 20 minutes for CD 8 and for 30 minutes for CD4. The incubation was preformed 
on a rotating drum. The rosetted cells were separated by placing the polypropylene tube 
in the MPC for 2 - 3 minutes. The supernatant was aspirated out and can be kept to 
represent a depleted population, the rosetted cells are located on the walls of the tube 
held there by the magnetic field. The rosetted cell population is then washed a further 
five times with PBS + 1% FCS. The cells were resuspended in culture fluid, RPM I1640 
+ 20% FCS, and counted. The resuspended cells were stored on ice until required.
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2.3. CELL LINES.
2.3.1. HT-2.
The HT-2 cell line was obtained from the Cetus Corporation, 1400 Fifty-third Street, 
Emeryville, California 94608, U.S.A.. The cells were maintained at a cell density of 4 x 
104 cells/ml in RPMI 1640 supplemented with 10% FCS, 20 units/ml recombinant IL-2 
(rIL-2) (BCL, Boehringer Mannheim House, Bell lane, Lewes, East Sussex BN7 1LG) 
and 2 x 10 5 M 2-P-mercaptoethanol (20 mM stock made up in PBS). The cells were 
split and fed every 48 hours. HT-2 cells are derived from murine T helper cells, more 
specifically from the strain BalbNc (Watson, 1979). The cells are dependent on either 
murine, rat or human IL-2.
2.3.2. LBRM TG6.
The LBRM TG6 cell line was also obtained from the Cetus Corporation. The cells 
were maintained at a cell density of 105 cells/ml in Iscove's modification of Dulbecco's 
MEM (IDMEM) + 10% FCS. LBRM TG6 is a subclone of LBRM 33 (Larrick, 1985). 
The cells are resistant to both 5 x 10 5 M 8 azaguanine and 2 x 10 5 M 6 thioguanine, and 
the cells died when cultured in conventional HAT and in hypoxanthine/azaserine 
supplemented medium. LBRM TG6 produce IL-2 only in the presence of lectin and IL- 
1.
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2.3.3. B9.
B9 cells were a gift from Dr Lucien Aarden, Central Laboratory of the Netherlands, Red 
Cross Blood Transfusion Service. The B9 were maintained at a cell density of 4 x 104 
cells/ml in Iscoves Modified Dulbecco's MEM, 5% FCS, 5 x lO5 M mercaptoethanol, 
penicillin and streptomycin (Aarden, 1987). The cells were further supplemented with 8 
units/ml Hybridoma growth factor (HGF, Jansen). B9 may also be cultured in RPMI 
1640.
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2.4 MEDIA.
2.4.1. Rosewell Park Memorial Institute (RPMI) 1640.
RPMI 1640 (10 x) was obtained from Gibco, BRL and the culture media was prepared 
as per manufacturers instructions. Distilled/deionised water (ddH20) was autoclaved for 
20 minutes at a temperature of 120 0 C and a pressure of 1.2 kg/cm2. The ddH20  was 
allowed to cool before the RPMI 1640 (10 x) was added, sodium bicarbonate (7.5%, 
Gibco, BRL) was added to give either a final concentration of 2 g/1 in the case where it 
is to act as a CO2 buffer as well as a nutrient or a final concentration of 0.85 g/1 where 
N-[2-Hydroxyethyl]piperazine-N-[2ethanesulphonic] acid (HEPES) is the CO2 buffer of 
choice. HEPES (1M, Gibco, BRL) was added to the media to give the concentration of 
choice (usually 10 mM). Finally the various supplements were added as detailed 
elsewhere in the text, these were added prior to use. The bottle of media is then adjusted 
to the correct pH (between pH 7.2 and pH 7.4) by addition of either HC1 or Na OH.
2.4.2. Minimum Essential Medium with Hanks salts (MEM).
This media is a multi-purpose media that is used principally in this instance for washing 
cells (see section 2.2.1.). The media was prepared in a similar fashion to RPMI 1640. 
Distilled/deionised water was autoclaved and Hanks Balanced Salt Solution (10 x) 
(HBSS, Gibco, BRL) was added to the water after it had returned to room temperature. 
Amino acids (50 x, Gibco, BRL), Vitamins (MEM , 100 x, Gibco, BRL) and 20 mM 
HEPES were added to the water. Sodium bicarbonate (7.5%) was added to give a final 
concentration of 0.375 g/1. Prior to use 2mM glutamine (200 mM, Gibco, BRL) and 50 
units/ml/50 pg/ml penicillin/streptomycin ((100 x), Gibco, BRL) were added to the 
media. The pH of the media was then adjusted to between pH 7.2 and pH 7.4.
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2.4.3. Iscoves Modified Dulbeccos Medium (IMDM).
IMDM (lx, Gibco, BRL) was obtained as prepared media that was almost ready to use. 
As with other media the glutamine (200 mM) and the Penicillin/streptomycin were 
added prior to use.
2.4.4. Glutamine.
Glutamine (200 mM) was added to the bottle of media immediately prior to use. The 
reason for this is to do with the half-life of glutamine. Glutamine has a half-life in the 
order of 19 days at 4 °C, so it is important to replenish the glutamine lost. A rough 
calculation indicated that after 7 days at 4 °C only 80% of the original glutamine would 
be intact It is for this reason that glutamine was added every week to bottles of media 
in use for longer than a week to make up for this shortfall. Glutamine was an essential 
nutrient and energy source for the growing cell. Stock glutamine was for this reason 
stored at -20 °C.
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2.5. CALCIOTROPHIC HORMONES.
Calciotrophic hormones are naturally occurring substances that act to regulate calcium. 
Five calciotrophic hormones were studied as a group: 1,25 dihydroxyvitamin D3 
(l,25(OH)2D3), 24,25 dihydroxyvitamin D3 (24,25(OH)2D3), 25 hydroxyvitamin D3 
(25(OH)D3), parathyroid hormone (PTH) and calcitonin (CT).
2.5.1. The vitamin D metabolites.
All three D metabolites, l,25(OH)2D3, 24,25(OH)2D3 and 25(OH)D3, were obtained as a 
gift from Hoffman La Roche. The D metabolites were stored as ethanolic solutions. 
The concentration of each of the stock solutions were assessed by spectrophotometry. A 
working stock of lO5 M was set up for each of the metabolites in ethanol (Analar grade, 
BDH). Subsequently, each working stock underwent a ten fold dilution in ethanol to 
produce ranges that ran from 10 5 M to 1011 M.
2.5.2. Parathyroid Hormone.
Bovine (1-35) parathyroid hormone (b(l-35)PTH) was used as replacement for full 
length human PTH. The b(l-35)PTH fragment is biologically active in all human 
systems thus far studied. The b(l-35)PTH was purchased from the Sigma Chemical 
Company, U.K.. The b(l-35)PTH was dissolved in lOmM acetic acid/0.1% bovine 
serum albumin (BSA) to give a working solution of 105 M. The working stock was 
diluted in a ten-fold manner in acetic acid/0.1% BSA to produce a range from 10 5 M to 
10 11 M.
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2.5.3. Calcitonin.
Salmon calcitonin (sCT) was used and was supplied by Rorer Pharmaceuticals, U.K.. 
The concentration of the vials supplied was calculated to be 7.8 x 10-6 M. The sCT was 
present as a saline acetate solution and the working solution was as it was supplied. The 
range was constructed by an initial dilution (7.8 fold) to give a 10-6 M followed by ten­
fold dilutions to complete the range (10-6 M to 1011 M).
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2.6. SEX HORMONES.
Three sex hormones were studied as a group : oestrogen, progesterone and 
dihydrotestosterone (DHT). All these hormone preparations were active both in vivo 
and in vitro. These hormones function within the endocrine system to control 
reproduction. However, they have also been implicated in other physiological systems.
2.6.1. Oestrogen.
Oestrogen is a female sex hormone that exerts dominant control over the development of 
all the accessary sex organs and secondary sex characteristics. Oestrogen was obtained 
from the Sigma Chemical company, U.K.. Oestrogen was purchased as a lyophilised 
product and it was reconstituted in ethanol to give a working stock of 10 5 M.
2.6.2. Progesterone.
Progesterone is also a female sex hormone that is present in significant amounts during 
the luteal phase of the menstrual cycle. Progesterone was obtained from the Sigma 
Chemical Company, U.K.. The progesterone was purchased as a lyophilised product 
and reconstituted in ethanol to produce a working solution of 10*5 M.
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2.6.3. Dihydrotestosterone.
Testosterone is the male sex hormone that is required among others for spermatogenesis. 
In man, virtually all the obvious masculine secondary sex characteristics are testosterone 
dependent Dihydrotestosterone is the biologically active form of testosterone found in 
the body. DHT was obtained from the Sigma Chemical Company, U.K.. The DHT was 
purchased as a lyophilised product and reconstituted in ethanol to produce a working 
solution of lO5 M.
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2.7. LYMPHOCYTE ACTIVATION (MITOGENESIS).
Lymphocyte activation by mitogens provide a means of looking at immune function. 
The lymphocyte activation assay along with cytokine assays provide a baseline 
evaluation of immune function.
2.7.1. Cell Preparation.
Venous blood was added as aseptically as possible to a universal containing 
preservative-free heparin such that the final concentration was of the order of 20 
units/ml (see section 2.1.). The heparinised blood was mixed in a ratio of 1:1 with 
MEM. Peripheral blood mononuclear cells are separated by density gradient 
centrifugation over Ficoll - Hypaque, washed 3 x in MEM and resuspended in 1 ml 
RPMI 1640 media (see section 2.2.1.). The cells were counted and resuspended at (a) 
106 cells/ml and (b) 2 x 106 cells/ml in complete RPMI 1640 (without HEPES) 
supplemented with 20 % pooled human sera (PHS). Complete media consists of RPMI 
1640 with Glutamine, pen/strep and sodium bicarbonate.
2.7.2. Mitogens.
Three distinct mitogens were used in the system, phytohaemagglutinin (PHA), 
concanavilin A (ConA) and pokeweed mitogen (PWM). Each new batch of mitogen 
was calibrated to check the optimum stimulating concentration (see section 3.3.).
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Phytohaemagglutinin (PHA).
PHA is a lectin extracted from kidney beans (phaseolus vulgaris), it is a TH cell 
mitogen. PHA (Sigma Chemical Company, U.K.(Cat No L-9132)) was resuspended in 
sterile deionised water to give a stock solution of 1000 fig/ml. PHA stock was aliquoted 
and stored at -20 °C. Prior to use an aliquot of stock PHA was further diluted in 
complete RPMI 1640 (without PHS) to give a working concentration of 10 |Lig/ml (a 
100-fold dilution).
Concanavilin A (ConA).
Con A is extracted from jack beans (conavalia ensiformis), it is a T§ cell mitogen. ConA 
(Sigma Chemical Company, U.K.(Cat No C-2010)) was resuspended in sterile deionised 
water to give a stock solution of 5 mg/ml. ConA stock was aliquoted and stored at -20 
°C. Before use an aliquot of the stock was further diluted in complete RPMI 1640 
(without PHS) to produce a working stock of 100 |Xg/ml (a 50-fold dilution).
Pokeweed Mitogen (PWM).
PWM is extracted from pokeweed roots (Phytolacca americana), it is a T-cell dependent 
B-cell mitogen i.e. it activates B-cells only in the presence of T-cells. PWM (Sigma 
Chemical Company, U.K.(Cat No L-9379)) was prepared at a concentration of 50 
|ig/ml in complete RPMI 1640 (without PHS), aliquoted and stored at -20 °C. Prior to 
use an aliquot of the stock was further diluted to give a working concentration of 0.2 
|Lig/ml ( a 250-fold dilution) in complete RPMI 1640 (without PHS).
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2.7.3. Cell Culture.
The lymphocyte activation assay was set up in 96 well, U-shaped microtiter plates 
(Bibby Sterlin Ltd., U.K.) (see figure 2.7.1.). All cultures were set up in triplicate and in 
a final volume of 200 pi. Each well contains 100 pi of cells and 100 pi of mitogen. In 
the case where PWM is the mitogen the stock cells were the cells resuspended at 2 x 106 
cells/ml. The cultures were incubated at 37 °C in a humidified atmosphere of 5 % 
CCk/Air for a total of 72 hours.
2.7.4. Labelling and Harvesting.
The most commonly used method of detecting lymphocyte activation is the 
incorporation of tritiated thymidine (3H-thy) into deoxyribonucleic acid (DNA), which 
correlates well with the number of lymphocytes in the S-phase of the cell cycle. The 
working stock contains 50 pCi 3H-thy (Cat No TRK 418, Amersham International p.l.c., 
U.K.(lmCi/ml)), 50 pM 'cold' thymidine (stock 5mM) (Sigma Chemical Company, 
U.K.) and complete RPMI 1640 (without PHS). The equivalent of 1 pCi was added to 
each well (20pl) at 68 hours. The cultures were incubated in the presence of the label 
for further four hours.
After 72 hours the microtiter plates were harvested on a Titertek cell harvester 
(manufactured by Skatron for Flow Laboratories). The cell harvester transfers the cells 
from the wells to clearly defined discs on a glass-fibre filter mat (Skatron Ltd., U.K.) 
and unbound 3H-thy passes through the filter into the reservoir. The filter mats 
containing the cells were gently covered with two changes of 5 % trichloroacetic acid 
(TCA) (Sigma Chemical Company, U.K.) for ten minutes followed by two changes of 
methanol (A.R. Quality, James Burrough (FAD) Ltd., U.K.).
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Lymphocyte Activation
96-WELL MICROTITER 
PLATE
Each well contains in 200 | i l ; 
1 .Cells ; 105 cells(PHA & ConA)
CULTURE 
68 HOURS, 5% CO2  /AIR, 37°C
CULTURE 
4 HOURS, 5% CO2  /AIR, 37°C
2 x 1 0  cells(PWM)
2.M itogen; PHA(5 pg/ml) 
ConA(50 pg/ml) 
PWM(0.1 pg/ml)
3.Test substance
LABEL
ADD 1 (iCi 3H-thymidine 
to each well
HARVEST;
TITERTEK CELL HARVESTER
CALCULATE
THE CPM AND THE 
STIMULATION INDICES
TRANSFER
DISCS TO SCINTILLANT
I
COUNT
ON RACKBETA COUNTER
FIGURE 2.7.1.
The protocol for performing the lymphocyte activation assay. The assay has a 
total culture time of 72 hours. The method for detecting lymphocyte 
proliferation was thymidine incorporation.
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The discs containing the radioactive material were removed from the filter mats and 
placed in clearly labelled minivials (Pony Vials, Canberra Packard International S.A., 
Switzerland) and allowed to dry. The scintillation fluid was prepared by adding 4 grams 
of 2,5 Diphenyloxazole (Scintillation Grade (PPO), United Technologies Packard, U.K.) 
to one litre of methylbenzene (Pronalys A.R. (toluene), May & Baker, U.K.). Three mis 
of scintillation fluid were added to each vial, the vials were then counted on a LKB 1216 
Rackbeta II liquid scintillation counter (Pharmacia U.K.). The counter was programmed 
to measure low energy beta emissions.
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2.8. THE MEASUREMENT OF INTERLEUKIN - 2 (IL-2).
Assays for IL-2 fall into two main categories : the bioassay and the enzyme linked 
immunoabsorbant assay (ELISA). For practical as well as historical reasons the 
bioassay is the assay of choice with most researchers. In general, bioassays measure the 
proliferative effect of IL-2 on particular responsive cells. In the search for a suitable 
assay the following responsive cells were evaluated:
(i) Human lymphoblasts derived from PBMCs stimulated with ConA and cultured for 
ten days
(ii) Mouse splenocytes stimulated with ConA and cultured for ten days
(iii) The murine T-helper cell line, HT-2
Although all three options produced a suitable IL-2 assay (see section 4.3 for evaluation) 
the HT-2 cell line was the preferred option.
Under normal circumstances ELIS As would be the method of choice for the 
measurement of IL-2. However, the sensitivity of the commercially available ELISA 
kits were not as yet comparable to a good bioassay. An in-house ELISA for IL-2 was 
developed and compared to the commercially available IL-2 ELISA kit (Quantine, R & 
D Systems, Inc., U.S.A.). The in-house ELISA was no better than the commercially 
available kit which in turn was not as sensitive as the HT-2 bioassay.
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2.8.1. Preparation of IL-2 Supernatants.
Venous blood was collected aseptically into a sterile universal containing enough 
preservative-free heparin to give a final concentration of 20 units/ml (see section 2.1.). 
The heparinised blood was mixed with MEM. PBMCs were separated by density 
gradient centrifugation over Ficoll-Hypaque, washed three times and resuspended in 1 
ml complete RPMI 1640 (with HEPES) (see section 2.2.1). The cells were counted and 
resuspended at 2 x 106 cells/ml (see section 4.4.) in complete RPMI 1640 (with HEPES) 
supplemented with 4 % FCS. The cells were stimulated with purified 
phytohaemagglutinin ((PHA), Wellcome Diagnostics, U.K.). The PHA solution was 
made up in complete RPMI 1640 at 2 |ig/ml (see section 4.4.). The PHA solution and 
the cells were mixed in a ratio of 1:1 in a 24 well tissue culture cluster (Bibby Sterlin 
Ltd., U.K.). The cells were cultured for 48 hours at 37 °C in a humidified 5 % C02/Air 
atmosphere. The conditioned media containing IL-2 were harvested by centrifugation at 
400 x g for 10 minutes at 4 °C. The supernatants were removed and passed through a 
0.22 fim sterile filter (Millipore U.K.). The IL-2 containing supernatants were stored at 
-20 °C until assayed.
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2.8.2. IL-2 Bioassay.
The responsive cells in the bioassay were the HT-2 cell line which were derived from 
the murine T helper cells. The cells were maintained in culture by continually seeding 
at 4 x 104 cells/ml (see section 2.3.1.). Twenty-four hours prior to the assay the cells 
were split to 105 cells/ml in fresh media containing recombinant IL-2. The reasoning 
behind this was to maximise yield and to ensure that cells going into the assay were in 
the log phase of their growth curve. On the day of an assay the cells were washed three 
times in complete RPMI 1640 (with HEPES), resuspended at a cell density of 1.5 x 105 
cells/ml in complete RPMI 1640 supplemented with 20 % FCS. The bioassay was set 
up in 96 well, U-shaped microtiter plates (Bibby Sterlin Ltd., U.K.) (see figure 2.8.1). 
Eight serial dilutions of the IL-2 containing supernatants (neat, 1:1, 1:3, 1:7, 1:15, 1:31, 
1:63, and 1:127) were set up in triplicate down the plate (100|il/well). The serial 
dilutions were carried out in complete RPMI 1640 (with HEPES). Cells (100|il) were 
added to each serial dilution which meant that each serial dilution was diluted by a 
further 1:1 and that the final FCS concentration was 10 %. The standard curve was 
constructed by serially diluting recombinant IL-2 ((200 units/ml), B.C.L.) such that 
eleven dilutions were obtained (200, 100, 50, 25, 12.5, 6.25, 3.12, 1.56, 0.78, 0.39 and 
0.19 units/ml). Cells were added (100|il) to each serial dilution. The bioassay was 
incubated at 37 °C in a humidified atmosphere of 5 % C02/Air for 20 hours. At 20 
hours the assay was labelled with 3H-thymidine (see section 2.7.4.) and incubated for a 
further 4 hours at 37 °C in a humidified atmosphere of 5 % C02/Air. The cells were 
harvested on a Skatron cell harvester (see section 2.7.4.) and the discs were counted on a 
LKB rackbeta II counter.
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IL-2 Assay
SERIAL DILUTION 
1 :1
100 pi of previous 
dilution
CULTURE 
20 HOURS, 5% CO 2 /AIR, 37° C
HARVEST;
ADD 1 pCi 3H-thymidine 
to each well
LABEL
96-WELL MICROTITER PLATE 
Each well contains in 200 \i\ ;
1. HT-2 cells; 1.5x10 4 cells 
2.Serial dilution of IL-2 supernates
Each well contains 100 pi of 
complete RPMI 1640 with the 
exception of the first well which 
has no complete RPMI 1640.The 
first and second wells get 100 pi 
of the IL-2 containing 
supernates.The dilutions were 
started at the second well. Each 
dilution was carried out in 
triplicate.
CULTURE 
4 HOURS, 5% CQ2 /AIR, 37° C
COUNT
ON RACKBETA COUNTER
“►  TITERTEK CELL HARVESTER
I
TRANSFER
DISCS TO SCINTILLANT
FIGURE 2.8.1.
The protocol for the IL-2 bioassay utilising the HT-2 cell line. The assay has a 
total culture time of 24 hours. The method for detecting cell proliferation was 
thymidine incorporation.
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2.8.3. Calculation of Results.
A consequence of using the bioassay to measure IL-2 activity in a sample was that a 
simple extrapolation from a standard curve of one value was not feasible. The solution 
to the problem of variation due to biological aspects of the assay to some extent was 
overcome by the use of serial dilutions of the sample and producing an activity curve for 
each sample. The accepted methodology was that 1 unit of IL-2 activity was the amount 
required to produce 50 % maximum activity. The sample can then be compared to the 
standard.
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2.9. MEASUREMENT OF INTERLEUKIN - 1 (IL-1).
The wide range of biological activities attributed to interleukin-1 (IL-1) both in vivo 
and in vitro are considered essential to mount an immune response. This range of 
activities have in turn led to a great variety of methods employed to measure the 
monokine. Probably the most significant of these activities, and for this reason the vast 
majority of bioassays are based on this activity, was the capacity of IL-1 to stimulate T- 
cells to produce IL-2. IL-1 also causes an increase in body temperature in vivo which 
may occur to aid the body's immune response to bacteria and viruses by enhancing the 
effects of IL-1 on T-cell proliferation. Indeed, there have been assays developed that 
assess IL-1 through increases in body temperature, although these assays are fraught 
with reproducibility problems.
Like IL-2 assays, the alternative to bioassays for IL-1 are the ELISA's. IL-1 ELISA's 
are now reaching the stage where they can be considered viable alternatives to the 
bioassay. The commercially available ELISA's are moving towards the sensitivity and 
reproducibility of the better IL-1 bioassays.
A highly sensitive two cell bioassay for detection of IL-1 was used. A commercially 
available ELISA kit (Cistron Biotechnology, Pine Brook, NJ 07058, U.S.A.) for 
measuring IL-lp was also employed on some of the samples to double check that none 
of the effects were assay derived.
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2.9.1. Standard IL-1 Preparation.
The cost of recombinant IL-1 was prohibitive in its use as a standard. The solution 
was to use an in-house IL-1 standard and calibrate this with reference IL-1 standard 
obtained from the National Institute for Biological Standards and Controls, Blanch Lane, 
South Mimms, Potters bar, Herefordshire, EN 63 QG. Sufficient in-house standard was 
prepared to last a significant length of time. PBMCs were obtained from normal venous 
blood as described previously (section 2.2.1.) with a few modifications. After the initial 
centrifugation over lymphoprep™, the autologous serum (plasma:MEM(l:l)) was 
pipetted off into a sterile universal container. The cells were removed and washed three 
times in MEM. After the final wash the cells were resuspended in RPMI 1640 with 
HEPES and counted using a haemocytometer. The cell concentration was adjusted to
1.2 x 106 monocytes/ml, this concentration could be obtained in two ways either by 
assuming a ratio of 1:3 - 4 (monocytes:lymphocytes) and counting the lymphocytes 
(section 2.2.1.) or by specific staining for the monocytes. The cells were resuspended in 
RPMI 1640 with HEPES and 10 % autologous serum (5 % final concentration, bearing 
in mind that the blood was diluted 1:1 with MEM). The monocytes were stimulated 
with 20 ng/ml LPS and cultured for 18 hours at 37 °C in a humidified atmosphere of 5 % 
C02/Air. At the end of the incubation period the cells were pelleted by centrifugation 
(400 x g for 10 minutes). The supernatant was carefully removed and sterile filtered 
through a 0.2 pm single use filter (Millipore (U.K.) Ltd.). The supernatant was assayed 
as soon as possible, and once standardised, the in-house standard was aliquoted into 0.5 
mis. aliquots and stored at -20 °C.
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2.9.2. IL-1 Bioassay.
The bioassay of choice was the sensitive two cell bioassay developed by Larrick 
(Larrick, 1985). The assay system has two distinct advantages over the more commonly 
used lymphocyte activating factor (LAF) assay, it was highly sensitive and the 
incubation period was only 24 hours. The principle behind the assay can be described in 
simple terms. Upon incubation of the LBRM TG6 cell line, a thioguanine resistant 
mutant of the murine lymphoma cell line LBRM 33, with a suboptimal concentration of 
PHA and a given concentration of IL-1 the cells produce IL-2. This IL-2 allows the HT- 
2 cells, an IL-2 dependent cell line derived from murine T-helper cells, to proliferate in 
response. The LBRM TG6 and the HT-2 cells were cocultured. Normally in bioassays 
employing two cell lines the first cell line has to be removed before the second cell line 
is added. However, in this assay both cells can be cocultured thereby lowering the 
incubation time. This was possible because the 6-thioguanine resistant (hypoxanthine- 
guanine phosphoribosyl transferase negative) mutant of the LBRM 33 cell line, LBRM 
TG6, ceases thymidine incorporation in hypoxanthine-azaserine supplemented media. 
Prior to addition of tritiated thymidine, hypoxanthine and azaserine were added to block 
DNA synthesis by LBRM TG6 cells. The incorporation of thymidine then reflects only 
the DNA synthesis by the HT-2 cells thereby a sensitive, short term assay was possible. 
Both the HT-2 cells and the LBRM TG6 cells were maintained in culture as described in 
section 2.3.1. and 2.3.2. respectively. It was important to ensure that both cell lines 
were used in the assay when in the middle of their log growth phase.
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The standard IL-1 preparation was diluted one hundred-fold in RPMI 1640 with 
HEPES. The standard curve was constructed by setting up a further eleven two-fold 
serial dilutions of the IL-1 standard (1/100). The serial dilutions (100 |il) were carried 
out in a round bottomed 96-well microtiter plate (Bibby Sterlin Ltd., U.K.), each 
dilution being set up in triplicate (see figure 2.9.1). The controls were RPMI 1640 ( no 
suboptimal PHA) and RPMI 1640 (with suboptimal PHA). The cells were counted and 
the appropriate number of cells pooled together. The pooled cells were pelleted and 
washed three times in RPMI 1640. The cells were resuspended at 1.5 x 105 HT-2 
cells/ml and 1 x 106 LBRM TG6 cells/ml in complete RPMI 1640 supplemented with 20 
% F.C.S.. At this point 100 pi of cells were added to the control wells that contained 
RPMI 1640 (no suboptimal PHA). PHA was now added to the remainder of the cells at 
a working concentration of 2 jig/ml (final concentration in the assay 1 Jig/ml). The cells 
stimulated with PHA were now added to the remainder of the wells.
The supernatant samples containing IL-1 were diluted five-fold initially. A curve for 
each sample was constructed by serially diluting ten-fold this initial dilution. Each 
sample then consisted of four dilutions (100 |xl) each in triplicate (1/5, 1/50, 1/500 and 
1/5000). The cells stimulated with the suboptimal PHA were added to each well (100 
pi). The assay was incubated at 37 °C in a humidified atmosphere of 5 % CO/Air for 
16 hours.
At 16 hours the LBRM TG6 will have had sufficient time to respond to the IL-1. 
Equal volumes of the azaserine stock (200 p.g/ml, Sigma Chemical Co., U.K.) and 
hypoxanthine stock (2 x 103 M, Sigma Chemical Co., U.K.) were mixed together. Each 
well receives 20 pi of this mixture i.e. 10 |Hg/ml azaserine and 10 4 M hypoxanthine. 
The assay was incubated for a further four hours at 37 °C in a humidified atmosphere of 
5 % CO^Air. This concentration of azaserine reduces thymidine incorporation by 
LBRM TG6 by 99 %.
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IL-1 Assay
SERIAL DILUTION 
1 :10
10 pi of previous 
dilution
Each well contains 100 pi of 
complete medium with the exception 
of the first well which contains 90 pi 
of complete medium. The IL-1 
containing supernate (20 pi) was 
added to the first well and the serial 
dilutions were started at the first well.
Metabolic Block 
Add 10 pi Azaserine 
(200 pg/ml)
10 pi Hypoxanthine
(2 x 1 0  ' 3 M)
CULTURE
16 HOURS, 5% C 0 2 /AIR, 37° C
CULTURE 
4 HOURS, 5% C 0 2 /AIR, 37° C
I
CULTURE
4 HOURS, 5% C 0 2 /AIR, 37° C
COUNT
ON RACKBETA COUNTER
96-WELL MICROTITER 
PLATE
Each well contains in 200 j i l ;
1. HT-2 cells; 1 .5 x 1 0  4cells
2. LBRM TG6 cells; 10 5 cells
3. Serial dilution of IL-1 
supernates
4. Sub-optimal PHA (1 pg/ml)
LABEL 
ADD 1 pCi 3H-thymidine 
to each well
HARVEST;
TITERTEK CELL HARVESTER
TRANSFER
DISCS TO SCINTILLANT
FIGURE 2.9.1.
The protocol for the IL-1 bioassay utilising both the LBRM TG6 and HT-2 cell 
line (Larrick, 1985). The assay has a total culture time of 24 hours. At 16 hours 
a metabolic blocking step is used to prevent the LBRM TG6 cell line from 
proliferating any further. The method for detecting HT-2 cell proliferation was 
thymidine incorporation.
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At 20 hours 1 (iCi of tritiated thymidine was added to each well (section 2.7.4.). The 
tritiated thymidine incorporated was almost exclusively down to the number of HT-2 
cells in the S-phase of the cell cycle. The assay was incubated for a further four hours at 
37 °C in a humidified atmosphere of 5 % CO^Air. The assay was harvested as 
described previously (section 2.7.4.).
2.9.3. Calculation of IL-1 in samples.
The amount of IL-1 present in a sample was calculated in a similar fashion to IL-2 
(section 2.8.3.). A curve was constructed for each sample plotting % maximum against 
reciprocal of dilution. One unit of activity was defined as the point where 50 % 
maximum activity was obtained.
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2.9.4. IL-lp ELISA.
The IL-ip ELISA was supplied in kit form by Cistron Biotechnology, box 2004, 10 
Bloomfield Avenue, Pine Brook, NJ 07058, U.S.A.. The kit was supplied as a microtiter 
plate coated with a monoclonal antibody to IL-lp (anti-IL-lp). The ELISA was carried 
out as outlined in the protocol supplied with the k it Briefly, the samples and standards 
were added to the plate and incubated under cover for 2 hours at 37 °C. The plate was 
washed three times with wash buffer (PBS + 0.02 % Triton X-100 + 0.04 % 
thimerosal). The second antibody (anti-IL-lB polyclonal) was now added to the plates 
and incubated under cover for 2 hours at 37 °C. The plates were washed a further three 
times with wash buffer. The anti-rabbit IgG - HRP (horse radish peroxidase) conjugate 
was added to the plates and incubated under cover at room temperature for 30 minutes. 
The plate was washed three times with the wash buffer. The substrate was added to the 
plate, the substrate was prepared beforehand by dissolving 2 tablets of o- 
Phenylenediamine (OPD) in 10 mis deionised water and hydrogen peroxide (70 fil) was 
added prior to use. The plate was incubated at room temperature for 15 minutes, after 
which the reaction was halted by the addition of 50 fil 4N sulphuric acid. The plate was 
now read at 490 nm on a Dynatech MR 700 microplate reader.
2.9.5. Calculation of results.
The samples were diluted 1 in 10 in complete RPMI 1640 before being used in the 
ELISA. The net optical density (OD) was calculated by subtracting the average NSB 
wells (non-specific binding) from the OD reading obtained for the samples and 
standards. The standard curve was constructed by plotting the net OD against the IL-1 (3 
concentration. The IL-lp in each of the samples was then determined by extrapolation 
from the standard curve.
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2.10. THE MEASUREMENT OF INTERLEUKIN - 6 (IL-6).
Interleukin-6 (IL-6) was a comparative newcomer to the cytokine arena. As such the 
number of bioassays was smaller and the ELISA's were at the developmental stage. IL- 
6 was originally known as hybridoma growth factor (HGF) and this factor was produced 
by human mononuclear leukocytes and acts on hybridoma and plasmacytoma cells.
2.10.1. Preparation of IL-6 Supernatants.
The preparation of supernatants containing interleukin-6 (IL-6) was comparatively 
easy. IL-6 is produced by monocytes and not lymphocytes, there was no need for the 
monocytes to be stimulated but the cells do require the presence of serum. PBMCs were 
obtained as previously described (section 2.2.1.). Briefly, the cells were separated by 
density gradient centrifugation, washed three times with MEM and resuspended in 
RPMI 1640 with HEPES. The cells were counted and adjusted to a final concentration 
of 106 cells/ml. The PBMCs were cultured in complete media supplemented with 5 % 
F.C.S. at 37 °C in a humidified atmosphere of 5 % C02/Air for 18 hours. The cultures 
were set up in 24-well clusters (Bibby Sterlin Ltd., U.K.). At the end of the incubation 
the cells were pelleted (400 x g, 10 minutes, 4 °C) and supernatants sterile filtered. The 
IL-6 containing supernatants were stored at -20 °C until assayed.
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2.10.2. The IL-6 Bioassay.
The bioassay chosen to measure IL-6 was the one based on the B9 cell line. The B9 
cells were maintained in cultured as described in section 2.3.3.. The standard used in the 
IL-6 bioassay was recombinant IL-6 (200,000 international units/ml (~ 20 jig/ml), Koch 
- Light Ltd., Rookwood Way, Haverhill, Suffolk, CB9 8PB). A stock solution of 
recombinant IL-6 was prepared at 400 units/ml. A standard curve was constructed by 
serial two-fold dilutions of this stock solution (100 |il in each well (11 dilutions) in 
triplicate). The samples were also diluted two-fold serially (8 dilutions). The B9 cells 
were counted, pelleted, washed and resuspended at a working concentration of 104 
cells/ml. The cells were added to the standard and samples (100 |il). The assay was set 
up in 96-well round bottomed microtiter plates (Bibby Sterlin Ltd., U.K.) (see figure 
2.10.1). The assay was incubated at 37 °C in a humidified atmosphere of 5 % CC)2/Air 
for 68 hours.
At 68 hours the cells were labelled with tritiated thymidine (section 2.7.4.) and 
incubated for a further four hours. After 72 hours in culture the assay was harvested on 
a Skatron cell harvester (section 2.7.4.) and the discs transferred to vials and counted on 
an LKB Rackbeta II counter.
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IL-6 Assay
SERIAL DILUTION 
1 :1
100 |xl of previous 
dilution
Each well contains 100 pi of 
complete RPMI 1640 with the 
exception of the first well which 
has no complete RPMI 
1640.The first and second wells 
get 100 pi of the IL-6 containing 
supernates.The dilutions were 
started at the second well. Each 
dilution was carried out in 
triplicate
96-WELL MICROTITER 
PLATE 
Each well contains in 200 p,l;
1. B9 cells; 10^ cells
2.Serial dilution of IL-6 supernates
CULTURE
68 HOURS, 5% C 02 /AIR, 37° C
CULTURE
4 HOURS, 5% CO 2 /AIR, 37 C
COUNT
ON RACKBETA COUNTER
LABEL
ADD 1 pCi 3H-thymidine 
to each well
HARVEST;
TITERTEK CELL HARVESTER
I
TRANSFER
DISCS TO SCINTILLANT
FIGURE 2.10.1.
The protocol for the IL-6 bioassay utilising the B9 cell line (Aarden, 1987). 
The asssay has a total culture time of 72 hours. The method for detecting B9 
cell proliferation was either thymidine incorporation or the MTT reaction.
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2.10.3. Calculation of IL-6 data.
As in the case of the other bioassays, the samples are serially diluted to produce a 
curve. The amount of IL-6 was established at the dilution of sample that produced 50 % 
response. The amount is then adjusted by comparing to the standard curve.
2.10.4. Alternative detection of proliferation.
At 68 hours instead of adding [3H]-thy it was possible in this assay set up to use the 
tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
to ascertain the number of live cells. The MTT forms the basis of a colormetric assay, 
the system works because active mitochondria possess enzymes (dehydrogenase 
enzymes) that cleave the tetrazolium ring to yield a coloured product that was purple. 
MTT was obtained from the Sigma Chemical Co. Ltd. and was dissolved in PBS to give 
a concentration of 5 mg/ml. The MTT was added to the assay four hours prior to the 
end of the incubation i.e. at 68 hours. The final concentration of MTT in the assay was 
500 |ig/ml. The incubation was continued to 72 hours. The reaction was halted by the 
addition of 50 |il of a stop solution (10 % Triton x-100 and 0.5N HC1). After the purple 
crystals were dissolved the plate was read on a Dynatech MR 700 microplate reader, 
using a test wavelength (X) of 570 nm, a reference wavelength of 630 nm, and a 
calibration setting of 1.99. The advantage of using this method of detection are two - 
fold, firstly to cut out the need for radioactivity and secondly the volumes of both cells 
and samples can be reduced successfully.
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2.11. THE MEASUREMENT OF SOLUBLE INTERLEUKIN - 2 RECEPTORS (sIL- 
2R).
Soluble interleukin-2 receptors (sIL-2R) concentrations are considered to be a good 
marker for immune system activation. The sIL-2R were thought to be derived from 
proteolytic cleavage of the membrane receptor for IL-2 (tac subunit, p55). The 
activation of the immune system leads to the switching on of the expression of the tac 
subunit which in turn leads to an increase in the amount of sIL-2R released by activated 
cells into the surrounding fluid whether it be serum or tissue culture fluid.
2.11.1. sIL-2R Enzyme linked Immunoabsorbant assay.
The amount of sIL-2R was measured in sera or in cell free tissue culture supernatants. 
The assay is carried out using a sIL-2R test kit supplied by T-cell Sciences, Inc., 840 
Memorial Drive, Cambridge, MA02139. The Cellfree ® Interleukin-2 Receptor test kit 
is based on a sandwich enzyme immunoassay. It was an enzyme linked 
immunoabsorbant assay (ELISA). Basically, the first anti-IL-2R monoclonal antibody 
was absorbed onto a polystyrene plate. The sample or standard was added and bound to 
the coating antibody. An enzyme conjugated anti-IL-2 monoclonal antibody directed 
against a second epitope on the sIL-2R molecule was then added. The second 
monoclonal bound to the captured sIL-2R thereby completing the sandwich. The 
detection involved adding the substrate for the conjugated enzyme and measuring the 
coloured product that was formed. The amount of colour was in proportion to the 
amount of sIL-2R present. The reaction was halted at an appropriate time.
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2.11.2. sIL-2R; The assay.
The protocol for the Cellfree ® interleukin-2 receptor kit was as provided in the test 
kit. Briefly, the plate was coated with anti-IL-2R coating antibody, 100 fil of the coating 
antibody solution was added to each well. The plate was covered and incubated at 4 °C 
for 18 hours (overnight). The coating antibody solution was discarded. The unoccupied 
binding sites on the plastic were now saturated with a blocking buffer. The blocking 
buffer usually contains a protein that binds and fills the unoccupied sites. The blocking 
buffer in this case was as supplied by the manufacturer. Each well was covered and 
incubated with 300 fil of blocking buffer for 2 hours at 37 °C. The plates were now 
ready to use in the assay.
The blocking buffer was discarded and the wells were washed three times with 350 fil 
washing buffer. The washing buffer was made up as per manufacturers instruction from 
a 10 x stock, it was a PBS based buffer. The plates were now ready to receive the 
samples and standards. There were five standards, 0, 100, 400, 800 and 1600 units/ml. 
The standards were carried out in duplicate. Two wells were set aside as blanks. Each 
well used in the assay received 100 fil of sample diluent except for the two blank wells.
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The sample diluent was supplied by the manufacturer and was serum protein in a 
buffered solution. The standards (50 fil) were added in duplicate to the appropriate 
wells, and the samples (50 |il) were added to the remainder of the wells designated to the 
samples. The plate was agitated to mix the contents of each well thoroughly. The plates 
were covered and incubated at 37 °C for 2 hours. The standards and samples were 
discarded and the wells were washed three times with washing buffer (350 fil). The 
HRP - conjugated antibody (100 fil) was added to all wells with the exception of the 
blanks and incubated at 37 °C for 2 hours. About 5 minutes before the end of the 
incubation the substrate solution was made up. Two O-phenylenediamine (OPD) tablets 
were dissolved in 20 mis of substrate diluent (supplied). The substrate diluent contains 
hydrogen peroxide in a buffered solution. The plates were removed from their 
incubation and the contents of the wells discarded, the wells were washed three times 
with 350 fil washing buffer. All wells including the blank wells receive 100 fil of the 
OPD substrate solution. The plates were incubated at room temperature for 30 minutes. 
The reaction was stopped by the addition of 50 fil of the stop solution. The stop solution 
was 2N sulphuric acid ( H2S04) and was prepared by adding 5.8 mis of concentrated 
H2S04 to 94.2 mis distilled water. The plates were now read at 490 nm against the 
substrate blank on a Dynatech MR 700 microplate reader. The plate have to be read 
within two hours of adding the stop solution.
2.11.3. Calculation of Results.
A standard curve was constructed by plotting the concentration of the standard sIL-2R 
in units/ml against the absorbance at 490 nm. The amount of sIL-2R in each sample was 
then calculated using the standard curve.
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2.12. CHARACTERISATION OF MESSENGER RNA (mRNA).
Ribonucleic acid (RNA) has a central role to play in the proposed mode of action of 
the steroid hormone and clearly messenger RNA (mRNA) is the site of the primary 
change in going from a steady state to a regulated state. The mRNA in reality represents 
the phenotype of a cell and as such is a manifestation of the cellular genotype and the 
environment in which the cell finds itself. It is therefore important to characterise the 
mRNA of a controlled cell to determine the importance of regulatory hormones.
2.12.1. Isolation of RNA.
There have been many procedures for the extraction of RNA, but on the whole the 
methods of choice are usually based on the Guanidinium extraction method pioneered 
by Cox (Cox, 1968). Recently it has become possible to extract RNA without the use of 
Caesium Chloride cushions favoured by Chirgwin (Chirgwin, 1979). The method 
chosen was a single step isolation by Acid Guanidinium Thiocyanate Phenol - 
Chloroform (AGPC) extraction (Chomozynski, 1987).
Basically a denaturing solution was prepared that contains 4 M guanidinium 
thiocyanate (Fluka Chemicals Ltd., Peakdale Road, Glossop, Derbyshire SK 13 9 XE.), 
25 mM sodium citrate (BDH) pH 7.0,0.5 % sarcosyl (Sigma Chemical Co. Ltd.) and 0.1 
M 2 - (3 - mercaptoethanol (Sigma Chemical Co. Ltd.). Cells were washed with cold 
PBS and pelleted. The cell pellet (~ 107 cells) was mixed with 1 ml denaturing solution. 
The cell pellets / denaturing solutions were hand homogenised ( about 20 strokes). After 
the cells were disrupted, 100 jal of 2 M sodium acetate (BDH) pH 4.0 was added and the 
solution mixed. At this point 1 ml of water saturated phenol (Rathbum Chemicals Ltd.) 
was added to the mixture. Finally, 200 |il of chloroform / isoamyl alcohol (49 : 1) was 
added and the solution was vortexed for 10 seconds. The solution was incubated on ice 
for 15 minutes.
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The solution was transferred to microcentrifuge tubes and the tubes were centrifuged 
in a microcentifuge at full speed for 15 minutes in the cold room (4 °C ). The solution 
separates into two distinct phases, the aqueous phase contains the RNA and the phenolic 
phase which contains the protein and the DNA. The aqueous phase was pipetted off into 
fresh microcentrifuge tubes (~ 0.5 mis). To the aqueous phase, 0.5 mis of 'cold' 
isopropanol was added. The RNA was precipitated out by incubating this solution on 
dry ice for 30 minutes. The precipitate was pelleted by centrifugation in a 
microcentrifuge at full speed for 15 minutes in the cold room. The supernatant was 
discarded and the RNA pellet was taken up in denaturing solution. At this stage the 
samples were pooled to give a final volume of 300 pi RNA in denaturing solution.
The RNA was then precipitated out again by adding 2 volumes of cold ethanol (600 
pi) and incubating on dry ice for 30 minutes. The RNA was pelleted by centrifugation 
on a microcentrifuge for 10 minutes in the cold room. The RNA pellet was washed 
twice with 1 ml of 'cold' 70 % ethanol. The pellet was then lyophilised and resuspended 
in 60 pi of sterile water and stored at - 20 °C.
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2.12.2. Assessing Quantity and Quality of RNA.
The RNA preparation was run on a 1 % agarose (Gibco BRL) gel to check the quality 
of the RNA. This allows visualisation of in particular the two distinct bands at 18S and 
28S which are produced by the ribosomal RNA (constitutes 80 - 85 % of total RNA). 
There is also a band at 5S but this band is more difficult to see. The amount of RNA can 
be quantified in two distinct ways. The first method is to use the DNA dipstick™ kit 
(distributed by British Biotechnology Ltd., Watlington Road, Cowley, Oxford OX 4 
5LY.). In this procedure it was a case of spotting some nucleic acid onto a strip and 
following the manufacturers instructions and reading the colour of the spot after 
treatment. This method has the advantage that it uses very little sample and the 
disadvantage that it is an estimation by eye of the concentration of a dilution and relies 
on picking the right dilution to measure. The second method is the most commonly 
used, it relies on the optical density (OD) of RNA at 260 nm. The advantage of this 
method is that from the OD an accurate concentration can be calculated. The major 
disadvantages are that the volume of sample is relatively high and the sample once 
measured has usually then to be utilised in the actual analysis of the RNA.
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2.12.3. Northern blot analysis of RNA.
The accepted procedure for analysing RNA is the Northern blot. The northern blot was 
patterned on the Southern blot hence its name. Essentially the nature of the technique is 
to denature the secondary structure of the RNA by mixing the RNA with an agent such 
as formaldehyde that breaks the hydrogen bonds between the base pairs. The outcome 
of this is that the RNA is unfolded and becomes linear. The RNA is then subjected to 
gel electrophoresis, nitrocellulose blotting, hybridisation with a labelled DNA sequence 
complementary to the RNA being studied. The northern blot indicates both the size and 
the presence of a specific mRNA. It also can indicate the amount relative to other 
mRNAs. The procedure is ideal when comparing the amounts of specific RNA 
produced in cells under different conditions.
The RNA sample was prepared for gel electrophoresis as outlined in the protocol 
provided with the Hybridisation transfer membrane (Genescreen Plus™, Dupont). 
Briefly the required amount of RNA was dissolved in an appropriate solution containing 
: 50 % formamide (deionised)(Gibco BRL), 6 % formaldehyde (BDH, U.K.) and 12 mM 
Tris - 6 mM sodium acetate - 0.3 mM EDTA, pH 7.5 (TAE buffer). This solution was 
incubated at 60 °C for 15 minutes. The RNA solution was transferred to ice and stored 
until loaded onto the gel. The gel was prepared by adding 1.5 g of agarose (Gibco BRL, 
U.K.) to 110 mis of distilled water and microwaved until dissolved. The gel solution 
was allowed to cool at room temperature until the temperature of the gel solution 
reached 60 - 65 °C. At this point 15 mis of 120 mM Tris - 60 mM sodium acetate - 3 
mM disodium ethylenediaminetetra - acetate (sodium EDTA), pH 7.5 (10 x TAE) and 
24.3 mis of formaldehyde (final concentration 6 %, BDH, U.K.) were added to the gel 
solution ; the solution was mixed and poured. The gel solution was poured onto an 
appropriate gel cast and allowed to set. The gel was placed in a gel tank that contained 
the electrophoresis buffer ; 12 mM Tris - 6 mM sodium acetate - 0.3 mM sodium EDTA, 
pH 7.5 (TAE). The tracking dye was added (5 |il) to each of the RNA samples (0.01 %
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Orange G in 50 % glycerol and 50 % 2 x TAE buffer). The electrophoresis was set up to 
run for 210 minutes at a voltage of 80 V.
The gel was removed from the gel tank and rinsed briefly with distilled water to 
remove excess formaldehyde. The gel was incubated in 50 mM sodium hydroxide for 
30 minutes to aid the transfer of larger RNA. The gel was neutralised by incubating the 
gel in 50 mM tris, pH 7.0 for 30 minutes. The gel was now ready to blot. The 
genescreen plus™ was cut to size, the bottom right hand comer was marked (care was 
taken to mark the correct side). The genescreen plus™ was wet with distilled water. The 
membrane was then soaked in 1.5 M sodium chloride - 0.15 M sodium citrate (10 x 
SSC) for 15 minutes. A large glass plate was placed on the bench and 2 pieces of filter 
paper (Whatman 3MM) were cut to the same size of this plate. The plate was wet with 
10 x SSC and the filter papers were placed on the glass plate soaking up the 10 x SSC 
and acting as a reservoir. The gel was now placed on top of the filter paper making sure 
that there were no air bubbles and spacers were placed all round the gel. The membrane 
was placed on top of the gel again making sure that there were no air bubbles. Two 
pieces of filter paper identical in size to the gel were then placed on top of the 
membrane. A stack of tissues were placed on top of the filter paper and a small weight 
was placed on top. The transfer was allowed to proceed overnight (about 18 hours). The 
membrane was removed carefully and allowed to dry at room temperature. The 
formaldehyde reaction was reversed by baking at 80 °C for two hours.
The blot was probed with commercially available probes that were labelled in the 
laboratory with radioactive phosphorus (P32). The IL-2 probe was a probe cocktail, an 
equimolar mixture of four exons each 30 or 31 bases in length, supplied by British Bio - 
technology Ltd., U.K.. The IL-2R (Pr - 1) probe was a 40 base antisense synthetic 
oligonucleotide supplied by Oncogene Science, Inc., U.S.A.. The abl probe was 
provided by Dr J. W. Gow, Department of Neurology, Southern General Hospital, 
Glasgow. The probes were labelled by an 5' end labelling technique. The probe to be 
labelled was incubated with the enzyme T4 Polynucleotide kinase (1 jul), T4 kinase 
buffer (21 |il) (including excess Adenosine diphosphate (ADP)) and P32 labelled
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Adenosine triphosphate (3 |il) (ATP). The reaction mixture was incubated for 45 
minutes at 37 °C. At the end of the reaction 170 |il of sterile water was added to the 
mixture. The labelled ATP that was not exchanged was separated from the labelled 
RNA by column chromatography. The reaction mixture was passed down a G 50 
sephadex column (Pharmacia LKB Biotechnology) and the labelled probe fraction 
collected. The unexchanged ATP was retained in the column whereas the probe passed 
through relatively quickly. The column was washed with a further 150 p.1 sterile water 
to flush out as much of the hot probe as possible.
The nitrocellulose blot was sealed into a plastic bag together with 5 mis of the 
hybridisation solution (SSPE (20 x : 175.3g (3 M) sodium chloride, 27.6g (0.18 M) 
sodium dihydrogen phosphate and 7.4g (0.02 M) sodium EDTA pH 7.4), SDS (10 % 
sodium dodecyl sulphate) and salmon sperm DNA ) and incubated for 15 minutes at 63 
°C. This is known as the prehybridisation period and the object of this is to block any 
unoccupied sites with salmon sperm DNA. The labelled probe was then added to the 
bag containing the blot and the bag was resealed and incubated at 63 °C overnight.
The blot was removed from the bag transferred to a sandwich box and washed with 5 x 
SSPE : 0.1 % SDS for 20 minutes at room temperature. The blot was then washed in 1 x 
SSPE : 0.1 % SDS for 20 minutes at room temperature. The blot was removed from the 
box and excess liquid was shaken off and monitored to check the background. The blot 
was placed in bag and sealed in order to retain the moisture. The blot was 
autoradiographed i.e. placed in a cassette together with film at - 70 °C. The film was 
developed and the blot studied.
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CHAPTER 3.
LYMPHOCYTE ACTIVATION - THE EFFECT OF CALCIOTROPHIC AND SEX
HORMONES.
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3.1. LYMPHOCYTE ACTIVATION.
The stimulation of peripheral blood mononuclear cells (PBMC), T and B cells, by non 
specific mitogens or specific antigens provides an insight into immune function. 
Lymphocyte activation is usually seen as the initial stage in evaluating the effects of 
certain parameters on the immune system. The lymphocyte activation assay has the 
advantage of being rapid, reproducible and the assay requires a relatively small amount 
of peripheral blood.
The method used to detect lymphocyte activation was incorporation of tritiated 
thymidine into DNA, which reflects accurately the number of lymphocytes in the S- 
phase of the cell cycle. Cell proliferation may be required for lymphocyte 
differentiation into effector cells, however, care was necessary when interpreting these 
results as cell division is not considered a function per se. Lymphocyte activation can 
generate information about cell phenotype and function.
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3.1.1. Mitogen induced Lymphocyte activation.
Over the last thirty years mitogens have become the agents of choice when it comes to 
assessing lymphocyte activation. Nowell (Nowell, 1960) laid the groundwork for this 
when he discovered that phytohaemagglutinin (PHA), a lectin extracted from kidney 
bean, could transform small lymphocytes into proliferating lymphoblasts in cell culture. 
Since then a number of other mitogens have been identified that can stimulate a sizeable 
proportion of the lymphocyte population. These lectins accomplish lymphocyte 
activation by binding to specific sugar moieties on the lymphocyte membrane, and 
therefore activation can be inhibited by the addition of the free sugar. Mitogens can be 
characterised into T-cell mitogens, B-cell mitogens or mitogens that act on both T and B 
cell populations. The largest proportion of cells within peripheral blood are the T- 
lymphocytes and as a result T-cell mitogens are the best characterised and utilised. The 
most routinely used mitogens to evaluate lymphocyte activation were PHA, 
concanavalin A (Con A) and pokeweed mitogen (PWM).
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3.2. MITOGENS.
Mitogens are defined as substances that have the ability to induce blast-cell 
transformation and mitosis in a manner similar to antigens. The mitogen binds to a 
specific cell surface receptor and the signal thus generated causes a chain of events in 
the nucleus culminating in the lymphocyte entering the growth phase of the cell cycle. 
A large proportion of the mitogens that have been characterised are derived from plant 
proteins. These substances are more commonly referred to as lectins. These lectins 
have binding sites with a specificity for particular sugars. Whereas antigens stimulate a 
specific colony of cells, mitogens stimulate a large proportion of lymphocytes.
3.2.1. Phytohaemagglutinin (PHA).
Phytohaemagglutinin has been the most extensively studied mitogen. As mentioned 
previously it is a lectin extracted from kidney beans (phaseolus vulgaris). The PHA 
preparation used for lymphocyte activation has a molecular weight of 126 Kd. The 
protein consists of four subunits. The lectin recognises oligosaccharide on the surface of 
the lymphocyte.
3.2.2. Concanavalin A (Con A).
Concanavalin A is a lectin extracted from Jack beans (canavalia enisformis), it 
constitutes 3-4 % of Jack bean proteins. Con A has a molecular weight of 102 Kd and is 
a tetramer. It binds residues of a-D-mannopyranose and a-D-glucopyranose with 
unmodified hydroxyl groups at C3, C4 and C6. Con A also has binding sites for Ca++ 
and for a transition metal ion such as Mn++. Con A will not bind to the sugar residues 
until the two metal binding sites (in each subunit) are filled. The binding of these ions 
facilitates a conformational change that allows the binding of the specific sugars.
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3.2.3. Pokeweed Mitogen (PWM).
Pokeweed mitogen was extracted from pokeweed roots (Phytolacca americana), it has 
a molecular weight of 32Kd. PWM was a monomer and has an affinity for N-acetyl-P- 
glucosamine oligomers.
3.2.4. Lymphocytes - The target for mitogens.
Both PHA and Con A are termed T-cell mitogens, and are polyclonal in nature as they 
react with the lymphocyte cell surface non-specifically (i.e. not as an antigen). They 
perform the same task as an antigen but target a larger population. As a consequence of 
the sugar specificity of these mitogens it appears that T-helper cells are preferentially 
stimulated by PHA and T-suppressor cells by Con A. However, the differences are not 
as clear cut as PHA has a specificity for oligosaccharides. PWM on the other hand 
activates B-cells but this occurs only in the presence of T-cells and is therefore 
considered a T-cell dependent B-cell mitogen.
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3.3. STANDARDISATION OF MITOGEN CONCENTRATION FOR OPTIMAL 
LYMPHOCYTE ACTIVATION.
3.3.1. The standardisation of the lymphocyte activation assay.
A lymphocyte activation assay was set up (section 2.7.) with peripheral blood 
mononuclear cells from 7 normal volunteers. The PBMCs were cultured in the presence 
of a range of concentrations for each of the mitogens. The PHA was set up at the final 
concentrations of 10, 5, 2 and 1 (ig/ml, likewise the Con A was set up at 100,50, 20 and 
10 jug/ml. PHA and Con A were added to cultures that contained cells at 5 x 105 
cells/ml. PWM was added to cells that had a cell density of 106 cells/ml.
The results were expressed both as counts per minute (cpm) and as stimulation indices 
(SI) according to the formulae;
mean cpm mitogen - mean cpm control
stimulation index = -----------------------------------
mean cpm control
3.3.2. The optimal concentrations of PHA, Con A and PWM.
Table 3.3.1. records the variation in the cpms and stimulation indices at the various 
concentrations of the three mitogens. Each result was expressed as the mean of 7 
normal individuals with the standard error of the mean (SEM) in parenthesis.
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Standardisation of mitogen concentration for 
optimal lymphocyte activation
PHA
M-g/ml
CPM 
(x 10-2)
SI
(x 10-2)
ConA
M-g/ml
CPM 
(x lO’2)
SI
(x lO 2)
PWM
(ig/ml
CPM
(x lO’2)
SI
(x lO 2)
10 73.8 0.58 100 28.3 0.22 0.5 30.5 0.23
(10.3) (0.07) (2.7) (0.02) (3.3) (0.03)
5 77.8 0.61 50 55.5 0.43 0.1 33.2 0.25
(10.2) (0.07) (10.9) (0.07) (3.9) (0.03)
2 38.2 0.30 20 29.6 0.23 0.05 15.3 0.11
(5.4) (0.02) (4.8) (0.03) (1.2) (0.02)
1 12.5 0.09 10 21.3 0.16 0.01 7.9 0.05
(2.1) (0.02) (3.8) (0.02) (1.1) (0.01)
TABLE 3.3.1.
The table presents the data from a set of experiments designed to optimise the 
concentrations of mitogens required for lymphocyte activation. The data were 
presented as both the cpm and also the stimulation index. The data were the mean of 7 
normal volunteers with the standard error of the mean (SEM) in parenthesis.
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The data clearly demonstrates that the optimum concentration for the stimulation of 
PBMCs by the three mitogens were as follows;
PHA 5 |ig/ml 
Con A 50 |lg/ml 
PWM 0.1 |ig/ml
These concentrations of mitogen were used in the subsequent assays for lymphocyte 
activation.
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3.4. CALCIOTROPHIC HORMONES - A ROLE IN THE IMMUNE SYSTEM ?
The demonstration that 1,25 dihydroxyvitamin D3 receptors are present on activated T 
and B cells suggested a wider role for the metabolite (Provvedini, 1983; Bhalla, 1983). 
A possible role in the immune system was postulated by Tsoukas et al, when 
l,25(OH)2D3 was shown to inhibit interleukin-2 activity (Tsoukas, 1984). l,25(OH)2D3 
was not the only calciotrophic hormone with receptors in cells of the immune system. 
In 1974, Marx et al (Marx, 1974) demonstrated that cultured human lymphocytes 
expressed calcitonin receptors. This observation was followed some years later by the 
discovery of parathyroid hormone receptors on circulating bovine lymphocytes 
(Yamamoto, 1983; Perry HI, 1984). An explanation for these observations has not been 
forthcoming. In view of these findings a study was set up to look at the effects of five 
calciotrophic hormones on lymphocyte activation. The five calciotrophic hormones 
studied were;
1.25 dihydroxyvitamin D3
24.25 dihydroxyvitamin D3 
25 hydroxyvitamin D3
(l,25(OH)2D3) 
(24,25(OHI2D3)
(25(OH)D3)
bovine (1-35) parathyroid hormone (b(l-35)PTH)
salmon calcitonin (sCT)
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3.4.1. Lymphocyte activation in the presence of calciotrophic hormones.
PBMCs were obtained by density gradient centrifugation (section 2.2.1.) from ten 
normal healthy individuals. The cells were set up for a lymphocyte activation assay 
(section 2.7.) in the presence of a range of calciotrophic hormones (section 2.5.). Each 
well in the 96 well microtiter plate contained 105 PBMCs (2 x 105 PBMCs in the case of 
PWM), PHA (5 (ig/ml) or Con A (50 |ig/ml) or PWM (0.1 fig/ml), and a given 
concentration of one of the calciotrophic hormones. Each test was carried out in 
triplicate. The tests are incubated at 37 °C in a humidified atmosphere of 5 % CCh/Air 
for 68 hours. At 68 hours, 1 jiCi of tritiated thymidine was added to each well and the 
tests were incubated for a further four hours. The results were expressed as counts per 
minute of tritiated thymidine incorporated and as stimulation indices.
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3.4.2. l,25(OH)2D3 - The effective inhibitor.
The effects of the five calciotrophic hormones (l,25(OH)2D3, 24,25(OH)2D3, 
25(OH)D3, b(l-35)PTH and sCT) on lymphocyte activation were documented in tables 
3.4.1., 3.4.2., 3.4.3., 3.4.4. and 3.4.5. respectively. The first impression from the 
tabulated data was, that of the calciotrophic hormones studied, only l,25(OH)2D3 had a 
significant inhibitory effect on lymphocyte activation. PTH and CT appeared to 
enhance lymphocyte activation but this effect never reached significance, however, 
24,25(OH)2D3 and 25(OH)D3 did appear eventually to inhibit lymphocyte activation. 
24,25(OH)2D3 and 25(OH)D3 appeared to inhibit at higher concentrations (107 M) but 
this also did not achieve statistical significance.
Closer inspection of the cpm presented in table 3.4.1. reveals that l,25(OH)2D3 
inhibits lymphocyte activation stimulated by all three mitogens. Whereas the inhibition 
of PHA - induced lymphocyte activation by l,25(OH)2D3 achieves significance at 1010 
M, the inhibition of Con A - and PWM - induced lymphocyte activation does not 
achieve significance until 109 M (PWM) and 108 M (Con A). The stimulation data 
similarly achieves statistical significance confirming this observation. The data for 
l,25(OH)2D3 is presented as a graph in figure 3.4.1.. The normal physiological range 
for l,25(OH)2D3 concentration in serum occurs between 1011 M and 10'10 M ; only the 
inhibition of PHA induced activation occurs within this range.
Tables 3.4.2. and 3.4.3. present the effects of 24,25(OH)2D3 and 25(OH)D3 on 
lymphocyte activation. In each case there was no significant difference in activation 
whether the cells were stimulated with PHA, Con A or PWM. However, there appeared 
to be a trend that suggested a slight inhibition of activation at higher concentrations of 
these metabolites. The normal serum concentrations for these metabolites are between 
10'10 M to 10 9 M for 24,25(OH)2D3 and between 10 8 M and 107 M for 25(OH)D3.
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Lvmphocvte Activation induced bv PHA. Con A and
PWM in the presence of 1.25 dihydroxyvitamin D3
l,25(OH)2D3 PHA 
5 flg/ml
ConA
50|ig/ml
PWM
0.1p,g/ml
(Molar) CPM SI CPM SI CPM SI
(x lO 3) (x 10'3) (x lO'3) (x 10*3) (x 10'3) (x 10‘3)
0 28.4 0.84 17.7 0.54 14.7 0.24
(2.2) (0.14) (1.6) (0.11) (1.9) (0.06)
IO-13 28.9 1.14 19.0 0.78 15.1 0.33
(2.1) (0.28) (1.5) (0.20) (2.0) (0.09)
10-i2 28.8 1.02 18.3 0.65 15.1 0.30
(2.0) (0.22) (1.4) (0.15) (2.1) (0.08)
10-u 27.4 0.95 18.5 0.67 14.7 0.29
^ •9) (0.20) (1.3) (0.15) (1.9) (0.08)lO-io 22.9 0.83 18.1 0.64 13.7 0.26
(1.8) £.0.19) (1.4) (0.15) (1.7) (0.06)
10-9 14.7* 0.58 14.7 0.59 12.8* 0.27
(1.1) jp .ii) (1.0) £0.12) (1.4) (0.06)
10-8 12.7* 0.51 13.3* 0.55 12.7* 0.31
(1.0) (0.08) (1.0) £>.10) (1.4) (0.07)
10-7 14.9* 0.61 13.8* 0.58 13.7* 0.32
(1.2) (0.13) (0.9) (0.12) (1.5) (0.09)
TABLE 3.4.1.
The table presents the data from an experiment designed to show the effect of 
l,25(OH)2D3 on either PHA, Con A or PWM induced lymphocyte activation. The data 
were presented as both the cpm of tritiated thymidine incorporated and the stimulation 
index (SI) for each l,25(OH)2D3 concentration. The data were the mean of 10 normal 
volunteers with the standard error of the mean (SEM) in parenthesis. The statistical 
analysis carried out on the data was a paired Wilcoxon test (* p < 0.05) comparing 0 
with all other concentrations of l,25(OH)2D3.
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FIGURE 3.4.1.
The figure represents the data from table 3.4.1. in the form of a graph. 
The data points in each figure are the mean of 10 normal individuals 
and the error bars represent the standard error of the mean (SEM). 
The data are cpm of tritiated thymidine incorporated. The data was 
subjected to a paired Wilcoxon statistical test (*p< 0.05) comparing 0 
to all other concentrations of 1,25 dihydroxyvitamin D3.
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Lvmphocvte Activation induced bv PHA. Con A and
PWM in the presence of 24.25 dihydroxyvitamin D3
24,25(OH)2D3 PHA
5|Hg/ml
ConA
50|ig/ml
PWM
0.1|ig/ml
(Molar) CPM SI CPM SI CPM SI
(x lO'3) (x lO'3) (x lO 3) (x lO 3) (x lO'3) (x lO'3)
0 31.6 0.91 19.7 0.54 15.4 0.22
(2.0) (0.13) (1.7) (0.05) (2.3) (0.03)
10-13 30.0 0.96 19.3 0.63 15.2 0.28
(2.0) (0.18) (1.2) (0.14) (2.1) (0.09)
1012 28.3 0.95 18.2 0.60 13.7 0.23
(2.2) (0.18) (1.2) (0.13) (1.3) (0.05)
10-n 26.5 0.95 17.7 0.66 13.7 0.27
(1.8) (0.15) (1.4) (0.14) (1.8) (0.07)lO-io 27.7 1.00 18.0 0.65 14.3 0.29
(2.2) (0.21) (1.4) (0.15) (1.9) (0.08)
10-9 28.5 0.92 19.1 0.59 14.8 0.25
(1.9) (0.20) (1.3) (0.13) (1.7) (0.06)
10-8 30.2 0.97 19.5 0.65 15.7 0.29
(2.2) (0.22) (1.4) (0.17) (1.9) (0.09)
10-7 34.1 0.92 22.3 0.55 16.3 0.20
(2.5) (0.23) (1.5) (0.14) (2.1) (0.04)
TABLE 3.4.2.
The table presents the data from an experiment designed to show the effect of 
24,25(OH)2D3 on either PHA, Con A or PWM induced lymphocyte activation. The data 
were presented as both the cpm of tritiated thymidine incorporated and the stimulation 
index (SI) for each 24,25(OH)2D3 concentration. The data were the mean of 10 normal 
volunteers with the standard error of the mean (SEM) in parenthesis. The data were 
subjected to a paired Wilcoxon test (* p < 0.05) comparing 0 with all other 
concentrations of 24,25(OH)2D3.
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Lymphocyte Activation induced bv PHA. Con A and
PWM in the presence of 25 Hvdroxwitamin D3
25(OH)2D3 PHA
5p,g/ml
ConA
50fig/ml
PWM
0.1|Hg/ml
(Molar) CPM SI CPM SI CPM SI
(x 10*3) (x lO 3) (x lO’3) (x lO'3) (x 10’3) (x 10'3)
0 33.9 1.0 20.6 0.63 16.5 0.26
(3.1) (0.22) (2.0) (0.15) (2.2) (0.07)
1013 28.4 0.80 19.7 0.53 16.1 0.21
(2.3) (0.13) (1.3) (0.07) (2.1) (0.02)
10-12 28.3 0.86 18.3 0.58 15.5 0.24
(2.2) (0.20) (1.5) (0.15) (2.0) (0.04)
10-11 27.2 0.86 18.5 0.61 15.1 0.25
(2.4) (0.13) (1.6) (0.12) (2.0) (0.06)
lO-io 28.2 1.05 18.8 0.74 15.3 0.32
(2.1) (0.17) (1.5) (0.14) (2.0) (0.06)
10-9 28.9 0.90 20.1 0.69 16.0 0.29
(2.3) (0.13) (1.5) (0.14) (2.0) (0.06)
10-8 31.2 0.86 21.0 0.64 16.8 0.26
(2.4) (0.20) (1.8) (0.18) (2.1) (0.08)
10-7 34.4 1.16 23.4 0.82 16.0 0.31
(2.6) (0.18) (2.3) (0.17) (1.6) (0.06)
TABLE 3.4.3.
The table presents the data from an experiment designed to show the effect of 
25(OH)D3 on either PHA, Con A or PWM induced lymphocyte activation. The data 
were presented as both the cpm of tritiated thymidine incorporated and the stimulation 
index (SI) at the various concentrations of 25(OH)D3. The data were the mean of 10 
normal volunteers with the standard error of the mean (SEM) in parenthesis. The 
statistical analysis took the form of a paired Wilcoxon test comparing 0 with all other 
concentrations of 25(OH)D3. There were no significant differences.
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Lvmphocvte Activation induced bv PHA. Con A and
PWM in the presence of bovine (T -  35 )  PTH
b (1 - 35) PTH PHA
5|ig/ml
ConA
50|Xg/ml
PWM
0.1p,g/ml
(Molar) CPM SI CPM SI CPM SI
(x 10’3) (x 10'3) (x lO 3) (x 10‘3) (x 10*3) (x lO'3)
0 27.4 0.38 23.4 0.32 14.5 0.11
(1.8) (0.06) (1.5) (0.05) (1.9) (0.02)
1013 25.8 0.38 22.1 0.32 13.8 0.12
(1.8) (0.05) (1.4) (0.04) (1.9) (0.03)
lO*12 25.8 0.33 21.4 0.28 13.1 0.09
(1.5) (0.06) (1.5) (0.05) (1.6) (0.02)
1011 25.4 0.36 21.5 0.30 12.7 0.10
(1.4) (0.08) (1.3) (0.06) (1.5) (0.03)
lO-io 25.0 0.30 21.8 0.25 12.7 0.07
(1.6) (0.07) (1.3) (0.05) (1.6) (0.02)
10-9 25.2 0.34 22.9 0.29 13.7 0.10
(1.4) (0.08) (1.6) (0.06) (1.8) (0.02)
10-8 27.3 0.39 22.9 0.30 15.4 0.11
(2.0) (0.07) (1.4) (0.03) (2.0) (0.02)
10-7 30.7 0.47 25.6 0.37 15.8 0.13
(1.7) (0.07) (2.0) (0.05) (2.2) (0.03)
TABLE 3.4.4.
The table presents the data from an experiment designed to show the effect of 
bovine (1 - 35) parathyroid hormone on either PHA, Con A or PWM induced 
lymphocyte activation. The data were presented as both the cpm of tritiated thymidine 
incorporated and the stimulation index at the various concentrations of b (1 - 35) PTH. 
The data were the mean of 10 normal volunteers with the standard error of the mean 
(SEM) in parenthesis. The data were subjected to a paired Wilcoxon test comparing 0 to 
all other concentrations of b (1 - 35) PTH. There were no significant differences.
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Lvmphocvte Activation induced by PHA. Con A and
PWM in the presence of salmon calcitonin
sCT PHA ConA PWM
5|ig/ml 50(Xg/ml 0.1|ig/ml
(Molar) CPM SI CPM SI CPM SI
(x lO’3) (x lO'3) (x lO 3) (x lO 3) (x 10'3) (x lO’3)
0 33.6 0.57 26.1 0.44 14.6 0.12
10-13
(2.1)
31.1
(0.16)
0.65
(1.7)
24.8
(0.11)
0.49
(1.6)
14.3
(0.03)
0.14
IO-12
(2.2)
31.5
(0.13)
0.61
(2.1)
24.4
(0.10)
0.47
(1.7)
14.0
(0.03)
0.14
1 0 -u
(1.8)
31.7
(0.10)
0.80
(1.8)
24.4
(0.07)
0.60
(1.5)
14.2
(0.03)
0.19
lO-io
(2.0)
31.3
(0.20)
0.46
(1.5)
25.7
(0.14)
0.38
(1.5)
14.5
(0.04)
0.10
10-9
(2.3)
32.9
(0.12)
0.50
(1.7)
24.7
(0.09)
0.39
(1.5)
14.1
(0.02)
0.11
10-8
(2.1)
34.7
(0.12)
0.76
(1.5)
25.3
(0.09)
0.56
(1.6)
15.0
(0.03)
0.18
10-7
(2.0)
43.0
(0.14)
0.75
(1.6)
28.1
(0.11)
0.48
(1.8)
17.7
(0.04)
0.16
(4.4) (0.13) (1.7) (0.09) (2.6) (0.04)
TABLE 3.4.5.
The table presents the data from an experiment designed to show the effect of 
salmon calcitonin on either PHA, Con A or PWM induced lymphocyte activation. The 
data were presented as both the cpm of tritiated thymidine incorporated and the 
stimulation index at the various concentrations of sCT. The data were the mean of 10 
normal volunteers with the standard error of the mean (SEM) in parenthesis. The data 
were statistically analysed using a paired Wilcoxon test comparing 0 with all other 
concentrations of sCT. There were no significant differences.
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Tables 3.4.4. and 3.4.5. depict the effects of PTH and CT on lymphocyte activation. 
Physiological concentrations in serum are between 1012 M and 5 x 1012 M for PTH and 
between 0 and 1.3 x 1011 M for CT. Again there were no significant differences 
throughout the range studied as far as the lymphocyte activation assay was concerned. It 
was of interest that both PTH and CT appeared to show the enhancement of lymphocyte 
activation. Although observed both in terms of cpms and stimulation indices the 
enhancement was not statistically significant. The enhancement was perhaps more 
noticeable in lymphocyte activation in the presence of calcitonin.
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3.5. SEX HORMONES AND THE IMMUNE SYSTEM.
Clinical observations have detected striking differences between the immune 
responsiveness of males and that of females (Ahmed, 1985). In general, the humoral 
and cell mediated immunity displayed by females is superior to their male counterpart. 
Women are more resistant to a variety of infections (Thompson, 1963, Washburn, 1965 
and Goble, 1971) and this may have a bearing on the well known statistic that they live 
longer. Perhaps as a consequence of this more sensitive immune system, woman also 
have exaggerated responses to autoantigens and hence are more susceptible to 
autoimmune diseases. A striking example of this is seen in the ratio of females to males 
with systemic lupus erythematosus (SLE) - about 9 : 1 (Dubois, 1974, Komreich, 1976). 
Pregnancy is a time of considerable endocrine changes and as such can dramatically 
alter the course of concurrent autoimmune diseases. The alterations in the circulating 
levels of sex hormones may account in part for improvement in for example the clinical 
features of rheumatoid arthritis in pregnancy (Hench, 1938). Pregnancy has also been 
shown to depress cell mediated and mitogen responses (Purtillo, 1972).
There is more evidence for a role of sex hormones in autoimmune disease if one looks 
at what happens when oral contraceptives are administered to patients with autoimmune 
diseases. The disease course may be altered by such regimes : for example, 
administration of oestrogen - containing contraceptives to lupus patients is associated 
with exacerbation of the disease (Ahmed, 1985). Oral contraceptives have, however, 
also been shown to protect against rheumatoid arthritis (Wingrave, 1978).
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All the evidence, however, does not come from females: orichidectomy in males 
delays thymic involution and causes a thymic hypertrophy. It has also been reported 
that orichidectomy increased protection against viral and fungal and bacterial and 
parasitic infections (Cohn, 1979). Clearly the immune system does not function in 
isolation but is intricately involved with other physiological systems in particular the 
endocrine system. In view of the involvement of oestrogen in bone metabolism it 
seemed important to investigate the relationship between the sex hormones, the 
calciotrophic hormones and the immune system.
3.5.1. A comparison of l,25(OH)2D3 and the various sex hormones as they effect 
lymphocyte activation.
In section 3.4., a significant inhibition of PHA induced proliferation was observed 
when cells were cultured in the presence of l,25(OH)2D3. Evidence exists for a similar 
effect when cells are stimulated in the presence of various sex hormones (Holdstock, 
1982). The aim of this work was to compare such inhibition in the presence of 
l,25(OH)2D3 with the inhibition in the presence of various sex hormones. The sex 
hormones studied were oestrogen, progesterone and dihydrotestosterone (DHT).
PBMCs were obtained from nine healthy individuals by density gradient 
centrifugation (section 2.2.1.). The cells were set up as for lymphocyte activation assay 
(section 2.7.) in the presence of PHA (5 |ig/ml) and a range of concentrations for 
l,25(OH)2D3, oestrogen, progesterone and dihydrotestosterone (1013 M - 107 M). Each 
well contains 105 cells, PHA at 5 |ig/ml and a specific concentration of either 
l,25(OH)2D3, oestrogen, progesterone and dihydrotestosterone all in a final volume of 
200 |xl. Each test was again carried out in triplicate. The tests were incubated at 37 °C 
in a humidified atmosphere of 5 % CO^Air for 68 hours. At 68 hours, 1 fiCi of tritiated 
thymidine was added to each test well and the tests were incubated for a further four 
hours. The test wells were harvested and counted (section 2.7.4.). The results were 
expressed as counts per minute (cpm) of tritiated thymidine incorporated.
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3.5.2. Inhibitory effects of l,25(OH)2D3 and of the sex hormones.
The effects of l,25(OH)2D3 and the three sex hormones (oestrogen, progesterone and 
dihydrotestosterone) on PHA induced lymphocyte activation are documented in table
3.5.1. (the results are expressed as the mean with the standard error of the mean (SEM) 
in parenthesis). The inhibition of PHA induced lymphocyte activation by l,25(OH)2D3 
achieves significance at concentrations as low as 1012 M and was sustained throughout 
the test range. The sex hormones, on the other hand, exhibit an entirely different pattern 
of inhibition. All three sex hormones show a distinct U-shaped inhibition with peak 
inhibition occurring at 1011 M (figure 3.5.1.). Of the sex hormones tested, progesterone 
was the most effective inhibitor of PHA induced lymphocyte activation.
3.5.3 l,25(OH)2D3 - The odd one out.
l,25(OH)2D3 was a more potent inhibitor of PHA induced lymphocyte activation than 
either of the sex hormones tested. Progesterone was the most effective sex hormone 
when it comes to inhibition of PHA induced lymphocyte activation. Progesterone 
matches l,25(OH)2D3 up to 1CH1 M as far as inhibition was concerned. The sex 
hormones exhibit a characteristic U-shaped curve throughout the range of 
concentrations. A possible explanation for this phenomenon i.e. the abolition of 
inhibition at concentrations higher than 1010 M could be down regulation of the sex 
hormone receptor. It could be that this phenomenon was not apparent in l,25(OH)2D3 
because at the higher concentrations a second mechanism was involved in l,25(OH)2D3 
or alternatively l,25(OH)2D3 was acting through a completely different mechanism from 
the sex hormones.
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A comparison of the effects of 1.25 dihvdroxwitamin D3. oestrogen, 
progesterone and dihvdrotestosterone on PHA - induced lymphocyte
activation
Steroid
Hormone
Concentration
(Molar)
l,25(OH)2D3
CPM
(x lO'3)
Oestrogen
CPM
(x lO'3)
Progesterone
CPM
(x lO'3)
Dihydrotestosterone
CPM
(x 10*3)
0 17.4 15.7 15.6 15.4
(1.6) (1.5) (1.6) (1.5)
10 13 15.3 14.8* 14.2 14.4
(1.3) (1.4) (1.4) (1.6)
10-12 14.1* 14.4 12.6* 14.1
(1.6) (1.3) (1.5) (1.6)
10-11 13.2* 13.9* 12.3* 13.4*
(1.5) (1.4) (1.4) (1.5)lO-io 11.1* 14.3* 13.1* 14.1*
(1.4) (1.4) (1.6) (1.7)
10-9 8.4* 14.6 13.6* 14.4*
(1.2) (1.3) (1.5) (1.7)
10-8 7.4* 14.8* 14.2 15.1
(1.4) (1.5) (1.2) (1.5)
10-7 8.7* 15.8 15.5 15.4
(1.5) (1.5) (1.6) (1.5)
TABLE 3.5.1.
The table presents the data from an experiment that compares the effects of the 
various sex hormones (oestrogen, progesterone and dihydrotestosterone) with 
l,25(OH)2D3 with regard to PHA induced lymphocyte activation. The data is presented 
as the mean of 9 normal individuals with the standard error of the mean (SEM) in 
parenthesis. The data is the cpm of tritiated thymidine incorporated. The data were 
statistically analysed using a paired Wilcoxon test (* p < 0.05) comparing 0 and all other 
concentrations for each substance under test.
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FIGURE 3.5.1.
The figure represents the data from table 3.5.1. in the form of a graph. The 
data points for each hormone in the figure is presented as the mean of 9 
normal individuals. The data points are the cpm of tritiated thymidine 
incorporated.
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3.6. INHIBITION BY l,25(OH)2D3 - A KINETIC EFFECT.
The inhibition of PHA induced lymphocyte activation by l,25(OH)2D3 was now 
established, it was important to ascertain the mechanism of this effect. It was possible 
that l,25(OH)2D3 exerted its effect on lymphocyte activation by altering the kinetics of 
the response of lymphocytes to mitogen. If this was the case then l,25(OH)2D3 would 
alter the time at which maximum activation would occur. This of course could in theory 
be earlier or later. However, it is easy to envisage a situation where l,25(OH)2D3 
slowed down the rate of lymphocyte activation thereby delaying the maximum 
activation and creating the impression of inhibition at the time when the assay was 
harvested i.e. 72 hours. The aim of this next experiment was to establish whether 
l,25(OH)2D3 altered the kinetics of the lymphocyte activation response.
3.6.1. The time course of l,25(OH)2D3 inhibition in PHA induced PBMC's.
PBMCs were obtained from four normal individuals by density gradient centrifugation 
(section 2.2.1.). The cells were set up for a lymphocyte activation assay (section 2.7.). 
The cells were cultured in the presence of PHA (5 |Lig/ml) and a range of l,25(OH)2D3 
concentrations (1013 M - 10 8 M) (section 2.5.). The cultures were incubated at 37 °C in 
a humidified atmosphere of 5 % CO^Air. The cultures were harvested at either 24, 48, 
72, 120 or 168 hours. Four hours prior to harvesting the cultures 1 fiCi of tritiated 
thymidine was added to each well. The cultures were harvested on a cell harvester and 
the results were expressed as counts per minute of tritiated thymidine incorporated.
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A study of the kinetics of the effect of
1.25 dihvdroxwitamin D3 on PHA induced
lvmphocvte activation
3H-Thymidine incorporation (CPM) (x 10 3) 
Length of Incubation (hours)
l,25(OH)2D3
Molar
24 48 72 120 168
0 0.1 12.7 36.3 18.8 4.2
(0.02) (1.4) (1.6) (2.5) (1.0)
10-13 0.08 12.3 39.3 20.4 4.5
(0.01) (1.1) (1.5) (2.9) (1.0)
10-i2 0.07 12.1 36.6 20.2 4.6
(0.01) (1.0) (2.0) (2.9) (1.0)
1 0 -n 0.07 11.8 35.1 20.5 4.3
(0.01) (0.9) (1.9) (4.6) (1.1)lO-io 0.06 10.8 30.4 10.1 4.1
(0.01) (0.8) (2.5) (2.7) (1.4)
10-9 0.06 10.4 20.8 4.2 1.9
(0.01) (0.6) (3.1) (0.9) (0.4)
10-8 0.06 9.9 15.9 3.0 1.7
(0.01) (0.5) (2.2) (0.7) (0.3)
TABLE 3.6.1.
The table presents the data from an experiment that investigates the kinetics of 
the l,25(OH)2D3 inhibition of the PHA induced lymphocyte activation. The data are 
presented as the mean of 4 normal individuals with the standard error of the mean 
(SEM) in parenthesis. The numbers are the cpm of tritiated thymidine incorporated. 
Statistics were inappropriate.
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3.6.2. l,25(OH)2D3 - Not a kinetic effect.
The question of l,25(OH)2D3 exerting a kinetic effect on lymphocyte activation is 
dealt with in table 3.6.1.. The data reveals that the inhibition of lymphocyte activation 
by l,25(OH)2D3 was present at all the time points assayed. At longer time points i.e. 
greater than 72 hours interpretation of the results are more complicated as the cells will 
not be as viable at these times. However, the trend of inhibition remains the same and 
this argues against the proposed kinetic effect. l,25(OH)2D3 therefore specifically 
inhibits lymphocyte activation and this does not occur through changes in the kinetics of 
lymphocyte activation. The data also confirm that peak activation occurs at 72 hours.
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3.7. l,25(OH)2D3: A DIRECT ACTION ON LYMPHOCYTE ACTIVATION ?
It is possible that l,25(OH)2D3 was acting directly on the lymphocyte activation 
process. l,25(OH)2D3 could quite conceivably act at the level of transduction of the 
mitogenic signal to inhibit activation directly. A second possibility is that l,25(OH)2D3 
was having a nonspecific effect on the tritiated thymidine incorporation. The following 
experiment was set up to test both of these possibilities.
3.7.1. Does l,25(OH)2D3 interfere with PHA induced activation ?
PBMCs from four normal individuals were obtained by density gradient centrifugation 
(section 2.1.1.). The cells were set up in a lymphocyte activation assay (section 2.7.). 
The cells were cultured in the presence of PHA (5 fig/ml). The cultures were incubated 
at 37 °C in a humidified atmosphere of 5 % CCh/Air. l,25(OH)2D3 (1CH0 M) was added 
to certain cultures at various time points. Controls received the vehicle alone at these 
points. The additions were made at 0, 24 and 48 hours. The assays were pulsed at 68 
hours with tritiated thymidine and cultured for a further 4 hours. The cells were 
harvested and counted the results were presented as counts per minute.
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The effect of adding 1.25dihydroxyvitamin D3 
at various time points
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FIGURE 3.7.1.
The figure represents the effect of 1,25 dihydroxyvitamin D3 on PHA induced 
lymphocyte activation. The l,25(OH)2D3 was added at various time points, 
at the start of the culture (0 hours) and at 24 and 48 hours. The data are 
presented as the mean of four individuals with the standard error of the mean 
(SEM) represented as error bars. Statistical tests were inappropriate.
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3.7.2. l,25(OH)2D3 - A genuine inhibitor.
The effect of adding 1010 M l,25(OH)2D3 at different times is represented in figure 
3.7.1.. It was obvious that the maximal inhibitory effect was obtained when 
l,25(OH)2D3 was added at the start of the culture. Addition of l,25(OH)2D3 at 24 and 
48 hours resulted in an inhibition but this inhibition was not as pronounced. The data 
argues against the l,25(OH)2D3 interfering with the activation process as inhibition can 
be observed when the l,25(OH)2D3 was added after the activation cascade was well 
underway. The fact that the inhibition was not constant regardless of the addition time 
of the l,25(OH)2D3, - indeed there was a graduated response - indicates that the 
inhibition effect by l,25(OH)2D3 is not due to a nonspecific effect on tritiated thymidine 
uptake.
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3.8. DOES l,25(OH)2D3 ALTER VIABILITY ?
The final hurdle to establish that the inhibition of PHA induced lymphocyte activation 
by l,25(OH)2D3 was a genuine effect was to investigate the viability of the cells in 
culture. Could the l,25(OH)2D3 related inhibition be due to the l,25(OH)2D3 causing 
cell death at the higher concentrations of this vitamin D metabolite?
3.8.1. Cell viability in the presence of l,25(OH)2D3.
PBMCs were obtained from eight normal healthy volunteers by density gradient 
centrifugation (section 2.1.1.). The cells were set up in a lymphocyte activation assay. 
The cells were cultured in the presence of PHA (5 fig/ml) and in the presence of a range 
of l,25(OH)2D3 concentrations (1013 M - 10 7 M). The viability of the cells were 
assessed by trypan blue exclusion (section 2.2.4.) at the beginning of the culture. The 
cells were cultured at 37 °C in a humidified atmosphere of 5 % CCte/Air for 72 hours. 
At 72 hours the viability was again assessed by trypan blue exclusion. Briefly, 10 jil of 
cells were added to 10 |LiI of Trypan blue and the number of viable cells were counted 
along with the total number of cells. The percentage viability was obtained for each 
l,25(OH)2D3 concentration.
3.8.2. l,25(OH)2D3 - No profound effect on viability.
Table 3.8.1. describes the viability of the PBMCs prior to culture in the presence of 
l,25(OH)2D3 and the viability of the same PBMCs after 72 hours in the presence of 
l,25(OH)2D3. Clearly, there was no difference in the viability of the cells at the end of 
the culture period regardless of the l,25(OH)2D3 concentration. Although the viability 
has gone down from the initial value at the start of the culture this was as expected. The 
results would indicate that the inhibition of mitogen induced lymphocyte activation by 
l,25(OH)2D3 was not secondary to a cytotoxic effect.
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The viability of cells cultured in the
presence of 1.25 dihvdroxvvitamin D3
l,25(OH)2D3
(Molar)
Viability 
0 hours 
Percentage(%)
Viability 
72 hours 
Percentage(%)
0 98.6 79.0
(1.0) (9.3)
10-13 98.6 76.7
(1.0) (10.9)
IO-12 98.6 83.1
(1.0) (1.5)
1 0 -n 98.6 76.7
(1.0) (12.7)
lO-io 98.6 80.8
(1.0) (13.1)
10-9 98.6 81.7
(1.0) (8.7)
10-8 98.6 88.2
(1.0) (9.6)
10-7 98.6 79.7
(1.0) (6.7)
TABLE 3.8.1.
The table presents the data from an experiment to assess the effect of 1,25 
dihydroxyvitamin D3 on the viability of PBMCs cultured for 72 hours. The data was 
presented as the percentage viability as measured in a trypan blue exclusion experiment. 
The data was obtained from 8 normal individuals and the mean was presented with the 
standard error of the mean in parenthesis. Statistics were carried out between 0 and all 
other l,25(OH)2D3 concentrations using a paired Wilcoxon test and no significant 
differences were obtained between the different 1,25 dihydroxyvitamin D3 
concentrations at either time point.
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3.9. l,25(OH)2D3 THE EFFECTIVE INHIBITOR OF LYMPHOCYTE ACTIVATION.
Both PTH and CT failed significantly to alter lymphocyte activation stimulated by the 
mitogens, PHA, Con A and PWM. This was observed despite the fact that lymphocytes 
possess the appropriate receptors. Careful examination of the data reveals a trend of 
enhanced lymphocyte activation although this never achieved significance. It may be 
that the receptors for PTH and CT are not important to the mature lymphocyte 
participating in the immune system, but may be important earlier on in the cells 
development. It is known that CT and PTH can influence the proliferation of immature 
T-cells.
The D3 metabolites, 24,25(OH)2D3 and 25(OH)D3, also failed to significantly alter 
lymphocyte activation by the three mitogens. The active metabolite of vitamin D3, 
l,25(OH)2D3 significantly inhibited lymphocyte activation by all three mitogens. The 
normal physiological range of l,25(OH)2D3 in normal serum occurs between 1011 M 
and 1010M. The inhibition of PHA induced lymphocyte activation by l,25(OH)2D3 
becomes significant at 1010 M. These observations would argue in favour for a role for 
l,25(OH)2D3 in immunoregulation. Con A and PWM stimulated lymphocyte activation 
achieve significance at 10 8 M and 10 9 M respectively (Smith, 1990).
In order to fully appreciate the significance of the inhibition of lymphocyte activation 
by l,25(OH)2D3 the percentage inhibition was calculated. The data presented in table
3.9.1. represents the percentage inhibition by l,25(OH)2D3 for all three mitogens. The 
percentage inhibition was calculated using the following formulae;
cpm(experimental culture)
percentage inhibition (%) = 1 ..............................    x 100
cpm(control culture)
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Inhibition of PHA Con A - and PWM - induced lymphocyte activation 
in the presence of 1.25 dihvdroxwitamin D3 expressed as a percentage
l,25(OH)2D3
(Molar)
PHA
Inhibition (%)
ConA
Inhibition (%)
PWM
Inhibition (%)
0 0 0 0
lO 13 -2.4 -6.4 -2.3
(12.3) (12.2) (10.2)
IO-12 -2.6 1.8 -4.4
(10.6) (14.5) (13.3)
10-“ -0.6 -1.4 0.4
(14.5) (14.1) (10.1)
10-1° 19.1* 1.0 8.7*
(13.9) (11.8) (8.4)
10*9 49.8* 17.9* 12.6*
(9.9) (22.0) (12.9)
10-8 54.9* 21.9* 10.5*
(5.6) (13.5) (15.3)
10-7 48.1* 22.4* 6.5*
(9.0) (14.5) (11.3)
TABLE 3.9.1.
The table presents the data from the experiment that demonstrated the inhibition 
of PHA, Con A and PWM induced lymphocyte activation by 1,25 dihydroxyvitamin D3 
(see section 3.4.2.) expressed as the percentage inhibition. The formulae is presented in 
the text. The data was obtained from 10 normal individuals and the mean and the 
standard error of the mean are presented in parenthesis. Statistics were carried using a 
paired Wilcoxon test (* p < 0.05) comparing 0 with all other concentrations of each 
substance under review.
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Inhibition of PHA - induced lymphocyte activation in the
presence of 1.25 dihydroxyvitamin D3. oestrogen, progesterone
and dihvdroxvtestosterone
Steroid
Hormone
Concentration
(Molar)
l,25(OH)2D3 
% inhibition
Oestrogen 
% inhibition
Progesterone 
% inhibition
Dihydroxytestosterone 
% inhibition
0 0 0 0 0
IO-13 12.1 5.7 9.0 6.5
IO-12 19.0 8.3 19.2 8.4
10-n 24.1 11.5 21.2 13.0
lO -io 36.2 8.9 16.0 8.4
10-9 51.7 7.0 12.8 6.5
10-8 57.5 5.7 9.0 1.9
10-7 50.0 -0.6 0.6 0
TABLE 3.9.2.
The table presents the data from the experiment that demonstrated the inhibition 
of PHA induced lymphocyte activation by 1,25 dihydroxyvitamin D3, oestrogen, 
progesterone or dihydrotestosterone (see section 3.5.2.) expressed as the percentage 
inhibition. The formulae is presented in the text. The data was obtained from 9 normal 
individuals and the mean and the standard error of the mean are presented in parenthesis.
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It is clear that PHA induced lymphocyte activation is inhibited to a greater extent than 
either PWM or Con A induced lymphocyte activation. Inhibition of PHA induced 
lymphocyte activation in excess of 50 % was achieved by l,25(OH)2D3 whereas 
inhibition of lymphocyte activation stimulated with Con A and PWM does not exceed 
23 % and 13 % respectively. As discussed previously each of these mitogens stimulate a 
different population of cells in the lymphocyte activation process. PHA is 
predominantly a T-helper/inducer (Th) mitogen, it is therefore likely that at 
physiological concentrations of l,25(OH)2D3 this subset of cells is the main target for 
the inhibition effect. The significant inhibition observed in Con A and PWM induced 
lymphocyte activation occurs at 100-fold and 10-fold greater concentrations of the 
l,25(OH)2D3 respectively. This inhibition albeit, a small inhibition, can be explained by 
minor effects on Th cells. Con A is predominantly a T-suppressor/cytotoxic (Ts) 
mitogen, however, for the Ts cells to proliferate requires the activation of a population 
of Th. PWM is a T-cell dependent B-cell mitogen, and the T-cell on which it is 
dependent is a Th cell. This Th cell allows the B-cell to proliferate. It is conceivable 
that an inhibition of this Th cell by l,25(OH)2D3 causes the observed inhibition. The Th 
cells secrete the cytokine interleukin-2, which is by definition the T-cell growth factor 
(TCGF).
The sex hormones, oestrogen, progesterone and dihydrotestosterone have also been 
demonstrated to have some inhibitory effect on PHA induced lymphocyte activation. In 
many ways the inhibition by these hormones is similar to the inhibition by l,25(OH)2D3. 
Table 3.9.2. expresses the data in the form of a percentage inhibition, which was 
calculated using the same formulae as was used for table 3.9.1.. In the case of 
l,25(OH)2D3, inhibition of about 60 % was achieved whereas oestrogen, progesterone 
and dihydrotestosterone produce maximum inhibition of 11.5 %, 21.2 % and 13.0 % 
respectively. The maximum inhibition occurs at 1011 M and could therefore be 
important. At 107 M, the lymphocyte activation is back to control levels in the presence 
of the sex hormones. The characteristic U-shaped curve is perhaps a consequence of 
down regulation of their respective hormone receptors.
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CHAPTER 4.
INTERLEUKIN -2 (IL-2) ACTIVITY - THE EFFECT OF CALCIOTROPHIC AND
SEX HORMONES.
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4.1. INTERLEUKIN - 2 (IL-2).
Interleukin-2 (IL-2) was the first immune hormone to be discovered and characterised 
(Robb, 1981). It has a crucial role to play in the generation of a successful immune 
response and an understanding of its role has done much to explain the unique properties 
of the immune system. IL-2 was originally called T-cell growth factor (TCGF) and this 
name adequately reflected its principal function. IL-2 functions to promote the 
proliferation of T-cells that have been triggered by a specific antigen, resulting in a 
clone of identical cells all of which were specific for a particular antigen. Although T- 
cells are the main target for IL-2, IL-2 receptors (IL-2R) have been identified on other 
cell types (Mizel, 1989). As a result of the distribution of these receptors, B-cells, 
Natural killer cells (NK) and Lymphocyte activated killer cells (LAK) were also 
responsive to IL-2. It should be noted that resting T-cells do not possess the high 
affinity IL-2R, it is only in the presence of an antigen presenting cell (macrophage) and 
an appropriate antigen that these receptors are expressed (Gillis, 1978).
4.1.1. IL-2 : Its biochemistry.
Biochemical analysis of IL-2 has revealed that it is a glycoprotein which is 
heterogeneous in respect of size and charge. IL-2 is secreted as a single polypeptide 
chain with an approximate molecular weight of 15.5 kilodaltons (Kd), with a slightly 
basic isoelectric point (pi 8.2 after the removal of sialic acid residues) and is 
hydrophobic in nature (Robb, 1981). The heterogeneity can be explained by variable 
glycosylation and sialation of a single protein, the single protein being confirmed by 
monoclonal antibodies.
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Molecular biology enabled Taniguchi et al (Taniguchi, 1983) to produce a 
complementary DNA (cDNA) for IL-2. The cDNA predicted a mature protein of 
15,420 daltons with an NH2 terminal sequence identical to that found from analysis of 
the purified protein. Also it has been revealed that the primary translational product of 
IL-2 messenger RNA (mRNA) contains the classical hydrophobic signal sequence 
suggesting that IL-2 is released by the pathway associated with all other secretory 
proteins (Mizel, 1989). The genomic organisation of the IL-2 gene is such that IL-2 is 
encoded by four exons separated by one short and two long introns (Fujita, 1983). The 
set-up is similar to other cytokines which points to the existence of a common genetic 
progenitor.
4.1.2. Interleukin-2 : The pathway of discovery.
The major breakthrough in immunology that facilitated the discovery of IL-2 occurred 
when it was demonstrated that given the correct stimulus lymphocytes could proliferate 
(Nowell, 1960). Prior to this it was generally accepted that lymphocytes were incapable 
of proliferation. The proper stimulus in this case turned out to be the plant lectin 
phytohaemagglutinin (PHA), however, it soon became apparent that a number of other 
plant lectins could produce a similar response. It was only a matter of time until the 
plant lectins were replaced by specific antigens to give the proliferative response thereby 
validating the proliferative response as a genuine physiological phenomenon. Two 
groups (Kasakura, 1965; Gordon, 1965) described a soluble mitogenic factor derived 
from conditioned culture media obtained from mixed lymphocyte culture. At this 
juncture the scientific community believed that this factor only played a supportive role, 
perhaps amplifying a process signaled by antigen. Around this time lymphocytes were 
thought to be the only source of mitogenic factors and so the term lymphokine was 
coined to describe these factors present in the conditioned media. However, it soon 
became apparent that other cell types produce other mitogenic factors. In 1976, Morgan 
et al (Morgan, 1976) demonstrated that normal human T-lymphocytes could be cultured
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for extended periods in media that contained conditioned media derived from 
phytohaemagglutinin stimulated peripheral mononuclear cells. A year later, Gillis and 
Smith, employed Morgan's observation to produce murine cytolytic T-lymphocyte lines 
(CTLL) specific for tumour antigens (Gillis, 1977). In 1979 a CTLL was cloned by 
limiting dilutions to give a monoclonal cytotoxic T-cell line (Baker, 1979). Cloned 
CTLL cells were the key to unravelling the mystery behind the mitogenic factors. 
Having obtained a cell line derived from a single cell the question of a heterogenous cell 
population was solved. The mitogenic factor responsible for long term T-cell growth 
could now be characterised.
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4.2. THE MEASUREMENT OF INTERLEUKIN - 2 (IL-2).
The majority of assays that measure IL-2 are bioassays which assess the proliferative 
capacity of the lymphokine on responsive cells. Proliferation can be measured in 
several ways ; the most obvious being to look for an increase in viable cell number. 
However, the most commonly used method is to assess an increase in DNA synthesis by 
measuring incorporation of tritiated thymidine ([3H]-thy) into DNA. Incorporation of 
[3H]-thy reflects accurately the number of cells in the S-phase of the cell cycle. A third 
alternative is to assess the amount of active mitochondria in the culture. This can be 
achieved by measuring a colorimetric change brought about when the mitochondrial 
dehydrogenase enzymes cleave the tetrazolium ring present in M.T.T. (3-(4,5- 
dimethylthiazol-2yl)-2,5 diphenyl tetrazolium) (Mosmann, 1983). Bioassays require a 
short term culture in the presence of lymphokine and as a consequence are susceptible to 
biological variability. These assays also have a problem with specificity. The major 
advantage of the bioassays is that they are extremely sensitive.
The development of antibodies against IL-2 raised the possibility that 
immunochemical procedures for measuring IL-2 would be adopted. Enzyme linked 
immunoabsorbant assays (ELISA) have been developed to measure IL-2 (Gehman, 
1984), these assays although reliable are found to be one hundred times less sensitive.
I l l
For the most part all bioassays for measuring IL-2 are similar to each other the only 
variable being the cells that are used as responder cells. The responder cells used in the 
bioassay fall into three groups;
(i) Continuous IL-2 dependent cell lines
(ii) Mitogenic lectin induced IL-2 responsive cells
(iii) Short-term IL-2 responsive cells
The advantages and disadvantages of each of these groups are discussed in subsequent 
sections.
4.2.1. Continuous IL-2 dependent cell lines.
The production of IL-2 dependent cell lines is relatively easy if rodent splenocytes are 
the initial cell source. The splenocytes are stimulated with antigens and/or mitogenic 
lectins, and cultured long term with regular feeding with IL-2 and/or antigen. After this 
regime has been established for several weeks, the cells are cloned by the limiting 
dilution method. The cloned cells are then tested for responsiveness to exogenous IL-2 : 
the high responding clones are selected and continually grown in culture. The cell lines 
minimise the variation between assays, and the problems with specificity are limited as 
the cells have been selected for their ability to respond to IL-2. As a result the assay is 
specific, reproducible and sensitive, although care has to be taken in the interpretation of 
the results. The primary disadvantages of these cell lines is that they were difficult to 
maintain and were difficult to cyropreserve.
The cell line HT-2 are cells produced using just such a protocol. HT-2 cells were 
derived from murine T-helper cells by Watson (Watson, 1979). These cells require IL-2 
for continuous growth and without IL-2 the cells die. The T-cell mitogens Con A and 
PHA do not stimulate proliferation in long term culture of these cells. HT-2 represents a 
good cell line to use in an IL-2 bioassay.
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4.2.2. Mitogenic lectin induced IL-2 responsive cells.
Stimulation of splenocytes or thymocytes with mitogenic plant lectins induce a 
subpopulation of lymphocytes to become responsive to IL-2. The responsive cells can 
then be used in a assay for IL-2. Rodent splenocytes or thymocytes can be easily 
activated using Con A to provide a cell population that responds to IL-2. The 
population of cells obtained by this method also respond to a range of stimuli other than 
IL-2. This problem is particularly relevant when assessing IL-2 in an enriched 
supernatant which contains residual plant lectin. It is possible to get rid of the offending 
residual lectin but this is both laborious and time-consuming. It is also possible that the 
population of cells obtained in this fashion is stimulated by other cytokines (B-cell 
growth factor (BCGF) and interleukin-1(IL-1)) that are also present in the supernatants.
4.2.3. Short-term IL-2 responsive cells.
It is possible to stimulate T-lymphocytes with lectin or antigen and feed these cells 
with IL-2, to produce a cell population that is dependent on the lymphokine. The 
disadvantage of this system is that there is considerable variation depending on the 
donor cell.
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4.3. THE SEARCH FOR A SUITABLE ASSAY.
4.3.1. A comparison of types of bioassays.
A source of purified IL-2 was assessed in three distinct bioassay systems. The 
bioassay systems employed represent; a continuous IL-2 dependent cell lines, a 
mitogenic induced IL-2 responsive cells and a short-term IL-2 responsive cells. Serial 
doubling dilutions of the purified IL-2 were carried out in complete RPM I1640 and 100 
|il of each dilution added to three 96-well microtiter plate (U-shaped, Bibby Sterlin, 
U.K.) in triplicate. The responsive cells were prepared as follows;
HT-2 - a continuous IL-2 dependent cell line.
This cell line was maintained in culture as described in section 2.3.1.. Prior to assay 
the cells were washed three times in RPMI 1640 and resuspended at a cell density of 1.5 
x 105 cells/ml in complete RPMI 1640 + 20 % F.C.S..
Con A induced mouse splenocytes - a mitogenic lectin induced IL-2 responsive cells.
An intact spleen was dissected from Balb/c mouse, transferred to complete RPMI 1640 
and the splenocytes were gently teased out into the complete RPMI 1640. Tissue debris 
was allowed to settle to the bottom of a universal and the cells above the debris were 
transferred to a fresh universal and washed three times in complete RPMI 1640. The 
cell suspension was seeded in complete RPMI 1640 + 10 % F.C.S. at a cell density of 
107 cells/ml. The cells were stimulated with 2.5 [ig/ml of Con A. The cells were 
cultured for three days at 37 °C in a humidified atmosphere of 5 % COVAir. Prior to the 
assay the cells were washed and resuspended in RPMI 1640 + 20 % F.C.S. at a cell 
density of 106 viable cells/ml.
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Con A induced lymphoblasts - a short-term IL-2 responsive cell.
PBMCs were obtained from a normal individual by density gradient centrifugation 
(section 2.2.1.). The cells were resuspended in complete RPMI 1640 + 5 % F.C.S. at a 
cell density of 106 cells/ml. The cells were stimulated with 5 |ig/ml Con A and cultured 
at 37 °C in a humidified atmosphere of 5 % CCte/Air for 3 days. At day 3, the cells were 
washed and resuspended in complete RPMI 1640 + 5 % F.C.S. at 106 cells/ml and 
cultured under the same conditions for a further 4 days. At day 7 the cells were again 
washed and resuspended in complete RPMI 1640 + 5 % F.C.S. additionally 
supplemented with IL-2 containing supernatant (25 %) and cultured fo a further 3 days. 
Prior to the assay the cells were washed and resuspended in RPMI 1640 + 20 % F.C.S. 
at a cell density of 0.5 x 106 cells/ml.
The assays were started with the addition of the responder cells, 100 fil of the cell 
preparations were added to each well containing the IL-2 dilutions. The HT-2 assay was 
incubated for 24 hours at 37 °C in a humidified atmosphere of 5 % CCh/Air, 4 hours 
prior to the end of the assay 1 |iCi of [3H]-thy was added to each well. The Con A 
induced mouse splenocytes and the Con A induced lymphoblasts were incubated for 72 
hours under the same conditions and 18 hours prior to harvesting 1 fiCi of [3H]-thy was 
added to each well. All three IL-2 assays were harvested as in section 2.7.4..
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4.3.2. HT-2 - The assay of choice.
Figure 4.3.1. describes the dilution curves for purified IL-2 as assayed in each of the 
three bioassays. All three bioassays produced similar dilution curves indicating that the 
bioassays were most likely measuring the same factor, IL-2. When the concentration of 
the purified IL-2 was calculated using the accepted definition of a unit of IL-2 activity 
the figure from each of the bioassays were similar. One unit of IL-2 was defined as the 
amount of IL-2 required to give 50 % maximum activity.
The HT-2 assay was the assay of choice for measuring IL-2 in all subsequent work. 
The assay had two distinct advantages over the other bioassays ; a short incubation (24 
hours) and minimal preparation of responder cells.
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FIGURE 4.3.1.
The figure represents the dilution curve for purified IL-2 in the three 
assay systems. The data are presented as the cpm of tritiated thymidine 
incorporated against the dilution of the purified IL-2.
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4.4. STANDARDISATION OF INTERLEUKIN - 2 PRODUCTION.
Having made the choice of an assay system for measuring IL-2, the next step was to 
standardise a method for producing IL-2. Production of IL-2 was achieved by 
stimulating PBMCs with purified phytohaemagglutinin (Wellcome Grade). The 
variables in the system were length of stimulation, cell density and PHA concentration.
4.4.1. Optimisation of cell number, PHA concentration and length of incubation.
PBMCs were isolated from eight normal individuals by density gradient centrifugation 
(section 2.2.1.). The cells were resuspended in complete RPM I1640 (with HEPES) + 2 
% FCS to give the following final concentrations in culture, after addition of PHA, o f ;
(1) 5 x 106 cells/ml
(2) 2 x 106 cells/ml
(3) 1 x 106 cells/ml
(4) 0.5 x 106 cells/ml
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PHA was made up in complete RPMI 1640 (without FCS) such that when equal 
volumes of the PHA solution were added to cells, a final concentration o f ;
(1) 5 |Xg/ml
(2) 2 fig/ml
(3) 1 iig/ml
(4) 0.5 |Xg/ml
was achieved. The cultures were incubated at 37 °C in a 5 % CCte/Air humidified 
atmosphere for 24 hours or 48 hours. At the end of the incubation period the IL-2 
containing supernatants were harvested (section 2.8.1.). The IL-2 present in the 
supernatants was assessed in the HT-2 bioassay (section 2.8.2.).
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4.4.2. Standardisation - The verdict.
The results are presented in figures 4.4.1. and 4.4.2.. Figure 4.4.1. represents the 
dilution curves for the different cell concentrations stimulated with 2 fig/ml PHA for 48 
hours. Figure 4.4.2. portraits the dilution curves for the same cell concentrations 
stimulated with 1 |ig/ml for 48 hours. The cells stimulated with 5 |Lig/ml PHA gave a 
mixed response and were not represented ; the cells stimulated with 0.5 Jig/ml PHA did 
not produce detectable amounts of IL-2. The time of incubations was set at 48 hours, as 
the response at 24 hours was minimal. These data on the whole agree with published 
findings (Tsoukas, 1984).
Figure 4.4.1. indicates that densities of both 106 cells/ml and 0.5 x 106 cells/ml 
produce similar dilution curves when stimulated with 2 [ig/ml PHA. Figure 4.4.2. also 
indicates that 106 cells/ml and 0.5 x 106 cells/ml stimulated with 1 fig/ml produce 
similar dilution curves. Essentially if the dilution curves were compared then there was 
no significant difference between the cells stimulated with either 1 fig/ml or 2 (ig/ml 
PHA. So the choice becomes an economic one, i.e. a concentration of 1 |Xg/ml was 
chosen for subsequent assays. Comparison of the cell densities reveals a straight choice 
between 106 cells/ml and 0.5 x 106 cells/ml. There was very little between these two 
cell densities, the cell density of 106 cells/ml was selected because the dilution curve 
was slightly more linear and also the fact that most of the published work has used this 
cell density.
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FIGURE 4.4.1.
The figure represents the dilution curve for the standardisation of the cell 
concentration at 2 |ig/ml PHA. The data are the mean of 8 normal individuals 
and the error bars represent the standard error of the mean (SEM). The 
incubation time was 48 hours.
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The figure represents the dilution curves for the standardisation of the cell 
concentration at 1 |ig/ml PHA. The data are the mean of 8 normal individuals 
and the error bars represent the standard error of the mean (SEM). The 
incubation time for these supernatants was 48 hours.
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4.5. THE EFFECTS OF CALCIOTROPHIC HORMONES ON INTERLEUKIN -2 
ACTIVITY.
The results presented in section 3.4. demonstrate that l,25(OH)2D3 has a significant 
effect on lymphocyte transformation and that this effect may be mediated through the Th 
subset. IL-2 was the main cytokine produced by this subset of cells so it was decided to 
investigate the effects of the five calciotrophic hormones on IL-2 activity.
4.5.1. IL-2 activity in the presence of calciotrophic hormones.
PBMCs were isolated from nine normal individuals by density gradient centrifugation 
(section 2.2.1.). These cells were resuspended at a cell density of 106 cells/ml in 
complete RPMI 1640 + 1% F.C.S. and stimulated with 1 jug/ml PHA (section 2.8.1.) in 
the presence of a range of concentrations of the calciotrophic hormones (section 2.5.). 
The cells were cultured for 48 hours, at which time the supernatants were harvested. 
The amount of IL-2 activity in these supernatants was assessed using the HT-2 bioassay 
(section 2.8.2.). The results were expressed as units/ml IL-2.
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4.5.2. l,25(OH)2D3 - The effective IL-2 inhibitor.
Table 4.5.1. documents the IL-2 activity at the various concentrations of the 
calciotrophic hormones studied. There was no significant change in the IL-2 activity in 
the presence of either sCT or b(l-35)PTH. However, at 107 M b(l-35)PTH slightly 
inhibited IL-2 activity but this did not achieve statistical significance. In the case of the 
vitamin D3 metabolites, all three metabolites inhibited IL-2 activity. The active 
metabolite of vitamin D3, l,25(OH)2D3, significantly inhibited IL-2 activity at 1 0 10 M 
which is within the normal physiological range in serum (1011 M - 1010M). Both 
24,25(OH)2D3 and 25(OH)D3 achieved significance only at 107 M. 24,25(OH)2D3 
produced a greater inhibition than did 25(OH)D3 although compared to l,25(OH)2D3 the 
inhibition was minimal. The magnitude of inhibition fits in nicely with the order of 
affinity of the l,25(OH)2D3, 24,25(OH)2D3 and 25(OH)D3 for the vitamin D receptor 
(VDR).
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The effect of 1.25 dihydroxwitamin D3 
on IL-2 activity
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FIGURE 4.5.1.
The figure represents the IL-2 activity present in supernatants produced in the 
presence of 1,25 dihydroxyvitamin D3. The IL-2 activity is presented as the 
percentage of control data i.e. when the supernatants were obtained in the 
presence of the carrier (ethanol). The data are the mean of 9 normal 
individuals. The standard error of the mean are represented as error bars. 
Statistics in the form of a paired Wilcoxon test was carried out (*p< 0.05).
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Figure 4.5.1. depicts the inhibition of IL-2 by l,25(OH)2D3. The IL-2 was expressed 
as a percentage of the control value (100 %). The inhibition of IL-2 activity occurs from 
1012 M onwards and achieves significance at 1010 M. The IL-2 continues to fall 
throughout the range. Local extra-renal synthesis of l,25(OH)2D3 may result in 
concentrations in excess of normal sera (1011 M - 1010 M) at particular sites in the body 
and thus the effect seen at higher concentrations could be of physiological importance.
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4.6. THE EFFECTS OF l,25(OH)2D3 AND SEX HORMONES ON INTERLEUKIN -2 
ACTIVITY.
As demonstrated in section 3.5. the sex hormones can also inhibit lymphocyte 
activation in a manner similar to l,25(OH)2D3. In section 4.5., l,25(OH)2D3 was shown 
to inhibit IL-2 activity and this inhibition mirrored the inhibition of lymphocyte 
activation. A comparison of the effects of l,25(OH)2D3 and the sex hormones, 
oestrogen, progesterone and dihydrotestosterone on IL-2 activity was undertaken.
4.6.1 IL-2 activity in the presence of l,25(OH)2D3 and of various sex hormones.
PBMCs were obtained from four normal individuals by density gradient centrifugation 
(section 2.2.1.). The cells were cultured at a cell density of 106 cells/ml in complete 
RPMI1640 + 1 % F.C.S. in the presence of a range of l,25(OH)2D3 concentrations or of 
a range of either of the sex hormones (oestrogen, progesterone or dihydrotestosterone). 
The cells were stimulated with 1 (ig/ml PHA (Wellcome Grade) and cultured for 48 
hours at 37 °C in a humidified atmosphere of 5 % C02/Air. After the incubation period 
the supernatants were harvested (section 2.8.1.) and stored at -20 °C. The amount of IL- 
2 in each of the supernatants was determined in the HT-2 bioassay (section 2.8.2.). The 
results were expressed both as units/ml and as percentage (%) of control activity.
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Interleukin-2 Activity in the presence of 1.25 dihvdroxwitamin 
D3. oestrogen, progesterone or dihvdrotestosterone
Steroid
Hormone
Concentration
(M)
l,25(OH)2D3 
IL-2 Activity 
(units/ml)
Oestrogen 
IL-2 Activity 
(units/ml)
Progesterone 
IL-2 Activity 
(units/ml)
Dihydrotestosterone 
IL-2 Activity 
(units/ml)
0 10.3 9.2 9.9 11.1
(3.6) (3.1) (3.7) (4.7)
10-13 7.2 8.8 7.1 10.1
(2.5) (3.1) (2.7) (4.8)
lO 12 7.4 7.9 6.5 7.0
(2.7) (2.9) (2.4) (3.2)
10-n 5.1 5.9 5.9 6.0
(1.8) (1.9) (2.7) (3.5)
lO-io 4.9 7.3 7.1 7.2
(1.5) (2.8) (3.2) (2.7)
10-9 4.3 7.9 7.2 6.3
(1.0) (2.9) (3.2) (2.6)
lO'8 3.7 8.8 7.6 8.0
(1.0) (3.2) (2.9) (3.5)
lO-2 3.8 11.0 10.9 10.8
(1.0) (4.4) (5.2) (4.4)
TABLE 4.6.1.
The table presents the IL-2 activity present in supernatants produced in the 
presence of 1,25 dihydroxyvitamin D3 and the three sex hormones (oestrogen, 
progesterone and dihydrotestosterone). The IL-2 activity is presented as units/ml. The 
data are the mean of 4 normal individuals. The standard error of the mean are presented 
in parenthesis. Statistics were inappropriate.
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Interleukin-2 activity expressed as a percentage of control in the presence
of 1.25 dihydroxvvitamin D3. oestrogen, progesterone dihvdroestosterone
Steroid
Hormone
Concentration
(M)
l,25(OH)2D3 
IL-2 Activity 
(% control)
Oestrogen 
IL-2 Activity 
(% control)
Progesterone 
IL-2 Activity 
(% control)
Dihydrotestosterone 
IL-2 Activity 
(% control)
0 100 100 100 100
lO 13 72.4 95.4 71.3 85.0
(3.1) (4.1) (0.9) (5.0)
10-12 69.8 82.1 65.7 59.9
(3.6) (3.8) (3.0) (3.6)
10-u 49.1 65.5 55.2 49.3
(4.5) (2.0) (4.8) (8.6)
lO-io 51.2 74.2 67.4 70.4
(4.4) (5.8) (6.7) (4.6)
10-9 52.3 83.1 68.2 58.1
(10.1) (4.0) (11.3) (5.6)
10-8 40.6 94.8 79.4 73.3
(5.0) (5.7) (7.2) (5.0)
10-7 43.8 118.9 106.5 99.2
(6.6) (14.7) (14.6) (2.1)
TABLE 4.6.2.
The figure presents the IL-2 activity present in supernatants produced in the 
presence of either 1,25 dihydroxyvitamin D3 or either of the sex hormones (oestrogen, 
progesterone or dihydrotestosterone). The IL-2 activitys are presented as percentage of 
control. The data are the mean of 4 normal individuals. The standard error of the mean 
are represented as error bars. Statistics were inappropriate.
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4.6.2. Sex hormones - A different pattern of inhibition.
The effects of l,25(OH)2D3 and of the sex hormones on IL-2 activity are documented 
in table 4.6.1.. The first point is that the data follows much the same pattern as it did for 
lymphocyte activation. l,25(OH)2D3 inhibits IL-2 activity throughout the range of 
concentrations of the metabolite tested. The sex hormones inhibit the IL-2 activity 
initially with the peak inhibition coming at 1011 M. The sex hormones then become less 
effective inhibitors of IL-2 activity, in a dose dependent manner. As a result at 107 M 
the sex hormones have no effect on the IL-2 activity the IL-2 activity has returned to 
control levels. In figure 4.6.1., the IL-2 activity is represented graphically and each of 
the sex hormones can be seen to match the l,25(OH)2D3 over the range 0 M to 1011 M. 
From 1010 M to 107 M the l,25(OH)2D3 continues to inhibit the IL-2 activity whereas 
the sex hormones are less effective inhibitors. Table 4.6.2. presents the IL-2 activity 
results as percentage (%) control. This has the effect of minimising the error as the 
variation in the IL-2 activity between individuals was substantial when expressed as 
units/ml. The data was much tighter when presented in this form and confirms the 
conclusions derived from the units/ml data.
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The effect of 1.25 dihydroxyvitamin D3 and the Sex 
hormones on IL-2 activity
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Figure 4.6.1.
The figure represents the IL-2 activity present in supernatants produced in the 
presence of either 1,25 dihydroxyvitamin D3 or either of the sex hormones 
(oestrrogen, progesterone or dihydrotestosterone). The IL-2 activities are 
presented as units/ml. The data are the mean of 4 normal individuals. The 
standard error of the mean (SEM) are represented as error bars. Statistics were 
inappropriate.
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The effect of 1.25 dihydroxyvitamin D3 and the Sex 
hormones on IL-2 activity expressed as a percentage
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FIGURE 4.6.2.
The figure represents the IL-2 activity present in supernatants produced in the 
presence of either 1,25 dihydroxyvitamin D3 or either of the sex hormones 
(oestrogen, progesterone or dihydrotestosterone). The IL-2 activities are 
presented as percentage of control. The data are the mean of 4 normal 
individuals. The standard error of the mean (SEM) are represented as error 
bars. Statistics were inappropriate.
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4.6.3. Inhibition by l,25(OH)2D3 - A suggestion of a second mechanism.
l,25(OH)2D3 was a more potent inhibitor of IL-2 activity. All three sex hormones, 
however, match l,25(OH)2D3 as regards inhibition over the range 1013 M to 1011 M. At 
concentrations greater than 1011 M the sex hormones become less effective inhibitors of 
IL-2 activity. As was the case with the effects on lymphocyte activation the likely 
explanation was down regulation of the appropriate sex hormone receptor. It has to be 
remembered that like the sex hormones l,25(OH)2D3 is a steroid hormone - a seco 
steroid. It is therefore possible that the inhibition observed over the range 1013 M to 10- 
nM for each of the steroid hormones could be occurring through the same mechanism. 
Whereas with the sex hormones the down regulation of the steroid hormone receptor 
comes into play at 10 nM, this down regulation appears less important in the case of 
l,25(OH)2D3. A second mechanism may be involved in the inhibition of both IL-2 
activity and of lymphocyte activation (at concentrations in excess of 1 0 11 M).
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4.7. l,25(OH)2D3 - DOES IT PREVENT SECRETION OF INTERLEUKIN - 2 ?
A plausible explanation for the role of l,25(OH)2D3 in the inhibition of IL-2 activity is 
that it may be acting to prevent the secretion of IL-2 from the cell. As mentioned in the 
text earlier the mRNA for IL-2 produces a primary translational product that contains 
the classical hydrophobic signal sequence. This would suggest that the IL-2 is secreted 
in the same manner as other secretory proteins. It was therefore possible that 
l,25(OH)2D3 is interfering with the post translational modification of the IL-2. This 
scenario was investigated, because the assay system was known to be sensitive to 
unmodified recombinant IL-2 it was safe to assume that the assay could recognise any 
IL-2 that is translated and awaiting post-translational modification.
4.7.1. Comparison of normal supernatants and supernatants from lysed cells.
PBMCs from seven normal individuals were obtained by density gradient 
centrifugation (section 2.2.1.). The cells were stimulated with 1 |ig/ml PHA (Wellcome 
Grade) and cultured for 48 hours in the presence of a range of concentrations of 
l,25(OH)2D3 (section 2.5.1.) at 37 °C in a humidified atmosphere of 5 % CCh/Air. The 
cultures were set up in duplicate. One set of cells were harvested in the usual way 
(section 2.8.1.). The second set of cells were lysed by subjecting the cells to three 
cycles of freeze-thawing. The supernatant was then obtained by centrifugation followed 
by sterile filtering to remove cell debris. The supernatants from both harvesting 
methods were assessed for IL-2 activity using the HT-2 bioassay (section 2.8.2.).
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4.7.2. Inhibition by l,25(OH)2D3 still evident in supernatants from lysed cells.
Figure 4.7.1. documents the effect of l,25(OH)2D3 on IL-2 activity in both the 
supernatants from whole cells and from lysed cells. l,25(OH)2D3 inhibits IL-2 activity 
in both supernatant preparations. The curve obtained from the lysed cell supernatants 
was consistently lower than the curve obtained from the whole cell supernatants. There 
are two possible explanations for this ; one is that the IL-2 was sticking to the filter 
(which was possible considering the nature of the filters) the second is the possible 
release of inhibitor molecules during the lysis process that are binding to or competing 
with EL-2. The inhibitor molecules could take the form of the IL-2 receptor themselves. 
However, the fact remains that l,25(OH)2D3 was still inhibiting IL-2 in the lysed 
supernatants implying that l,25(OH)2D3 does not effect the secretion of IL-2. If 
l,25(OH)2D3 was inhibiting the IL-2 secretion then it would have been expected that the 
IL-2 activity would be constant throughout the range of l,25(OH)2D3. It is therefore 
unlikely that l,25(OH)2D3 was involved in the post-translational modification of IL-2. 
Interpretation of these results is made difficult by the fact that the signal sequence may 
indeed render the molecule inactive in the assay system.
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lysed cells and from normal supernatants in the 
presence of 1.25 dihydroxyvitamin D3
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FIGURE 4.7.1.
The figure represents the IL-2 activity present in supernatants produced in the 
presence of 1,25 dihydroxyvitamin D3. The supernatants were produced 
either by spinning down the cells or by subjecting the cells to three freeze - 
thaw cycles followed by centrifugation. The IL-2 activities are presented as 
units/ml. The data are the mean of 7 normal indiviuals. The standard error of 
the mean (SEM) are represented as error bars.
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4.8. l,25(OH)2D3 - DOES IT INTERFERE WITH THE ACTIVATION PROCESS ?
When the known facts are considered it is difficult to envisage l,25(OH)2D3 mediating 
its effect through the signal induction pathway. It is known that resting lymphocytes do 
not possess the vitamin D receptor (VDR) nor for that matter the high affinity IL-2 
receptor (IL-2R). Activated lymphocytes, on the other hand, do possess both receptors. 
The only conceivable way that l,25(OH)2D3 could alter the lymphocyte activation 
process by antigen or mitogen is to prevent the mitogen delivering its signal to the 
membrane. This would imply that the l,25(OH)2D3 has to function outside the cell.
4.8.1. PHA - Does it have to be present throughout ?
PBMCs from three normal individuals were obtained by density gradient 
centrifugation (section 2.2.1.). IL-2 containing supernatants were produced in two 
distinct ways. The first series of cells were set up in the usual way. The cells were 
resuspended at a cell density of 106 cells/ml in complete RPM I1640 and stimulated with 
1 (ig/ml PHA (Wellcome Grade). The cells were then cultured in the presence of a 
range of l,25(OH)2D3 concentrations (section 2.5.1.) at 37 °C in a humidified 
atmosphere of 5 % CCh/Air for 48 hours. The second series of cells were resuspended 
at a cell density of 106 cells/ml in complete RPMI 1640 and stimulated with 1 |ig/ml 
PHA (Wellcome Grade). The cells were incubated at 37 °C in a humidified atmosphere 
of 5 % CCh/Air for four hours. The cells were washed three times in complete RPMI 
1640 to remove as much of the PHA as was possible. These cells were then cultured in 
the presence of the range of l,25(OH)2D3 concentrations for a further 44 hours at 37 °C 
in a humidified atmosphere of 5 % CCh/Air. At the end of their respective incubations 
the IL-2 containing supernatants were harvested (section 2.8.1.). The IL-2 activity 
present was assessed in the HT-2 bioassay (section 2.8.2.).
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4.8.2. Inhibition by l,25(OH)2D3 - Not an effect on the activation signal.
The curves shown in figure 4.8.1. represent the effect of l,25(OH)2D3 on IL-2 activity 
of cells cultured for 48 hours. One set of data refers to when the cells were stimulated 
with PHA for 48 hours and cultured in the presence of a range of l,25(OH)2D3 
concentrations throughout. The second set of data was obtained from cells stimulated 
with PHA for four hours and cultured for the remainder of the time in the presence of a 
range of l,25(OH)2D3. Irrespective of whether the PHA was present on its own for four 
hours or was present throughout the incubation, l,25(OH)2D3 still inhibited the IL-2 
activity. The IL-2 activity in the supernatants derived from the cells stimulated with 
PHA for four hours prior to addition of l,25(OH)2D3 was lower than the supernatants 
derived from cells stimulated with PHA throughout. A possible explanation is that the 
PHA stimulus could continually stimulate the cells for 48 hours hence the higher IL-2 
activity in this set up. Figure 4.8.1. represents the IL-2 activity for one individual 
considered to be representative of the three individuals tested. Statistical tests are thus 
inappropriate.
The inhibition of IL-2 activity by l,25(OH)2D3 can therefore not be attributed to an 
effect on the activation signal. If l,25(OH)2D3 was affecting the activation signal then 
stimulation with PHA for four hours followed by a culture period in the presence of 
l,25(OH)2D3 should not produce an inhibition of the IL-2 activity. Clearly there was 
still an inhibition, it was therefore reasonable to assume that l,25(OH)2D3 was acting at 
a later stage possibly after the appearance of the VDR in the activated lymphocyte 
population.
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The effect of 1.25 dihydroxwitamin D3 on IL-2 activity 
when cells were stimulated either for the whole culture 
period or only for the initial four hours
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FIGURE 4.8.1.
The figure represents the IL-2 activity present in supernatants produced in the 
presence of 1,25 dihydroxyvitamin D3. The supernatants were produced 
either by stimulating with PHA in the presence of l,25(OH)2D3 for 48 hours 
or by stimulating with PHA alone for 4 hours, followed by culture in the 
absence of PHA but in the presence of l,25(OH)2D3 for a further 44 hours. 
The IL-2 activities are presented as units/ml. The data are the results from 1 
representative normal individual.
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4.9. INTERLEUKIN -2 ACTIVITY - A GENUINE INHIBITION BY l,25(OH)2D3.
Following on from chapter 3 where l,25(OH)2D3 was established as the most effective 
calciotrophic hormone as regards lymphocyte transformation, it has been established 
that the same is true for IL-2 activity. PTH and CT failed significantly to alter IL-2 
activity. 24,25(OH)2D3 and 25(OH)D3 did achieve a significant inhibition of IL-2 
activity, but this occurred at the higher concentrations tested (107 M). The inhibition of 
IL-2 activity correlates with the affinity for the D3 metabolites for the vitamin D 
receptor (VDR). l,25(OH)2D3 is therefore probably mediating its effect through the 
VDR.
The inhibition of IL-2 activity by l,25(OH)2D3 occurs within the physiological range 
of this metabolite i.e. between 1011 M and 10 10 M in sera. Given that extra-renal 
synthesis of l,25(OH)2D3 has been reported in monocytes it is possible that 
concentrations in excess of 1010 M could be attained in the local microenvironment. It 
was clear that the inhibition of IL-2 activity by l,25(OH)2D3 could be an important 
factor in immunoregulation. It was important to establish that the observed inhibition 
was not an artifact of the in vitro system, the fact that l,25(OH)2D3 could inhibit IL-2 
activity after lymphocyte activation was initiated suggests that the effect was not due to 
some interaction between the l,25(OH)2D3 and the activation signal (PHA) and 
therefore the effect was genuine.
It has been suggested that l,25(OH)2D3 may affect the secretion of the cytokine i.e. 
acts at the level of post-translational modification. This is unlikely as the supernatant 
produced from lysed cells exhibited an inhibition of the IL-2 activity. It is therefore 
possible to assume that the major effect of l,25(OH)2D3 does not occur through effects 
on post-translational events in the production of IL-2.
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CHAPTER 5.
1,25 DIHYDROXYVITAMIN D3 AND OTHER CYTOKINES.
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5.1. OTHER CYTOKINES.
The inhibition of interleukin-2 (IL-2) by l,25(OH)2D3 has been demonstrated in the 
previous chapter. It was now important to establish whether or not this effect was 
unique to IL-2 or whether other cytokines were influenced by l,25(OH)2D3. The 
activation of lymphocytes in the immune system is intimately involved with cells of the 
monocyte/macrophage (M<|)) lineage. As a consequence the effects of l,25(OH)2D3 on 
the monokines, interleukin-1 (IL-1) and interleukin-6 (IL-6) were studied.
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5.1.1. Interleukin -1  (IL-1).
Interleukin - 1 (IL-1) was initially described as a factor that acted as a co - mitogen for 
murine thymocytes stimulated with suboptimal concentrations of either PHA or Con A 
(Gery, 1972). Originally IL-1 was believed to be a product of activated macrophages 
(M<p) : now, it has become evident that IL-1 activities can be produced by virtually 
every nucleated cell type. IL-1 is produced by fibroblasts, endothelial cells, 
keratinocytes and smooth muscle to name but a few. The major source, however, 
remains the macrophage. It has been demonstrated that IL-1 is synthesised as a 33 
kilodalton (kD) precursor that is processed to give a final product that ranges from 13 - 
17 kD (Giri, 1985). There are two distinct species of IL-1, these are a  and p. The a  
(271 amino acids) and the P (269 amino acids) exhibit limited sequence homology (22 - 
26 %) (Mizel, 1988) although this sequence homology occurs at the biologically active 
carboxy-terminus. The a  and P molecules have also different isoelectric points (pi for a  
= 5, pi for P = 7). The pathway for IL-1 secretion is poorly understood, but it is known 
that the precursor for IL-1 lacks the classical hydrophobic sequence (Lomedico, 1987). 
As a consequence of the absence of the 15 - 17 kD protein inside the cell it is assumed 
that the processing of the precursor occurs either at the membrane or after secretion.
The target cells for IL-1 are many and varied but all share a common involvement in 
immune or inflammatory responses. IL-1 has been reported to effect fibroblasts, 
synovial cells, chondrocytes, endothelial cells, hepatocytes and osteoclasts outside the 
immune system. However, the target cell that concerns most scientists is the T-cell. 
The CD4 +ve Th cells respond to the dual signal of antigen in association with major 
histocompatability complex (MHC) class II and IL-1 generated by the monocyte. The 
result of this sequence is to allow the T-cell to proliferate and to release a variety of 
cytokines including IL-2. It was for these reasons that the effects of l,25(OH)2D3 on EL- 
1 activity in PBMCs were studied.
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5.1.2. Interleukin-6 (IL-6).
Like IL-1, interleukin-6 (IL-6) has a broad range of target cells and can influence the 
immune system in many ways. Indeed, it has previously been called ; hybridoma 
growth factor (HGF), plasmacytoma growth factor, hepatocyte stimulating factor, B-cell 
stimulating factor 2 and (32-interferon (Billiau, 1989; Kishimoto, 1988). Also like IL-1, 
IL-6 is a glycoprotein that is heterogeneous in size (23 - 30 kD). This heterogeneity is a 
consequence of differential glycosylation. The protein has a structure of 212 amino 
acids, the first 28 form the classic hydrophobic signal sequence. IL-6 is produced by a 
variety of cells, which include monocyte/macrophages, fibroblasts, endothelial cells, T 
and B cells, mesangial cells, keratinocytes and a number of tumour types. Normal cells 
do not produce IL-6 unless the cells are stimulated. IL-6 production can be stimulated 
by a variety of factors including IL-1, tumour necrosis factor a  (TNF a), platelet derived 
growth factor (PDGF), virus infection, double stranded RNA and cyclic AMP.
Generally, IL-6 is produced during the immune response and can effect both T-cell 
and B-cell differentiation. The effects of IL-6 are mostly seen when there is another 
stimulus present - more often than not, IL-1. Lymphocyte activation, as it happens, 
provides an excellent example of a synergistic effect between cytokines. The 
stimulation of lymphocyte proliferation by IL-6 involves a direct growth promoting 
signal and also an induction of IL-2 receptors. IL-6 is also involved with cytotoxic T- 
cells - the cytokine induces the generation of these cell types. This agrees with the 
postulated role for IL-6 in antiviral activity. IL-6 has also been implicated in B-cell 
growth and differentiation into antibody secreting cells. As a consequence of the key 
role that IL-6 has on lymphocyte activation, the effects of l,25(OH)2D3 were studied in 
the production of this cytokine.
145
5.2. INTERLEUKIN - 1 ACTIVITY - DOES l,25(OH)2D3 HAVE AN EFFECT ON 
INTERLEUKIN - 1 ACTIVITY.
Most of the work up to this point was carried out on PBMC's and therefore the cell 
population was mixed. It was important to establish whether or not l,25(OH)2D3 was 
acting on monocytes and the inhibition was mediated through these cells. PHA was 
used in order that the systems could be compared.
5.2.1. The effect of l,25(OH)2D3 on IL-1 activity.
PBMCs were obtained from eight normal individuals by density gradient 
centrifugation (section 2.2.1.). The cells were resuspended at 106 cells/ml in complete 
RPMI 1640 + 2 % F.C.S. and were either stimulated with PHA (1 fig/ml) or were 
unstimulated. The cells were cultured in the presence of a range of concentrations for 
l,25(OH)2D3 (1013 M - lO-7 M). The cells were cultured overnight (approximately 18 
hours) at 37 °C in a humidified atmosphere of 5 % C02/Air. The supernatants were 
harvested and stored at -20 °C until assayed for IL-1. An overnight incubation was 
chosen to maximise IL-1 while minimising IL-2 activity.
The IL-1 present in the supernatants was assessed using the IL-1 bioassay (section
2.9.3.). The samples were set up in triplicate as four dilutions of the supernatant (final 
dilutions in the assay of 1 in 10,1 in 100, 1 in 1000 and 1 in 10000). The standard curve 
was constructed from an in - house standard (section 2.9.2.) that had been calibrated 
against the standard obtained from the National institute of Biological Standards. The 
standard curve was made up of ten two - fold dilutions of a 1 in 100 dilution of the 
standard preparation (section 2.9.2.).
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5.2.2. IL-1 activity - Very little change.
The IL-1 activity in the presence of various concentrations of l,25(OH)2D3 in both 
stimulated cells (PHA) and unstimulated cells is presented in table 5.2.1.. There was not 
much difference in the amount of IL-1 activity produced by either stimulated or 
unstimulated cells throughout the range of l,25(OH)2D3 concentrations. The IL-1 
activity in unstimulated cells was significantly inhibited at 1010 M l,25(OH)2D3 but the 
IL-1 activity returned to control levels at higher concentrations of l,25(OH)2D3. The 
stimulated cells, however, were significantly inhibited at both 1013 M and 1011 M 
l,25(OH)2D3. At higher concentrations of l,25(OH)2D3 the IL-1 activity returned to 
control levels. The results are also represented in figure 5.2.1.. The inhibition of IL-1 
activity by l,25(OH)2D3 observed in both stimulated and unstimulated cells appears to 
be minor compared to the inhibition of IL-2 and lymphocyte activation by l,25(OH)2D3 
(section 4.5. and section 3.4.).
5.2.3. Minimal contribution by IL-1 to the inhibition of IL-2 by l,25(OH)2D3.
Although at some concentrations of l,25(OH)2D3 there appears to be a minor 
inhibition of IL-1 activity, there does not appear to be enough of an effect to account for 
the inhibition of IL-2 by l,25(OH)2D3. The observation that there was very little 
difference between the stimulated cells and the unstimulated cells argues that the 
contribution made by PHA stimulation on IL-1 activity was negligible and consequently 
strengthens the argument for the inhibition of IL-2 by l,25(OH)2D3 being a real effect in 
the system.
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Interleukin-1 activity produced in cells cultured in the presence of 1.25 
dihvdroxwitamin D3 and either stimulated or unstimulated with PHA
l,25(OH)2D3
(Molar)
IL-1 activity
(units/ml)
Unstimulated
IL-1 activity
(units/ml)
Stimulated
0 256.8 309.3
(92.8) (100.2)
10-13 194.8 213.5*
(69.1) (62.5)
IO-12 201.1 234.7
(60.7) (79.1)
1 0 -n 149.3 206.5
(46.8) (63.9)
lO-io 193.5* 224.8
(70.3) (68.7)
10'9 250.0 259.1
(108.1) (78.3)
10-8 263.3 332.1
(97.4) (125.3)
10-7 250.4 238.9
(90.5) (67.9)
Table 5.2.1.
The table presents the DL-1 activity present in supernatants produced in the 
presence of 1,25 dihydroxyvitamin D3 when stimulated with PHA or unstimulated. The 
data were obtained from 8 normal individuals and are presented as the mean with the 
standard error of the mean in parenthesis. The IL-1 activity is measured in units/ml. 
Statistics took the form of a paired Wilcoxon test (* p < 0.05) and compared 0 with all 
other concentrations of l,25(OH)2D3.
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FIGURE 5.2.1.
The figure represents the IL-1 activity in units/ml of cells that were either 
stimulated with PHA or unstimulated and cultured in the presence of 1,25 
dihydroxyvitamin D3. The data were obtained from 8 normal individuals. 
The standard error of the mean (SEM) are represented as error bars. The 
paired Wilcoxon statistical test was used to ascertain the significance of the 
results (*p> 0.05) comparing 0 with all other concentrations of 1,25 
dihydroxyvitamin D3.
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5.3. LIPOPOLYSACCHARIDE - A MORE APPROPRIATE STIMULUS FOR 
INTERLEUKIN - 1 ACTIVITY.
Monocytes are normally stimulated with lipopolysaccharide (LPS) which substitutes 
for the bacterial cell wall that acts as a stimulus in vivo. In this section the effects of 
l,25(OH)2D3 on IL-1 activity produced by PBMCs stimulated with LPS were studied.
5.3.1. The effect of l,25(OH)2D3 on LPS induced IL-1 activity.
PBMCs were obtained from seven normal individuals by density gradient 
centrifugation (section 2.2.1.). The cells were resuspended at 106 cells/ml in complete 
RPMI 1640 + 5 % F.C.S. and stimulated with 10 |Ug/ml LPS. The cells were cultured in 
the presence of a range of concentrations of l,25(OH)2D3 (10*13 M - 10*7 M) at 37 °C for 
18 hours in a humidified atmosphere of 5 % C02/Air. The supernatants were harvested 
and stored at -20 °C until assayed.
The IL-1 activity was assessed in the LBRM TG6/HT-2 bioassay (section 2.9.3.). The 
samples were set up in duplicate as eight dilutions five - fold dilutions (1 in 5, 1 in 25, 1 
in 125, 1 in 625, 1 in 3125, 1 in 15625, 1 in 78125 and 1 in 390625). The standard curve 
was constructed from a two - fold serial dilution of a 1 in 100 dilution of the in - house 
IL-1 standard preparation (section 2.9.2.).
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5.3.2. l,25(OH)2D3 - No real change in IL-1 activity.
The IL-1 activity in supernatants derived from PBMCs stimulated with 10 |ig/ml LPS 
and cultured in the presence of a range of l,25(OH)2D3 concentrations is presented in 
table 5.3.1.. IL-1 activity was initially enhanced by l,25(OH)2D3 with the peak 
enhancement occurring at 10*12 M with the IL-1 activity returning to control levels at 
higher concentrations of l,25(OH)2D3 (10-8 M). At 107 M the IL-1 activity appeared to 
be inhibited. The data is also presented in figure 5.3.1..
5.3.3. Inhibition of IL-2 by l,25(OH)2D3 - No IL-1 involvement.
These observations were the opposite of the ones presented in the previous section. 
The main difference between the two experiments are the method of stimulation. The 
important observation was that the effect of l,25(OH)2D3 on IL-1 activity is not a dose 
dependent effect in either case. This argues that the effect that was seen with 
l,25(OH)2D3 on IL-2 activity is not mediated through IL-1 activity.
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Interleukin-1 activity produced bv cells cultured in
the presence of 1.25 dihydroxyvitamin D3 and stimulated 
with LPS
l,25(OH)2D:
(Molar)
IL-1 activity 
(units/ml)
0 897.3
(188.7)
10-13 827.1
(233.1)
IO-12 1464.6
(713.9)
1 0 -n 1193.7
(428.4)
lO-io 1022.1
(256.8)
10-9 1001.7
(169.1)
10-8 916.8
(224.9)
10-7 585.7
(133.9)
TABLE 5.3.1.
The table presents the IL-1 activity present in supernatants produced in the 
presence of 1,25 dihydroxyvitamin D3 when stimulated with LPS. The data were 
obtained from 7 normal individuals and are presented as the mean with the standard 
error of the mean in parenthesis. The IL-1 activity is measured in units/ml. Statistics 
took the form of a paired Wilcoxon test (* p < 0.05) and compared 0 with the other 
concentrations of l,25(OH)2D3.
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FIGURE 5.3.1.
The figure represents the IL-1 activity present in supernatants produced in the 
presence of 1,25 dihydroxyvitamin D3 when stimulated with LPS. The data 
were obtained from 7 normal individuals and are presented as the mean with 
the standard error of the mean (SEM) represented as error bars. The IL-1 
activity is measured in units/ml. Statistics in the form of a paired Wilcoxon 
test comparing 0 to all other concentrations of 1,25 dihydroxyvitamin D3 
revealed no significant differences.
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5.4. NO EFFECT ON INTERLEUKIN - 1 ACTIVITY - A GENUINE
OBSERVATION.
The pattern of results obtained in section 5.3. was further investigated to ascertain 
whether the effect is genuine or an artifact arising from the stimulation with LPS (PHA 
as a stimulus does not effect HT-2 cells). It could be that the LPS present in the 
supernatant interferes with the LBRM TG6/HT-2 bioassay. To investigate this 
possibility the supernatants produced in section 5.3 were also assayed on the IL-ip 
ELISA kit obtained from Cistron Biotechnology, New Jersey, U.S.A.. This assay being 
an ELISA should not be influenced by excess LPS present in the supernatants.
5.4.1. IL-1 activity as measured by an ELISA.
The assay was set up as described in section 2.9. and the samples were diluted 1 in 10 
in complete RPMI 1640. The standards and the diluted samples were carried out in 
duplicate.
5.4.2. Assays produce same trend.
Table 5.4.1. depicts the IL-lp activity present in the supernatants obtained in section
5.3.. Clearly the pattern is the same so the results obtained in section 5.3. would appear 
to be genuine and the difference between the IL-1 activity in cells stimulated with PHA 
and LPS is a consequence of the stimulation signal. Figure 5.4.1. demonstrates that the 
graph obtained is essentially the same as figure 5.3.1..
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Interleukin-1 activity produced bv cells cultured in
the presence of 1.25 dihydroxyvitamin D3 and stimulated 
with LPS assessed bv an ELISA method
l,25(OH)2D3
(Molar)
IL-1 activity 
(units/ml)
0 108.3
1(H3
(17.5)
123.1
IO-12
(28.3)
151.8
10-u
(24.1)
179.4
lO-io
(31.9)
129.2
10-9
(34.3)
62.5
10-8
(18.8)
84.7
10-7
(17.5)
102.7
(16.1)
TABLE 5.4.1.
The table presents the IL-ip activity present in supernatants produced in the presence 
>f 1,25 dihydroxyvitamin D3 when stimulated with LPS. The data were obtained from 7 
lormal individuals and are presented as the mean with the standard error of the mean in 
>arenthesis. The IL-ip activity is measured in units/ml. Statistics took the form of a paired 
iVilcoxon test and compared 0 to all other concentrations of l,25(OH)2D3. There was no 
ignificant differences throughout the range.
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FIGURE 5.4.1.
The figure represents the IL-16 activity present in supernatants produced in 
cells stimulated with 10 ug/ml LPS and cultured in the presence of 1,25 
dihydroxyvitamin D3. The data were obtained from 7 normal individuals and 
are presented as the mean with the standard error of the mean (SEM) 
represented as error bars. The IL-1 activity is measured in units/ml. Statistics 
in the form of a paired Wilcoxon test comparing 0 to all other concentrations 
of 1,25 dihydroxyvitamin D3 revealed no significant differences.
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5.4.3. IL-1 activity can not account for the inhibition of IL-2 by l,25(OH)2D3.
The stimulus for the production of IL-1 was important. Depending on the stimulus an 
increase or a decrease in IL-1 activity could be attained in the presence of l,25(OH)2D3. 
The increase or decrease was not dose dependent and returned to control values at the 
higher concentrations of the l,25(OH)2D3. The dose dependent effects of l,25(OH)2D3 
on both IL-2 activity and cell proliferation can not therefore be accounted for by 
changes in the IL-1 activity.
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5.5. INTERLEUKIN - 6 ACTIVITY - DOES l,25(OH)2D3 H AVE A N  EFFECT ?
If IL-1 activity was not altered by l,25(OH)2D3 then perhaps IL-6 activity could be. 
Like IL-1, IL-6 is produced by the monocyte and therefore could also be a candidate for 
a possible mediator of the inhibition of IL-2 by l,25(OH)2D3.
5.5.1. The effect of l,25(OH)2D3 on IL-6 activity.
PBMCs were obtained from eight normal individuals by density gradient 
centrifugation (section 2.2.1.). The cells were resuspended in complete RPM I1640 at a 
cell density of 106 cells/ml. The cells were either stimulated with 1 jig/ml PHA 
(Wellcome Grade) or were unstimulated. The cells were cultured in the presence of a 
range of concentrations of l,25(OH)2D3 (1013 M - 10 7 M). The cells were cultured for 
18 hours at 37 °C in a humidified atmosphere of 5 % CCh/Air. The supernatants were 
harvested and stored at -20 °C until required in the assay.
The IL-6 activity was assessed in the B9 bioassay (section 2.10.2.). The IL-6 
containing supernatants were two - fold serially diluted in complete RPMI 1640. The 
B9 cells were incubated with these dilutions for 68 hours at which time MTT was added 
to each well (section 2.10.4.). The assay was assessed at 72 hours using the Dynatech 
MR 700 microplate reader.
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5.5.2. No sustained effect on IL-6 activity.
Table 5.5.1. illustrates the IL-6 activity present in cells stimulated with PHA (1 |Xg/ml) 
and unstimulated cells cultured in the presence of a range of l,25(OH)2D3 
concentrations. There was very little difference in the IL-6 activity in cells that were 
stimulated as compared to their unstimulated counterparts. The stimulated cells were 
slightly higher than the unstimulated cells. Like the IL-1 activity the IL-6 activity 
appears to increase initially as the l,25(OH)2D3 concentration is increased, also after 10* 
11 M the activity falls back to control levels. Figure 5.5.1. represents the data 
graphically. Again the similarities between the IL-1 activities (figure 5.2.1.) and the IL- 
6 activities are quite striking. The effect of l,25(OH)2D3 on both IL-2 activity and cell 
proliferation (section 4.5. and section 3.4.) can not be explained by an effect on IL-6 
activity.
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Interleukin-6 activity produced in cells cultured in the presence of 1.25
dihvdroxwitamin D3 and either stimulated or unstimulated with PHA
l,25(OH)2D3
(Molar)
IL-6 activity
(units/ml)
Unstimulated
IL-6 activity
(units/ml)
Stimulated
0 431.4 481.2
lO 13
(93.7)
481.8
(69.9)
515.6
IO-12
(105.1)
526.8
(88.9)
552.4
10-u
(131.5)
434.2
(109.4)
561.7
lO-io
(90.0)
391.1
(145.9)
370.7
10-9
(68.0)
474.5
(86.3)
502.9
10-8
(85.7)
480.8
(141.4)
467.4
10-7
(94.5)
406.6
(106.3)
427.6
(63.6) (106.2)
TABLE 5.5.1.
The table presents the IL-6 activity in cells either stimulated with PHA or 
unstimulated and cultured in the presence of 1,25 dihydroxyvitamin D3. The data are 
obtained from 7 normal individuals and are presented as the mean and the standard error 
of the mean are in parenthesis. The IL-6 activity was measured in units/ml.
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Figure 5.5.1
The figure represents the IL-6 activity present in supernatants derived by 
either from cells stimulated with PHA or unstimulated and cultured in the 
presence of 1,25 dihydroxyvitamin D3. The data are obtained from 7 normal 
individuals and are presented as the mean with the standard error of the mean 
(SEM) portrayed as error bars. The IL-6 activity is measured in units/ml. 
Statistics in the form of a paired Wilcoxon test comparing 0 to all other 
concentrations of 1,25 dihydroxyvitamin D3 revealed no significant 
differences.
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5.6. LIPOPOLYSACCHARIDE - A MORE APPROPRIATE STIMULUS ?
The IL-6 activity in the presence of l,25(OH)2D3 presented in section 5.5. was 
obtained using PBMCs stimulated with PHA. PHA is not a recognised stimulator of IL- 
6 so an experiment was set up to look at IL-6 activity in cells cultured in the presence of 
l,25(OH)2D3 and stimulated with LPS.
5.6.1. The effect of l,25(OH)2D3 on LPS induced IL-6 activity.
PBMCs were obtained from eight normal individuals by density gradient 
centrifugation (section 2.2.1.). The cells were resuspended in complete RPMI 1640 + 10 
% F.C.S. at a cell density of 106 cells/ml. The cells were stimulated with 10 |ig/ml LPS 
and cultured in the presence of a range of concentrations of l,25(OH)2D3 (10~13 M - 10 7 
M). The cells were incubated at 37 °C in a humidified atmosphere of 5 % CCh/Air for 
18 hours. The supernatants were harvested and stored at -20 °C until required in the 
assay.
The supernatants were assayed in the B9 bioassay. The samples were two-fold serially 
diluted in complete RPMI 1640. The assay was incubated at 37 °C in 5 % CC>2/Air for a 
total of 72 hours. Four hours prior to the end of the incubation MTT was added to each 
well (section 2.10.4).
5.6.2. IL-6 activity not altered by l,25(OH)2D3.
Table 5.6.1. lists the IL-6 activity of cells cultured in the presence of l,25(OH)2D3 and 
stimulated with LPS. The IL-6 activity initially increases with increasing l,25(OH)2D3 
concentration with maximum production occurring at 1011 M. As in section 5.4. at the 
higher concentrations of l,25(OH)2D3 the IL-6 activity returns to normal control levels. 
The data are presented in graph form in figure 5.6.1. and this resembles the figure 5.4.1.. 
The IL-6 activity in fact dips below the normal control levels at 10 8 M and 10 7 M.
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Interleukin-6 activity produced bv cells cultured in
the presence of 1.25 dihydroxyvitamin D3 and stimulated 
with LPS
l,25(OH)2D3
(Molar)
IL-6 activity 
(units/ml)
(x 10-3)
0 90.7
(15.3)
10-13 106.7
(20.0)
IO-12 105.5
(20.5)
10-n 120.0
(16.2)
lO-io 107.3
(11.0)
10-9 101.7
(18.8)
10-8 67.5
(9.7)
10-7 63.8
(8.4)
TABLE 5.6.1.
The table presents the IL-6 activity in supernatants from cells stimulated with 
LPS and cultured in the presence of 1,25 dihydroxyvitamin D3. The data are obtained 
from 8 normal individuals and are presented as the mean and the standard error of the 
mean are in parenthesis. The IL-6 activity was measured in units/ml.
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FIGURE 5.6.1.
The figure represents the IL-6 activity present in supernatants derived from 
cells stimulated with LPS and cultured in the presence of 1,25 
dihydroxyvitamin D3. The data are obtained from 8 normal individuals and 
are presented as the mean with the standard error of the mean (SEM) portrayed 
as error bars. The IL-6 activity is measured in units/ml. Statistics in the form 
of a paired Wilcoxon test comparing 0 with all other concentrations of 1,25 
dihydroxyvitamin D3 revealed no significant differences.
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5.7. 1,25 DIHYDROXYVITAMIN D3 ACTS DIRECTLY ON T - CELLS TO INHIBIT 
INTERLEUKIN - 2.
The effects of l,25(OH)2D3 on both IL-1 and IL-6 are less clear cut than the effect of 
this metabolite of vitamin D on IL-2 activity. The IL-1 and IL-6 activities followed the 
same pattern when cultured in the presence of l,25(OH)2D3. Initially at the lower 
concentrations of l,25(OH)2D3 (1CH3 M - 10*11 M) both activities appeared to be 
enhanced. At the higher concentrations both activities returned to the normal control 
levels.
The increased IL-1 and IL-6 could be seen as pointing towards an enhanced immune 
response. However, this was not the case as it has been shown that l,25(OH)2D3 did 
inhibit the immune response. The IL-1 and IL-6 could in fact be acting on other cells 
that were responsive to these cytokines. It is tempting to speculate that while 
l,25(OH)2D3 was shutting down the immune response it was also responsible for 
increasing the differentiation of the monocyte/macrophage lineage to form osteoclasts 
thereby enabling the performance of its recognised function, the mobilisation of 
calcium. It is also possible that the IL-1 and IL-6 were acting at the level of the bone 
cells; osteoclasts/osteoblasts.
An attempt was made using purified monocytes as the starting cell population. 
However as with the PBMC population unstimulated cells also produced significant 
amounts of IL-1 and IL-6. The IL-6 produced in unstimulated cells can be attributed to 
the FCS whereas the IL-1 produced under similar conditions must be a consequence of 
the cell separation procedure.
The role of l,25(OH)2D3 on the activity of other cytokines like IL-1 and IL-6 appears 
to be negligible. The inhibition of IL-2 by l,25(OH)2D3 is a major phenomenon in 
comparison to these cytokines.
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CHAPTER 6.
1,25 DIHYDROXYVITAMIN D3 AND THE T - CELL SUBSETS.
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6.1. THE TARGETS FOR 1,25 DIHYDROXYVITAMIN D3.
6.1.1. The lymphocyte.
The heterogeneous nature of lymphocytes is well established. There are two classes of 
lymphocytes each deriving their name from their maturation site. Lymphocytes that are 
dependent on the thymus for development are called thymus dependent cells or T-cells. 
Thymus independent lymphocytes include precursors of antibody producing cells and 
these are termed B-cells. The name arises from the situation in birds. In birds the 
antibody producing cells are dependent for their development on a gut associated 
lymphoid organ, the bursa of Fabricius, and this led to term B-cells. However, no bursa 
equivalent has been found in mammals but the term B-cells is still used to describe 
lymphocyte precursors of immunoglobulin producing cells throughout immunology. 
There is a third category of lymphocytes referred to as null cells. The null population 
includes lymphocytes called killer lymphocytes or K-cells which perform the function of 
killing some cells that have been sensitised with IgG antibody.
6.1.2. The T-cell.
With the development of antibodies as a research tool it soon became apparent that T- 
cells themselves are in fact a heterogeneous population. Antibodies to human T- 
lymphocyte surface determinants demonstrate the existence of at least two functionally 
distinct subsets, and that these subpopulations express unique cell surface molecules. 
The two distinct subsets are T helper/inducer cells and T suppressor/cytotoxic cells. T 
helper/inducer (Th) are often referred to as either CD4 +ve or T4 +ve cells, the CD4 
refers to T-cell determinant present on the membrane (CD, clonal determinant). T 
suppressor/cytotoxic cells (Ts) are referred to as CD8 +ve or T8 +ve cells. The 
terminology of the surface antigens were designated at the first international workshop
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on leukocyte differentiation antigens. The function of these subsets are very much as 
their names imply. Th cells provide helper/inducer function for T - T, T - B and T - 
macrophage interactions whereas Ts function in a suppressor mode and contain the 
majority of the cytotoxic T-cell activity.
With the development of more and more refined monoclonal antibodies and 
technological advancement it has become clear that even these subsets are 
heterogeneous. However these subsets i.e. T h and Ts provide a starting point for 
looking for the target for l,25(OH)2D3.
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6.2. METHODS FOR SUBSET PURIFICATION.
There are two methods that are commonly used to prepare purified subsets of T-cells. 
The first method and until recently the most popular method is the separation of subsets 
using plastic petri dishes coated with antibodies against the antigenic determinants 
(CD4, CD8). This technique is referred to as panning, and can be used for both positive 
selection and negative selection of the required subset. As mentioned in section 2.2.2. 
this technique was attempted but unfortunately the yield was unsatisfactory. The second 
method which is relatively new but is becoming increasingly more popular is to 
fractionate using an immunomagnetic separation (IMS) technique. The principle of this 
method is simple, - particles coated with the antibody against the determinant of choice 
are incubated with the unffactionated cell population. The core of the particles contains 
deposits of y ferric oxide (y Fe203) and confers superparamagnetic properties which 
allows a consistent and reproducible reaction to a magnetic field. Binding of the particle 
to the subset of lymphocytes followed by application of a magnetic field results in a 
separated subset of lymphocytes. The cells separated by this technique are in the order 
of 99 % pure and are greater than 95 % viable. The cells are capable of functioning in 
most biological assays without the need to remove these particles. The particles could 
be removed if required by incubation overnight at 37 °C in RPM I1640 + 1 % F.C.S..
169
6.3. SUBSETS IN LYMPHOCYTE ACTIVATION.
6 .3 .1 . The effect of l,25(OH)2D3 on lymphocyte activation - in Th and Ts.
PBMCs were obtained from eight normal individuals by density gradient 
centrifugation (section 2.2.1.). The cells were resuspended in PBS + 1 % F.C.S. at a cell 
density of 3 x 106 cells/ml. The subsets were fractionated using Dynal ® beads coated 
with the antibody against the determinants CD4 and CD8 (section 2.2.2.). The cells 
were counted and resuspended at 6 x 105 cells/ml for the CD4 +ve cells and 3 x 105 
cells/ml for the CD8 +ve cells. These concentrations are in keeping with the theoretical 
concentrations of subsets that would be present in a normal lymphocyte transformation 
assay. The lymphocyte transformation assay was set up as described in section 2.7. with 
the modified cell concentrations in the presence of a range of l,25(OH)2D3 
concentrations. The cells were cultured for a total of 72 hours at 37 °C in a humidified 
atmosphere of 5 % C02/Air. Four hours prior to the end of the incubation period, the 
cells were pulsed with 1 fiCi of tritiated thymidine (3[H]-thy). The cells were harvested 
and the counts per minute (cpm) of 3[H]-thy incorporated established.
6.3.2. T h proliferation inhibited by l,25(OH)2D3.
The effect of l,25(OH)2D3 on each of the subsets (Th and Ts) stimulated with PHA, 
Con A and PWM are documented in figure 6.3.1.. It is clear that it was only the T h cell 
population that was stimulated under the conditions used in the assay and in the original 
lymphocyte assay set up with unfractionated PBMCs (section 3.4.2.). The Ts cell 
population was not stimulated by any of the mitogens. There was therefore no apparent 
inhibition of lymphocyte activation by l,25(OH)2D3. The Th cell populations were 
significantly inhibited by l,25(OH)2D3 whether the cells were activated by PHA, Con A 
or PWM. PHA stimulated T h cells were significantly inhibited by 1010 M l,25(OH)2D3 
whereas Con A and PWM stimulated cells were significantly inhibited by 10 13 M
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The effect of 1.25 dihvdroxwitamin D3 on 
the proliferation of PHA. Con A and PWM  
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FIGURE 6.3.1.
The figure represents the proliferation of the two cell subsets stimulated 
with either PHA, Con A and PWM and cultured in the presence of 1,25 
dihydroxyvitamin D3. The data are presented as the mean of 8 normal 
individuals and the error bars are the standard error of the mean (SEM). 
The statistical test carried out on the data was the paired Wilcoxon test test 
(*p < 0.05) comparing 0 to all other concentrations of 1,25 
dihydroxyvitamin D3.
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l,25(OH)2D3. The proliferation obtained in these experiments with purified cell subsets 
was a degree of magnitude lower than when unfractionated cells were used. The reason 
for this are twofold ; the actual number of cells at the start of the culture were lower 
(although the number of T h  were similar) and secondly there was a lack of accessory 
cells which could function to amplify the lymphocyte activation response.
6.3.3. Inhibition of proliferation - mediated via T h  cells.
The observation that the T h  cells activated with PHA were significantly inhibited by 
l,25(OH)2D3 at 1010 M correlates well with the effects on unfractionated PBMCs 
(section 3.4.2.). This would then argue that the effect seen in unfractionated PBMCs is 
due to an effect on the T h  cell population.
The data obtained for the effects of l,25(OH)2D3 on Con A and PWM induced 
proliferation on T h  cells are a little more difficult to explain. However, by definition a 
mitogen promotes T-cell proliferation which would always require some activation of 
T h  cells. It is therefore possible that the T h  cells activated by these mitogens were the 
subpopulation of cells specifically targeted by the l,25(OH)2D3 hence the reason 
significance was attained at lower concentrations (1013 M). PHA on the other hand 
activates all T h  cells and therefore the inhibition takes more l,25(OH)2D3 to show up as 
significant.
What is apparent from these results is that l,25(OH)2D3 does not appear to mediate its 
inhibitory effect through cells of the cytotoxic/suppressor class. If l,25(OH)2D3 was to 
mediate the inhibitory effect through the Ts cell population then there would have been 
no comparable inhibition observed in the T h  cell population. However an inhibition was 
observed and this inhibition was comparable percentage wise with the results obtained 
from unfractionated cells. It is therefore possible to rule out the postulate that 
l,25(OH)2D3 mediates its effect via the differentiation of suppressor cells. The 
observation that l,25(OH)2D3 does not lead to an increase in Ts cells strengthens this 
particular argument.
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6.4. SUBSETS AND INTERLEUKIN - 2 ACTIVITY.
6.4.1. The effects of l,25(OH)2D3 on IL-2 activity - Th and Ts.
PBMCs were obtained from eight normal individuals by density gradient 
centrifugation (section 2.2.1.). The cells were resuspended in PBS + 1 % F.C.S.. The 
resuspended cells were fractionated to yield the T-cell subsets (section 2.2.2.). The cells 
were counted and resuspended in complete RPM I1640 + 1 % F.C.S. at 6 x 105 cells/ml 
for the T h cells and 3 x  105 cells/ml for the Ts cells. The cells were then stimulated with 
either PHA (1 Jig/ml, Wellcome Grade) or Con A (5 |ig/ml) in the presence of a range of 
l,25(OH)2D3 concentrations. The cells were cultured at 37 °C in a humidified 
atmosphere of 5 % CCh/Air for 48 hours following which the IL-2 containing 
supernatants were harvested. The IL-2 activity was assessed in the HT-2 bioassay 
(section 2.8.2.).
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6.4.2. As expected only Th produce IL-2 activity.
The IL-2 activity in the presence of l,25(OH)2D3 obtained in each of the subsets is 
presented in tables 6.4.1. and 6.4.2.. The results are expressed as the mean with the 
standard error in parenthesis. It is clear that l,25(OH)2D3 significantly inhibits IL-2 
activity in T h  cells and that this inhibition can be observed in cells stimulated with either 
PHA or Con A. The Ts cells as expected did not produce any IL-2 activity when 
stimulated with Con A and therefore l,25(OH)2D3 did not affect these cells. The Ts 
cells stimulated with PHA did produce a small amount of IL-2 activity and l,25(OH)2D3 
did inhibit this activity although no significance was attained. The IL-2 activity in these 
cells was probably due to contaminating T h  in some of the preparations as this activity 
was not uniformly found in all the individuals. The data are also represented graphically 
in figure 6.4.1., standard errors of the mean appear excessive, but the actual IL-2 activity 
was low and this may account for the large distribution of the results. However, the 
actual inhibition in terms of percentage was comparable to the inhibition observed in 
unfractionated cells i.e. at 1011 M there was inhibition in excess of 50 % (figure 6.4.2.).
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IL-2 activity in T-Helper cells cultured in the presence of
1.25 dihydroxyvitamin D3 and stimulated with either PHA or Con A
Mitogen l,25(OH)2D3
(Molar)
IL-2 Activity 
(units/ml)
PHA 0 3.55
PHA 10-13
(1.40)
3.06
PHA 10-12
(1.24)
3.12
PHA 10-n
(1.42)
2.92
PHA lO-io
(1.50)
2.86
PHA 10-9
(1.53)
2.39*
PHA 10-8
(1.18)
2.00*
PHA 10-7
(0.97)
1.62*
(0.85)
Con A 0 5.34
Con A lO-io
(2.99)
4.09*
(2.66)
TABLE 6.4.1.
The figure presents the IL-2 activity in TH cells stimulated with PHA and TS 
cells stimulated with Con A, both subsets were cultured in the presence of 1,25 
dihydroxyvitamin D3. The IL-2 activity was expressed as units/ml. The data are 
presented as the mean of 8 normal individuals with the standard error of the mean 
represented as error bars. Statistics in the form of a Wilcoxon test were carried out (* p 
< 0.05 ) comparing 0 with each of the concentrations of l,25(OH)2D3 tested for either 
mitogen.
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IL-2 activity in T-Suppressor cells cultured in the presence of
1.25 dihvdroxwitamin D3 and stimulated with either Con A or PHA
Mitogen l,25(OH)2D3
(Molar)
IL-2 Activity 
(units/ml)
Con A 0 1.64
Con A 1013
(0.80)
1.29
Con A 10-12
(0.64)
1.48
Con A 10-n
(0.72)
1.03
Con A lO - io
(0.50)
1.46
Con A 10-9
(0.75)
1.40*
Con A 10-8
(0.70)
1.50
Con A 10-7
(0.74)
0.94
(0.48)
PHA 0 1.26
PHA lO - io
(0.45)
1.05
(0.45)
TABLE 6.4.2.
The table presents the IL-2 activity of Ts cells stimulated with either PHA or Con A and 
cultured in the presence of 1,25 dihydroxyvitamin D3. The data were obtained from 8 
normal individuals. The data are the mean with the standard error of the mean in 
parenthesis. The data were subjected to the Wilcoxon test ((* p < 0.05) comparing 0 to 
each of the concentrations of l,25(OH)2D3 tested and stimulated with either mitogen.
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The IL-2 activity present in supernatants obtained from Th  
and Ts stimulated with PHA and Con A respectively and, 
cultured in the presence of 1.25 dihydroxyvitamin D3
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Figure 6.4.1.
The figure represents the IL-2 activity in TH cells stimulated with PHA and TS 
cells stimulated with Con A, both subsets were cultured in the presence of 1,25 
dihydroxyvitamin D3. The IL-2 activity was expressed as units/ml. The data 
are presented as the mean of 8 normal individuals with the standard error of the 
mean (SEM) represented as error bars. Statistics in the form of a paired 
Wilcoxon test were carried out (*p <0.05) comparing 0 with all other 
concentrations of 1,25 dihydroxyvitamin D3.
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The IL-2 activity present in supernatants obtained 
from TH cells stimulated with PHA and cultured in the
120 -i presence of 1.25 dihydroxyvitamin D3expressed as a
percentage
o  100"
T helper cells
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FIGURE 6.4.2.
The figure represents the IL-2 activity in TH cells stimulated with PHA and 
cultured in the presence of 1,25 dihydroxyvitamin D3. The IL-2 activity was 
expressed as the percentage of control. The data are presented as the mean of 8 
normal individuals with the standard error of the mean (SEM) represented as 
error bars.
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The low IL-2 activity observed in the T h  cells could be the result of low cell number or 
could be due to the lack of accessory factors normally provided by the depleted cells. 
However, what is clear is that l,25(OH)2D3 appears to act on the T h  cells and not the Ts 
cells when mediating its inhibition.
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6.5. INHIBITION BY l,25(OH)2D3 WAS NOT EXPLAINED BY INCREASED
DIFFERENTIATION OF Ts.
The promotion of differentiation by l,25(OH)2D3 is an established phenomenon. The 
discovery of the vitamin D receptor (VDR) in some tumour lines raised the possibility 
that the active D metabolite may effect cell differentiation. Physiological concentrations 
of l,25(OH)2D3 (1011 M - 1010 M) were shown to induce differentiation of both murine 
and human myloid leukaemic cells in vitro.
It was postulated by Tsoukas et al that the inhibition of PBMCs by l,25(OH)2D3 in 
terms of both proliferation and of IL-2 activity may be mediated by promotion of 
differentiation of suppressor cells. At the time this was a perfectly feasible proposition. 
However, the data presented in chapter 3 and 4 and in this present chapter argue against 
the involvement of suppressor cells in this response. In chapter 3 the inhibition of 
proliferation stimulated with Con A and with PHA by l,25(OH)2D3 suggested that the 
T h  cell mitogen and the Ts cell mitogen were both similarly affected. The Con A 
stimulated cells requiring slightly more l,25(OH)2D3 to achieve significance. In chapter 
4 it was demonstrated that l,25(OH)2D3 inhibited IL-2 activity and that this could 
account for the inhibition of lymphocyte proliferation. The present chapter has 
attempted to investigate the importance of the subsets T h  and Ts in the inhibition of both 
these immune functions by l,25(OH)2D3 and to establish whether or not suppressor cells 
have a role to play in the mechanism. It is clear from the data that the inhibition by 
l,25(OH)2D3 is restricted to the T h  cells as far as lymphocyte activation and IL-2 
activity is concerned. It is therefore possible to assume that the Ts cells are not involved 
in mediating the l,25(OH)2D3 effect.
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The observation that the stimulation of T h  cells by Con A  achieves significance at 10- 
13 M l,25(OH)2D3 is interesting bearing in mind that the proliferation of unfractionated 
cells stimulated with Con A does not achieve significance until 109 M. A possible 
explanation for this difference could be that whereas PHA acts as a general T h  cell 
mitogen, Con A may stimulate its suppressor cells by way of a specific population of T h  
cells which is particularly sensitive to l,25(OH)2D3. The same could be said for 
stimulation with PWM. In the unfractionated cells stimulated with Con A and PWM the 
effect of l,25(OH)2D3 on this specific population would be swamped by proliferation of 
other cell populations. It may be that this subpopulation of T h  cells is the actual target 
for l,25(OH)2D3.
181
CHAPTER 7.
1,25 DIHYDROXYVITAMIN D3 AND THE SOLUBLE INTERLEUKIN - 2
RECEPTOR.
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7.1. INTERLEUKIN - 2 RECEPTOR.
As with polypeptide hormones and other growth factors, the mode of action of 
interleukin-2 (IL-2) is mediated via binding to a specific cell surface receptor on 
responsive T-cells. Also like other hormone receptor interactions the binding of IL-2 to 
its receptor is characteristically a high affinity binding event. The IL-2 receptor (IL-2R) 
conforms to the definition of a true hormone receptor molecule with regard to the 
following criteria ; high affinity, saturability, ligand specificity and target cell specificity 
(Robb, 1981). These criteria were demonstrated by the use of biosynthetically 
radiolabelled EL-2. More significantly it has been demonstrated that the concentrations 
of IL-2 that bind with high affinity to IL-2R are the same as the concentrations of IL-2 
that promote T-cell proliferation. In the first instance it was thought that only T-cells 
stimulated with mitogenic factors were responsive to IL-2 however, it was later revealed 
that B-cells, Natural Killer cells (NK cells) and Lymphocyte activated killer cells (LAK 
cells) were also responsive (Mizel, 1989). The ability of cells to respond to IL-2 is 
intimately associated with the expression of the IL-2 receptor. Resting T-cells do not 
express the form of IL-2R required for the transmission of a proliferative signal. T-cells 
become responsive to IL-2 in the presence of antigen and a presenting cell e.g. a 
macrophage and an appropriate antigen.
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7.1.2. The structure.
Initially the structure of the IL-2 receptor proved elusive. The first monoclonal 
antibody against the IL-2 receptor was developed by Uchiyama et al (Uchiyama, 1981). 
A problem occurred when it was discovered that this antibody reacted with significantly 
more cell surface molecules than could be detected by high affinity radiolabelled IL-2 
(Leonard, 1982). In following up this observation it was shown that the excess cell 
surface molecules did in fact bind IL-2 albeit at a lower affinity than the high affinity 
IL-2 receptor (Robb, 1984). The cDNA isolated using this monoclonal antibody 
revealed that the product of this cDNA did bind IL-2 but only at a low affinity (Sabe, 
1984 and Greene, 1985). It was later established that authentic high affinity IL-2 
receptors consisted of two distinct polypeptide chains each containing an IL-2 binding 
site (Tsudo, 1986 and Teshigawara, 1987). These two polypeptide chains were 
designated the p75 chain (75kD) and the p55 chain (55 kD) and assigned either a  or P 
depending on which convention was used (first discovered v's highest molecular 
weight).
The identification and isolation of a leukaemic cell line that expressed only the p75 
chain made it possible to look at the distinct IL-2 binding characteristics of the two 
separate chains (Tsudo, 1986 and Teshigawara, 1987). It was established that the 
interaction between the two chains was not via a covalent disulphide bond. It appears 
that the chains interacted via non covalent forces to form a heterodimeric high affinity 
IL-2 receptor (Smith, 1988). It also emerged that the binding site for the p75 chain was 
separate and distinct from the p55 chain (figure 7.1.1.). If the chains were studied 
independently the p55 chain has a dissociation constant ( K d )  of 108 M (low affinity) 
whereas the p75 chain has a K d  of 109M (intermediate affinity) (Teshigawara, 1987). 
As a consequence of when both chains were expressed together in the same cell a 
receptor with a dissociation constant ( K d )  of 1041 M (high affinity) was formed. These 
observations argue for the individual chains recognising different residues on the IL-2 
molecule as there was evidently no competition for the IL-2.
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A diagramatic representation of the high affinity 
Interleukin - 2 receptor(IL-2R)
IL-2
p55 Outsidep75 \
Cell
Membrane
Inside
Figure 7.1.1.
The figure represents the high affinity IL-2R. The two chains, p75 and 
p55, present in the high affinity receptor bind IL-2 independently but 
also cooperate. The two chains are not covalently linked by disulphide 
bonds. The p75 chain binds IL-2 with an intermediate affinity and is 
constitutively expressed. The p75 chain is responsible for signal 
internalisation hence the larger cytoplasmic domain. The p55 (or Tac) is 
a low affinity receptor which is induced after cell activation.
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Instead, cooperation between the binding sites leads to a 100 - to 1000 - fold increase in 
the binding affinity of the heterodimer. The kinetics and the equilibrium constants of 
the individual chains were very different but when combined enhance the high affinity 
binding. IL-2 binds to and dissociates from the p75 chain very slowly whereas the IL-2 
reacts rapidly with the p55 chain. The high affinity receptor possesses a fast association 
rate derived from the fast acting p55 chain and a slow dissociation rate derived from the 
slow acting p75 chain. The kinetics in this situation combine to enhance the affinity of 
the receptor.
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7.2. THE SOLUBLE INTERLEUKIN - 2 RECEPTOR.
The extensive study of interleukin-2 and its interaction with its receptor led to the 
detection of a fully soluble form of the IL-2 receptor in culture supernatants (Rubin, 
1985). The identification and quantitation of this soluble IL-2 receptor (sIL-2R) was 
made possible by the development of a sandwich enzyme linked immunoabsorbant 
assay (ELISA) (Rubin, 1985). This ELISA employed two noncompetitive anti-IL-2R 
monoclonal antibodies. It soon became evident that the sIL-2R was present at low 
levels in sera from normal individuals and at elevated levels in sera from patients with 
various neoplastic disorders. It was apparent that this parameter was useful as a means 
of assessing immune function.
The sIL-2R protein was dependent on activation of the immune system. The 
glycosylated protein was fully soluble with a molecular weight of approximately 45 kD 
(Rubin, 1985, Rubin, 1986 and Hakimi 1987) and was probably generated by the 
proteolytic cleavage of the cell surface Tac protein (also referred to as p55) (Robb, 
1987, Loughnan, 1988 and Meidel, 1988). This was made more likely by the 
observation that there does not appear to be any evidence for an alternatively spliced 
Tac mRNA transcript The binding affinity of the sIL-2R was on a par with the p55 
chain. In certain circumstances the sIL-2R concentration has been elevated to such an 
extent that the IL-2 function was coincidentally impaired suggesting that the sIL-2R 
may act as an antagonist of IL-2 mediated responses. It was to this end that the effects 
of l,25(OH)2D3 on sIL-2R concentration were studied.
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7.2.1. sIL-2R expression in the presence of l,25(OH)2D3.
PBMCs were obtained from seven normal individuals by density gradient 
centrifugation (section 2.2.1.). The cells were resuspended at 106 cells/ml in complete 
RPMI 1640 + 2 % F.C.S. and stimulated with 1 |ig/ml PHA (Wellcome Grade) in the 
presence of a range of l,25(OH)2D3 concentrations (1013 M - 10 7 M). The cells were 
cultured for 48 hours at 37 °C in a humidified atmosphere of 5 % C02/Air. The 
supernatants were harvested and stored at -20 °C until assayed for both IL-2 activity and 
cell-free sIL-2R.
The IL-2 activity was assessed using the HT-2 bioassay (section 2.8.2.) and the sIL-2R 
was assessed using the commercially available Cellfree interleukin-2 receptor test kit (T- 
cell Sciences, Inc.; section 2.11.2.).
7.2.2. sIL-2R concentration increases as IL-2 activity decreases.
The IL-2 activity and the sIL-2R concentration for each of the concentrations of 
l,25(OH)2D3 are presented in table 7.2.1.. It is clear that while l,25(OH)2D3 inhibits IL- 
2 activity, l,25(OH)2D3 at the higher concentrations (greater than 1011 M) increases the 
concentration of sIL-2R in the supernatants. The data are also depicted in figure 7.2.1. 
and provide a clear demonstration of an all or nothing response of the sIL-2R. The 
concentration of sIL-2R appears to go along at a constant level between control and 10- 
11 M l,25(OH)2D3 and then between 1011 M and 1010 M (interestingly the physiological 
range) the amount of sIL-2R increases and maintains a plateau at this higher level. This 
increase in sIL-2R is statistically significant. On the other hand, the IL-2 activity was 
inhibited from the outset and becomes statistically significant at 1CH2 M.
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The effect of 1.25 dihydroxyvitamin D3 on both IL-2
activity and the amount of soluble IL-2 receptor
l,25(OH)2D3 IL-2 Activity soluble IL-2 receptor
(Molar) (units/ml) (units/ml)
0 30.0 980.0
10-13
(5.4)
26.7*
(129.9)
1010.0
IO-12
(5.1)
24.0*
(101.5)
967.1
10-n
(4.9)
19.0*
(104.5)
942.1
lO-io
(4.1)
20.4*
(97.4)
1422.1*
10-9
(3.9)
16.7*
(225.4)
1395.7*
10-8
(3.2)
12.9*
(177.3)
1348.6*
10-7
(2.3)
12.6*
(275.5)
1435.0*
(2.2) (252.5)
Table 7.2.1.
The table presents the IL-2 activity and the concentration of soluble IL-2 
receptor in the supernatant of cells stimulated with PHA and cultured in the presence of
1,25 dihydroxyvitamin D3. The data are presented as the mean of 7 normal individuals 
and the standard error of the mean are presented in parenthesis. Statistics in the form of 
a paired Wilcoxon test was performed on the data (* P > 0.05) comparing 0 with all 
other concentrations of l,25(OH)2D3.
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The effect of 1.25 dihydroxyvitamin D3 on the 
IL-2 activity and on the soluble IL-2 receptor
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FIGURE 7.2.1.
The figure represents the IL-2 activity and also the concentration of soluble 
IL-2 receptor in the supernatant of cells stimulated with PHA and cultured in 
the presence of 1,25 dihydroxyvitamin D3. The data are presented as the 
mean of 7 normal individuals and the standard error of the mean are 
represented as error bars. Statistics in the form of a paired Wilcoxon test was 
performed on the data (* p > 0.05) comparing 0 to all other concentrations of
1,25 dihydroxyvitamin D3.
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7.2.3. Increased sIL-2R occurs over the physiological range.
These observations imply that l,25(OH)2D3 over the physiological range (1011 M - 10- 
10 M) has a profound effect on the concentration of sIL-2R. Over this range the sIL-2R 
concentration was significantly increased. The implication is that l,25(OH)2D3 
increases the proteolytic cleavage of the high affinity IL-2 receptor and that the sIL-2R 
absorbs the IL-2 and consequently acts as an antagonist for IL-2 mediated responses. 
The IL-2 activity is inhibited throughout the range of l,25(OH)2D3 - not just at 
concentrations above 1011 M - which implies that there is was more than one 
mechanism at work in this system.
The data presented in chapters three and four regarding the effects of sex hormones on 
both lymphocyte activation and IL-2 activity should be considered at this juncture. In 
these chapters significant inhibitions of lymphocyte activation and IL-2 activity by the 
sex hormones were noted at 1010 M but the values returned to control levels at the 
higher concentrations. These data also hinted at the existence of two mechanisms. It 
was conceivable that l,25(OH)2D3 was acting as a classical steroid hormone up to and 
including 1011 M and for the remainder of the range of l,25(OH)2D3 concentrations (10- 
10 M - 10'7 M) the inhibition was occurring via changes in the sIL-2R concentrations. 
This implies that the initial inhibition was a result of classical genomic changes brought 
about by steroid hormones and that l,25(OH)2D3 had a unique contribution to make at 
concentrations in excess of 1011 M.
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CHAPTER 8.
THE EFFECT OF l,25(OH)2D3 ON SELECTED mRNAs.
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8.1. THE EFFECT OF l,25(OH)2D3 ON mRNAs FOR IL-2 AND IL-2R.
l,25(OH)2D3 was thought to act as a steroid hormone in the immune system. The first 
action of a steroid hormone is accepted as a change in the message going to the protein 
assembly apparatus. This chapter deals with the effect of l,25(OH)2D3 on the mRNA 
for IL-2 and on the mRNA for the IL-2 receptor.
8.1.1. The effect of l,25(OH)2D3 on mRNA for IL-2 and IL-2R at four hours.
PBMCs were obtained from a normal individual by density gradient centrifugation 
over Ficoll - hypaque (see section 2.2.1.). The cells were resuspended at a cell density 
of 106 cells/ml in complete RPMI 1640 + 2 % FCS and stimulated with 1 |ig/ml PHA 
(Wellcome) in the presence of either vehicle (ethanol), 1010 M or 107 M l,25(OH)2D3. 
The cells were cultured for 4 hours at 37 °C in a humidified atmosphere of 5 % C02/Air. 
The cells were harvested and washed in PBS. The RNA was extracted from the cells 
using an acid guanidinium thiocyanate - phenol - chloroform extraction (see section 
2.12.1). The mRNA was assessed (see section 2.12.2.) and characterised on a Northern 
blot analysis. The samples were run on a 1 % agarose/formamide gel. Each sample was 
run in three different positions in the gel, such that the gel could be cut in three resulting 
in three gels each possessing one of each of the samples. The RNA was transferred to 
the nitrocellulose (see section 2.12.3.). The three blots were probed with either an IL-2 
probe, an IL-2R probe or the abl probe. The probes were labelled by an end labelling 
reaction (see section 2.12.3). The probes were hybridised to the blots and 
autoradiographs were developed.
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8.1.2. l,25(OH)2D3 has little effect on IL-2 and IL-2R at four hours.
The autoradiograph depicted in figure 8.1.1. shows the amount of specific RNA for 
each of the three probes. Lanes 1 to 3 represent the amount of RNA specific for the IL-2 
message. Lane 1 was RNA from cells cultured in the presence of ethanol, lane 2 was 
RNA from cells cultured in the presence of 1010 M l,25(OH)2D3 whereas lane 3 was 
RNA from cells cultured in the presence of 107 M l,25(OH)2D3. There was no apparent 
difference in the amount of IL-2 message in each of these conditions. Lanes 4 to 6 were 
similarly set up and this time these lanes were a measure of the expression of the IL-2 
receptor. Again, there appeared to be no difference in the amount of message for IL-2R 
whether the cells were cultured in the presence of vitamin D or not Lane 7 to 9 were 
also set up in the same fashion but were probed with the abl probe. This is a house 
keeping gene and so should be present in the same amounts if the amount of RNA 
loaded onto each lane was the same. The autoradiograph is not very distinctive, the best 
that can be said is that at 4 hours the cells are not expressing much mRNA for either IL- 
2 or IL-2R. The amount of RNA loaded onto the gel was similar in each lane as 
assessed by the preparation gel. The blot hybridised to the abl gene however did not 
show very much RNA on the blots. An explanation therefore could be that the amount 
of RNA loaded onto the cell was inadequate or alternatively that the hybridisation 
conditions were too stringent. This set of results were therefore inconclusive.
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8.2. THE EFFECT OF l,25(OH)2D3 ON mRNA FOR IL-2 AND IL-2R AFTER A 
LONGER INCUBATION.
It remained possible that the l,25(OH)2D3 was inhibiting the IL-2 or IL-2R mRNA at a 
later stage i.e. there was no effect in the first four hours of culture. The time scale for 
the expression of vitamin D receptors after stimulation made it possible that an 
inhibition at this level would occur at a later time point.
8.2.1. The effect of l,25(OH)2D3 on mRNA for IL-2 and IL-2R at twenty hours.
PBMCs were obtained from a normal individual by density gradient centrifugation 
over a Ficoll - hypaque cushion (see section 2.2.1.). The cells were set up in culture at 
106 cells/ml in complete RPMI 1640 supplemented with 2 % FCS and stimulated with 1 
fig/ml PHA. The cells were cultured in the presence of either ethanol, 1 0 10 M 
l,25(OH)2D3 or 107M l,25(OH)2D3. The cultures were incubated at 37 °C in a 
humidified atmosphere of 5 % CCh/Air for 20 hours. At the end of the culture period 
the cells were pelleted and the RNA was extracted using the acid phenol thiocyanate 
chloroform method (see section 2.12.2). The mRNA was assessed (see section 2.12.2.) 
and characterised on a Northern blot analysis. The samples were run on a 1 % 
agarose/formamide gel. Each sample was run in two different positions in the gel, such 
that the gel could be halved resulting in two gels each possessing one of each of the 
samples. The RNA was transferred to the nitrocellulose (see section 2.12.3.). The two 
blots were probed with either the IL-2 probe or the IL-2R probe. The probes were 
labelled by an end labelling reaction (see section 2.12.3). The probes were hybridised to 
the blots and autoradiographs were developed.
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The effect of 1.25 Dihydroxvvitamin D3 on the mRNA for
IL-2 and IL-2R after a 20 hour culture 
6 5 4 3 2 1
Figure 8.2.1.
The amounts of mRNA complementary to both IL-2 and IL-2R in PBMCs stimulated 
with PHA and cultured in the presence of either 1 0 10 M or lO 7 M l,25(OH)2D3 or in the 
presence of ethanol (the carrier) are represented. The mRNA in lanes 1 and 4 were 
derived from cells cultured in the presence of ethanol, the mRNA in lanes 2 and 5 were 
derived from cells in cultured in the presence of 1CH° M l,25(OH)2D3 and the mRNA in 
lanes 3 and 6 were derived from cells cultured in the presence of lO 7 M l,25(OH)2D3. 
Lanes 1 to 3 were probed with IL-2R and lanes 4 to 6 were probed with IL-2. The figure 
clearly depicts an inhibition of both IL-2 and IL-2R at 1 0 10 M l,25(OH)2D3 and loss of 
inhibition at lO 7 M l,25(OH)2D3.
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8.2.2. Inhibition by l,25(OH)2D3 followed by recovery.
The autoradiograph shown in figure 8.2.1. depicts the amount of mRNA 
complementary to IL-2 and IL-2R. The mRNA was obtained from cells cultured in the 
presence of l,25(OH)2D3 for 20 hours. Lanes 1 to 3 were probed with IL-2R and lanes 4 
to 6 were probed with IL-2. Lane 1 contains the mRNA obtained from cells cultured in 
the presence of ethanol, lane 2 contains the mRNA from cells cultured in the presence 
of 1010 M l,25(OH)2D3 and lane 3 contains mRNA from cells cultured in the presence 
of 10 7 M l,25(OH)2D3. Lane 1 and lane 3 appear to be of similar intensity so the 
amount of message for IL-2R can be described as similar in cells cultured in the 
presence of ethanol and in the presence of 10*7 M l,25(OH)2D3. Lane 2 is less intense 
and clearly the message for IL-2R is inhibited by 1010 M l,25(OH)2D3. Lane 4 contains 
mRNA from cells cultured in the presence of ethanol, lane 5 contains mRNA from cells 
cultured in the presence of 1010 M l,25(OH)2D3 and lane 6 contains mRNA from cells 
cultured in the presence of lO 7 M l,25(OH)2D3. Again lanes 4 and 6 appear to be of 
similar intensity, this implies that there was no difference in the amount of message for 
IL-2 in cells cultured in the presence of either ethanol or 107 M l,25(OH)2D3. Lane 5 
appears to be less intense which would imply that the message for IL-2 is also inhibited 
by 10-10M l,25(OH)2D3.
8.2.3. l,25(OH)2D3 inhibits the message for both IL-2 and IL-2R.
At lO 10 M, l,25(OH)2D3 inhibits both the IL-2 and IL-2R directly and this accounts 
for the inhibition of IL-2 activity documented in chapter 4. It is interesting to note that 
the amount of message returns to normal levels at 10 7 M l,25(OH)2D3. It is therefore 
possible to conclude that the inhibition of IL-2 activity by l,25(OH)2D3 is not wholly 
explained by an inhibition of the message for IL-2. Clearly the expression of the IL-2R 
gene is closely linked to the IL-2 gene in that the expression follows the same pattern.
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8.3. THE INHIBITION OF IL-2 ACTIVITY BY l,25(OH)2D3 - TWO MECHANISMS.
These results presented in section 8.2. and section 7.2. strengthen the argument for a 
second mechanism in the inhibition of IL-2 activity by l,25(OH)2D3 speculated upon 
and mentioned previously. Clearly the effect on the message does not explain the 
sustained inhibition of IL-2 activity exhibited throughout the range of l,25(OH)2D3 
concentrations tested. It is tempting to speculate that over the range 0 to 1010 M 
l,25(OH)2D3 that the l,25(OH)2D3 is behaving like the sex hormones and inhibiting IL- 
2 activity through a genomic effect acting as a classic steroid hormone. At 
concentrations in excess of 1010 M l,25(OH)2D3 an effect on the soluble IL-2R is 
implicated. It is possible that the reason why the message for both IL-2 and IL-2R 
return to normal could be down regulation of the vitamin D receptor in much the same 
way as happens in the case of a classic steroid hormone. The increase in soluble IL-2R 
demonstrated to occur in cells cultured at concentrations of l,25(OH)2D3 greater than 
1011 M could mop up the IL-2 produced at these higher concentrations thereby 
continuing the inhibition throughout the range under scrutiny.
The assessment of the effect of l,25(OH)2D3 on mRNA only accounted for three 
concentrations (0, 1010 M and 10 7 M) of l,25(OH)2D3, it would have been better to 
look at the range of concentrations (0 to 107 M) to complete the argument. However, 
this was technically very difficult to achieve because of the large amount of PBMCs 
required in the extraction process to get adequate mRNA. The findings, however were 
in agreement with the work of Rigby et al (Rigby, 1987) who demonstrated an inhibition 
of IL-2 mRNA by 1CH0 M l,25(OH)2D3 at 24 hours. However, the effect of 
l,25(OH)2D3 at any other concentrations was not documented in his work.
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CHAPTER 9.
CONCLUSIONS.
2 0 0
It has long been established that l,25(OH)2D3 has a role to play in the immune system. 
The major breakthrough came when it was discovered that l,25(OH)2D3 could inhibit 
IL-2 activity (Tsoukas, 1984) and a role for l,25(OH)2D3 as an immunomodulatory 
hormone was proposed. This was quickly followed by the demonstration that 
l,25(OH)2D3 could inhibit IgG and IgM production (Lemire, 1984). Clearly, the 
mechanism of l,25(OH)2D3 inhibition had to be investigated.
It was proposed that in theory l,25(OH)2D3 could inhibit IL-2 activity through the 
following mechanisms;
(1) l,25(OH)2D3 could act on the cell to inhibit the production and/or secretion 
of IL-2 directly and this could possibly be at the level of the mRNA.
(2) l,25(OH)2D3 could act on the IL-2 receptors to increase the consumption of 
IL-2 thereby lowering the activity of the IL-2.
(3) l,25(OH)2D3 being a differentiation agent could promote the differentiation 
of suppressor lymphocytes.
These proposals have been addressed in this thesis. Given that l,25(OH)2D3 had such a 
profound effect on the immune system the other calciotrophic hormones (24,25(OH)2D3, 
25(OH)D3, PTH and calcitonin) were studied to ensure that l,25(OH)2D3 was unique as 
far as calciotrophic hormones were concerned. The inhibitory effect of l,25(OH)2D3 
was compared to the documented effect of other steroid hormones in particular the sex 
hormones (oestrogen, progesterone and dihydrotestosterone) on the immune system 
(Holdstock, 1982). IL-2 is one of an increasing number of cytokines so the effect of 
l,25(OH)2D3 on IL-1 and IL-6 was also studied. These cytokines could be involved in 
the particular culture system i.e. the IL-1 and IL-6 are produced by monocytes which 
were not excluded from the cell preparation.
2 0 1
In chapter 3 the effect of l,25(OH)2D3 on lymphocyte transformation was studied and 
this confirmed that l,25(OH)2D3 did inhibit lymphocyte proliferation. The use of 
different mitogens revealed that l,25(OH)2D3 had a greater effect on PHA induced 
lymphocyte transformation than either Con A or PWM induced lymphocyte 
proliferation. PHA is predominantly a T-helper cell mitogen and this suggested that the 
likely target for l,25(OH)2D3 may be the T-helper cell. The inhibition was shown to be 
unique to l,25(OH)2D3 in that none of the other calciotrophic hormones (24,25(OH)2D3, 
25(OH)D3, PTH and calcitonin) exhibited such an inhibition. The effect of sex 
hormones (oestrogen, progesterone and dihydrotestosterone) was slightly different in 
that there appeared to be an inhibition of lymphocyte transformation with concentrations 
up to 1011 M (0 to 1011 M) and at the higher concentrations this inhibition was 
abolished (1010 M to 10*7 M). In this chapter the effect of l,25(OH)2D3 was also 
demonstrated not to be a kinetic effect nor an effect on cell viability. In addition it was 
demonstrated that l,25(OH)2D3 did not effect the activation process. The inhibition of 
cell proliferation by l,25(OH)2D3 was therefore a genuine and unique effect.
In chapter 4 the effect of l,25(OH)2D3 and the other calciotrophic and steroid 
hormones on IL-2 activity was studied. It again transpired that of the calciotrophic 
hormones (24,25(OH)2D3, 25(OH)D3, PTH and calcitonin) only l,25(OH)2D3 had a 
significant inhibitory effect. The effect of the sex hormones (oestrogen, progesterone 
and dihydrotestosterone) on IL-2 activity was similar to the effect these hormones had 
on lymphocyte transformation. It was also demonstrated that the inhibition of IL-2 
activity was unlikely to arise from a defect in the secretion as lysed cells still exhibited 
an inhibition by l,25(OH)2D3. An inhibition of the activation process by l,25(OH)2D3 
was also ruled out ij this chapter.
Chapter 5 described the effect of l,25(OH)2D3 on other cytokines namely IL-1 and IL-
6. l,25(OH)2D3 had no significant effect on the IL-1 or IL-6 activity. The effect of 
l,25(OH)2D3 on IL-2 activity appeared to be unique to this cytokine.
2 0 2
In chapter 6 the effect of l,25(OH)2D3 on the T-cell subsets, T-helper and T- 
suppressor cells were studied. The l,25(OH)2D3 not surprisingly was shown to inhibit 
both cell proliferation and IL-2 activity in T-helper cells and have no real effect on the 
T-suppressor cells. This demonstrated that it was very unlikely that the l,25(OH)2D3 
was promoting the differentiation of T-suppressors as the inhibition still occurred in the 
absence of T-suppressor cells.
Chapter 7 looked at the effect of l,25(OH)2D3 on the sIL-2R concentration. 
l,25(OH)2D3 had the effect of increasing the concentration of the soluble IL-2R in 
supernatants at concentrations in excess of 10-11 M (1010 M to 10 7 M). The increase in 
sIL-2R concentration was an 'all or nothing' response and occurred over the 
physiological range (1011 M to 1010M) of the l,25(OH)2D3.
In chapter 8 l,25(OH)2D3 at 1010 M was shown to inhibit IL-2 production at the 
mRNA level and also to inhibit the interleukin-2 receptor (IL-2R) production at the 
mRNA level. It was also demonstrated that if the cells were cultured in the presence of 
lO7 M l,25(OH)2D3 then the message for both IL-2 and IL-2R returned to their original 
levels.
Taken together the results presented in this thesis would argue for the existence of not 
one mechanism but two mechanisms for the inhibition of IL-2 by l,25(OH)2D3. It can 
be argued that between the concentrations 0 to 1011 M that the l,25(OH)2D3 inhibits IL- 
2 activity directly i.e. at the level of the message for both IL-2 and its receptor. In other 
words over this range l,25(OH)2D3 is acting as a classic steroid hormone. In the classic 
steroid hormone situation down regulation of the steroid hormone receptor at the higher 
concentrations (1010 M to 10 7 M) is observed and this leads to the loss of effect (as 
demonstrated in chapter 3 and 4 by the sex hormones). However, this does not occur 
when l,25(OH)2D3 acts on the immune system. It is at this point that the proposed 
second mechanism would come into play. At concentrations in excess of 1011 M the 
inhibition of IL-2 activity is sustained by the increase in the sIL-2R concentration. The 
sIL-2R acts as an antagonist for the IL-2 effectively mopping up the free IL-2 thus
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allowing for the inhibition of IL-2 by l,25(OH)2D3 to continue over the range 0 to 10 7 
M.
Further work has to be carried out to confirm this hypothesis with regard to the 
postulated down regulation of the vitamin D receptor. However, the effect of the sex 
hormones on IL-2 activity support this theory in that the IL-2 activity quite clearly 
recovers and returns to control levels. It is also important to note that the initial 
inhibition (0 to 10 nM) of the IL-2 activity by the sex hormones (oestrogen, 
progesterone and dihydrotestosterone) mirrored the inhibition by l,25(OH)2D3. The 
inhibition over the range 0 to 10 nM by l,25(OH)2D3, oestrogen, progesterone and 
dihydrotestosterone of IL-2 activity were indistinguishable from each other.
It is perhaps significant that the switch from one mechanism to the other takes place 
over the physiological range of the l,25(OH)2D3 i.e. between 1011 M and 1010 M. 
There can now be little doubt that the inhibition of IL-2 activity by l,25(OH)2D3 is an 
important, unique and genuine physiological event.
The significance of having l,25(OH)2D3 acting as an immunomodulatory hormone 
remains unclear. l,25(OH)2D3 has long been established as a calcium regulatory 
hormone functioning primarily in the calcium and phosphorus homeostasis scheme. 
l,25(OH)2D3 is also thought to have a prominent role to play in bone remodelling. It is 
difficult to see the advantage gained from having the same metabolite acting on the 
immune system and on the mineral metabolism system. l,25(OH)2D3 has also been 
shown to act as a differentiation factor particularly on the myeloid cell lineage. It is 
possible that what l,25(OH)2D3 does by dampening down the immune response is to 
facilitate the differentiation of cells down the monocyte/macrophage pathway towards 
the production of osteoclasts. These osteoclasts could mobilise calcium through bone 
resorption allowing vitamin D to increase the pool of calcium via both the resorption of 
bone and the well documented effect of increasing calcium absorption at the intestine.
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The potential for using l,25(OH)2D3 as an immunosuppressive agent is complicated 
by the previously mentioned effect on the absorption of calcium from the gut. The 
administration of quite a small dose of l,25(OH)2D3 often introduces a risk of 
hypercalcemia and this has been borne out in several clinical studies (Cunningham, 
1985, and Morimoto, 1986). The solution to these problems lies in finding synthetic 
analogues to l,25(OH)2D3 which will inhibit the immune system but not stimulate gut 
absorption of calcium and bone resorption.
This approach has already yielded dividends in the management of the common skin 
disease, psoriasis. In this condition there is abnormal proliferation of squamous 
epithelial cells with a degree of dedifferentiation of the keratinocytes leading to skin 
plaques with excessive shedding of keratin scales. Oral administration of l,25(OH)2D3 
was associated with a degree of hypercalcemia (Morimoto, 1986) but topical application 
permitted resolution of the plaques without such a marked effect on serum calcium. 
Even more successful therapeutic results without complications have been obtained 
using topical application of the analogue calcipotriol.
In some other clinical situations the best approach to achieving satisfactory 
immunosuppression may be to use l,25(OH)2D3 or an analogue in combination with a 
smaller dose than usual of another more conventional immunosuppressant drug which 
may have undesirable toxic effects in high dosage. For example the renal toxicity of 
high doses of cylcosporin A might be ameliorated by employing smaller doses of 
cyclosporin A in addition to l,25(OH)2D3 or analogue.
Preliminary studies of the use of vitamin D metabolites in some types of lymphoma 
(Cunningham, 1985); the demonstration of vitamin D receptors in some breast cancers 
(Berger, 1987) ; the demonstration of differential survival rates in breast carcinoma 
relating to the presence or absence of l,25(OH)2D3 receptors (Colston, 1989) ; and the 
effect of l,25(OH)2D3 on some aspects of the diabetic patient (Frazer, 1981), all suggest 
that the effect of l,25(OH)2D3 on the immune system may turn out to be an important 
therapeutic tool. A clearer understanding of the mechanism of this action as described 
in this thesis is likely to be of considerable relevance.
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